Licit and illicit drug use during pregnancy: maternal, neonatal and early childhood consequences. by Finnegan, Loretta
2013
Licit and Illicit Drug Use 
during Pregnancy: 
Maternal, Neonatal and Early
Childhood Consequences
By Loretta Finnegan 
With A Call to Action by Franco Vaccarino and Colleen Dell
SUBSTANCE ABUSE IN CANADA
This document was published by the Canadian Centre on Substance Abuse (CCSA). 
CCSA activities and products are made possible through a financial contribution from Health Canada. 
The views of CCSA do not necessarily represent the views of the Government of Canada.
The subjects in the photographs used throughout this publication are models who have no relation to the content. 
The vignettes are fictional and do not depict any actual person.
Suggested citation: Finnegan, L. (2013). Substance abuse in Canada: Licit and illicit drug use during pregnancy: 
Maternal, neonatal and early childhood consequences. Ottawa, ON: Canadian Centre on Substance Abuse. 
© Canadian Centre on Substance Abuse 2013. 
CCSA, 75 Albert St., Suite 500 
Ottawa, ON K1P 5E7 
Tel.: 613-235-4048 
Email: info@ccsa.ca 
This document can also be downloaded as a PDF at www.ccsa.ca.
 
Ce document est également disponible en français sous le titre : 
Toxicomanie au Canada 2013 : Consommation de drogues licites et illicites pendant la grossesse :  
Répercussions sur la santé maternelle, néonatale et infantile
ISBN 978-1-77178-041-4
Foreword by Rita Notarandrea            2
Acknowledgements              3
Foreword by Anthony G. Phillips and Dan Goldowitz         4
Introduction              5
1.0 Epidemiology of Maternal Drug Use             8
2.0 Medical and Obstetrical Consequences of Drug Use in Women     14
3.0 Psychosocial Issues and Victimization in Pregnant Women Using Drugs    26
4.0 Outcomes of Newborns of Pregnant Women Using Drugs      34
5.0 Comprehensive Treatment Approaches for Pregnant Women Using Drugs    62
6.0 Early Childhood Outcomes          90
7.0 A Call to Action by Franco Vaccarino and Colleen Dell    106
Appendices          112
Licit and Illicit Drug Use 
during Pregnancy: 
Maternal, Neonatal and Early 
Childhood Consequences
Prepared for the Canadian Centre on Substance Abuse
Loretta P. Finnegan, M.D., LLD, (Hon.), ScD (Hon.); President, Finnegan Consulting, 
LLC; Professor of Pediatrics, Psychiatry and Human Behavior, Thomas Jefferson 
University (Retired); Founder and Former Director of Family Center, Comprehensive 
Services for Pregnant Drug Dependent Women, Philadelphia, PA; Former Medical 
Advisor to the Director, Office of Research on Women’s Health, National Institutes 
of Health, U.S. Department of Health and Human Services (Retired)
Table of Contents
1 Canadian Centre on Substance Abuse
SUBSTANCE ABUSE IN CANADA - Licit and Illicit Drug Use during Pregnancy
Every two years, the Canadian Centre on Substance Abuse 
(CCSA) produces a new report in the Substance Abuse in 
Canada series, with each edition shedding much-needed 
light on an important drug- and alcohol-related issue. The 
current report is devoted to drug use during pregnancy—
more specifically, the maternal, neonatal and early childhood 
consequences of using substances ranging from tobacco 
and alcohol, to marijuana, cocaine and heroin. Through this 
installment, we hope to bring the challenges faced by pregnant 
women “out of the shadows” so we can better meet their needs 
and those of their children.  
While this latest report covers a variety of topics, an important 
aim for CCSA was to ensure that it summarizes the latest 
knowledge in the biomedical literature pertaining to drug use 
and abuse during pregnancy. Through the work of CCSA’s 
Scientific Advisory Council (SAC) and the leadership of 
Dr. Franco Vaccarino, Professor of Psychiatry and Psychology 
at the University of Toronto, CCSA had the good fortune to 
connect with Dr. Loretta Finnegan, a world-renowned expert 
in the fields of women’s health, pediatrics and perinatal 
addiction. Dr. Finnegan authored the report and took the lead 
in researching it. We are deeply grateful for her contributions 
and fortunate to have been able to draw on her decades of 
experience on this complex issue.
Women who use drugs, alcohol and tobacco already face 
many health and social challenges. These challenges are 
further compounded during pregnancy, when substance use 
can profoundly affect the earliest stages of human development 
and have adverse outcomes that carry into early childhood and 
beyond. Clearly, we know that drug use has impacts on many 
lives. During pregnancy it affects the lives of the mother and 
child. Drug use also affects — and is affected by — their family, 
the larger community in which they live and even society as 
a whole through interactions with our healthcare and social 
systems. This report explores the full spectrum of impacts. 
One of the important — but arguably less broadly recognized — 
impacts pertains to the biomedical consequences of drug use 
and abuse during pregnancy. An important driver for this report 
was to ensure an up-to-date understanding of this area, as it 
is vital that professionals providing health care and support to 
pregnant women are well-informed about the latest evidence. 
This perspective is considered as part of the educational, 
motivational and tailored tool kit that treatment providers can 
employ to connect with women during their pregnancy — a 
period when women are more likely to seek care and support 
from the health community. 
Pregnancy is also a period when women might be more 
motivated to address the potential harms associated with their 
drug use. Because of this potential, it was considered important 
that the report inform and educate treatment providers about 
what is happening biologically to the fetus. We also took care 
to provide information about the measures that can be taken on 
the part of a pregnant woman and her community to reduce the 
harms to both the mother and her fetus. 
A further catalyst for the approach taken in the present report 
derives from learnings in the mental health field. The treatment 
provider can relay information to the mother on the biological 
context of substance use in pregnancy. This information 
can help prevent the mother feeling any sense of blame and 
judgment, which feeling could lead to her inaction.
The biomedical focus of the report did not permit a 
comprehensive, in-depth analysis of the many complex 
psychosocial factors associated with drug use during 
pregnancy. The report does, however, include an important 
chapter relating to psychosocial issues, as well as a section 
highlighting the value of a setting that provides a more holistic 
and comprehensive approach to care. This information on the 
setting for care underscores the importance of psychosocial 
themes such as those related to victimization that were included 
in the report. It also stresses the central role played by the family 
and community in any treatment response or prevention effort. 
The Call to Action found at the end of the report encourages 
ongoing efforts to integrate biomedical and psychosocial 
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To meet our goals of producing a report with a broad-based 
international perspective, the report was not designed to 
be country-specific or to focus only on the state of affairs in 
Canada, although it does highlight some Canadian data. For 
this reason, Dr. Finnegan, the report’s author, was a strong 
fit in her capacity as a world expert and she has provided a 
comprehensive, globally relevant report on the impacts of drug 
use during pregnancy on the fetus and on the infant.
There are a number of actions we need to take to address the 
challenges. This report is an important reminder of the need 
to continue to build our knowledge base as it pertains to the 
Canadian context. Some of this work will involve closing gaps 
in the knowledge pertaining to Canada-specific issues and 
some of it will involve adapting the knowledge derived from the 
international context to a Canadian context. But by concentrating 
our efforts on the areas identified in the Call to Action — among 
them, ensuring clinicians and their clients have access to the 
latest evidence and adopting a more holistic and multidisciplinary 
approach to treatment and prevention — we will be able to bring 
real change to frontline practices and to community responses, 
and we will help countless lives in the process.
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Non-medical abuse of drugs can occur at any stage of life. 
When such exposure occurs during pregnancy and in the post-
natal phase, it raises understandable concern about the impact 
on the health of the mother and child, as well as possible long-
term consequences for brain development in the new infant. As 
individuals our concerns are immediate and heartfelt, and yet 
as a society we have in many respects turned a blind eye to 
this tragic state of affairs. Women in the greatest need, arising 
in part from a dependency on illicit drugs, often have limited 
options for the long-term care they require. 
We can hope that publications such as this Substance Abuse 
in Canada report, which summarizes new and sophisticated 
research and clinical developments concerning maternal, 
neonatal and early childhood consequences of drug use during 
pregnancy, indicate that the tide is turning. Thanks to the efforts 
of a new cohort of researchers who appreciate the complex 
biological and social factors that give rise to addiction, there 
are real prospects for a much better scientific understanding of 
addiction as a chronic disorder that requires new and integrated 
treatment strategies for it to be addressed effectively. 
The urgency to deal effectively with drug use during pregnancy 
arises from the widly appreciated position that most aspects of 
our health and well-being are shaped by events that influence 
biological and psychological development early in life. Indeed, 
it may be argued that a probing analysis of addiction from 
the perspective of human development holds the key to the 
eventual understanding of this disorder. 
Paralleling these laudable long-term goals are many more 
immediate challenges such as:
• The gendered aspects of drug use during pregnancy 
with the attendant exacerbation of stigma; 
• The relative impact of the adverse consequences of 
licit drugs such as alcohol and tobacco, as distinct 
from more high profile illicit drugs including cocaine, 
methamphetamines and heroin; and
• The compromised nutritional status of the mother and 
child during formative periods of development. 
Clearly, simple approaches to this most complex form of human 
disorder are destined to failure. 
The Canadian Institutes of Health Research and NeuroDevNet, 
a network of centres of excellence in brain development, 
recognize that complex medical conditions, including 
addiction and mental ill-health, can be best understood from 
a multidisciplinary perspective that recognizes the biological, 
social and environmental determinants of such disorders. 
Accordingly, we applaud the initiative of the Canadian Centre 
on Substance Abuse (CCSA) for its invaluable work bringing 
evidence-based knowledge about issues of critical importance 
to the health impacts of addiction to a broad cross-section of 
Canadian society. 
For its part, the Institute of Neurosciences, Mental Health and 
Addiction remains committed to the support of research into 
all aspects of addiction, with the explicit goal of improving the 
understanding and treatment of substance abuse disorders 
in their many and varied forms. NeuroDevNet is very aligned 
with this stance and one of its key research projects is to 
understand how the fetus is impacted by exposure to ethanol 
and to diagnose and treat children who have been affected by 
ethanol during the early formation of the brain. It is clear that no 
level of embryonic exposure to ethanol or illicit drugs can be 
thought to be safe. 
Hopefully, the combined goals of an informed society and a 
multipronged research effort committed to innovative strategies 
to address complex medical problems can improve the 
treatment of addiction in the near term for both mother and 
child alike. 
Anthony G. Phillips, Scientific Director 
CIHR Institute of Neurosciences, Mental Health and Addiction
Professor, Department of Psychiatry, University of British Columbia
Senior Scientist, UBC/VCHRI Brain Research Centre
Dan Goldowitz, Co-director
Centre for Molecular Medicine and Therapeutics, Child and Family 
Research Institute
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Launched in 2005, the Substance Abuse in Canada series 
highlights key contemporary issues related to substance abuse 
along with specific areas for action in both policy and practice. 
Developed through analyses and reviews of the latest research 
evidence, each Substance Abuse in Canada report is intended 
for a broad audience that includes policy makers, program 
development personnel, researchers, educators and health 
professionals. Health journalists also make up an important 
readership of this report as they can help raise the public profile 
of the issues and help create the impetus for change.
This fourth Substance Abuse in Canada report addresses 
the medical and obstetrical consequence of drug abuse and 
dependency in pregnant women as well as the short- and 
long-term effects prenatal exposure to drugs can have on the 
development of their children. (Although we lack a large research 
portfolio in the area of childhood outcomes, studies indicate 
what can be expected when infants are exposed to drugs in 
utero.) This report also details the various treatment approaches 
essential to avoiding or reducing adverse outcomes in women 
who are pregnant and using substances and their infants, which 
includes comprehensive prenatal care and medication-assisted 
treatment. Finally, it concludes with a Call to Action that draws 
upon the themes explored throughout the earlier chapters. 
It should be noted that this report is not meant to be a systematic 
review of this topic area; instead, it is intended to provide 
readers with a high-level overview of this important health issue. 
The next report in the Substance Abuse in Canada series, to 
be published this coming spring, is a companion to the current 
report. It will focus on influences in childhood and adolescence 
that can affect later life substance abuse and the implications 
an understanding of those influences has for prevention and 
treatment.
A stigmatizing issue
Women’s drug abuse is a major public health problem in 
Canada and around the world. Too often have we heard 
dramatic statements from physicians and nurses about 
the growing numbers of pregnant women who use illicit 
substances, accompanied by descriptions of infants who suffer 
from prenatal exposure to drugs. 
Women who use drugs—especially pregnant women—are 
more heavily stigmatized than their male counterparts. This 
stigmatization makes them generally reluctant to “emerge from 
the shadows” and seek help for their problems. Even when they 
do, they tend to face significant barriers to obtaining appropriate 
medical and obstetrical services, from misinformation to denial 
and even inaction on the part of healthcare professionals. Such 
attitudes need to change, especially given that substance 
dependence is considered a chronic, relapsing brain disease 
that should be evaluated and treated in the same way as any 
other chronic disease.
Addressing the complex challenges related to the causes and 
outcomes of drug dependency in pregnant women requires 
a broad understanding of not only the medical aspects of 
addiction but also its psychological and sociological elements. A 
multifactorial and multidisciplinary approach is therefore needed 
to help women break free from their addictions and prevent the 
occurrence of negative consequences for themselves and their 
offspring. 
Addiction is just the beginning
Whether licit or illicit, psychoactive drugs act primarily upon the 
central nervous system, altering brain function and resulting in 
Introduction
THE SERIES TO NOW
The first Substance Abuse in Canada report, Current Challenges 
and Choices, examined a variety of topics, including the prevention 
of alcohol problems, alternative sanctions for cannabis use and 
possession, drug-impaired driving, and the abuse and diversion of 
prescription medication. 
The second report, Focus on Youth, looked at the prevalence of 
substance use and its associated harms among young people, 
exploring the underlying neurobiology of substance use in 
adolescence and identifying existing gaps in youth-centric services. 
The third edition, Concurrent Disorders, focused on the co-
occurrence of mental health and substance abuse problems, 
examining the interconnections between addiction and mental illness, 
the tremendous costs concurrent disorders places on Canada’s 
healthcare system, and why treating these complex cases requires 
new and innovative approaches.
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changes in perception, mood, consciousness and behaviour. 
They provide pleasure and ameliorate pain. And they can 
also cause physical dependence and tolerance, with many 
individuals finding they need to increase their dosage over time 
to achieve the same effects. 
Regardless of the pharmacological properties of the drugs 
used, the characteristics of the person taking them and the 
consequences of continued drug abuse combine to produce 
a multifactorial and exceptionally challenging condition for any 
individual, especially for pregnant women. Compulsive drug use 
is only part of the picture; factors such medical complications, 
family dysfunction, legal problems, educational deficits, low 
socioeconomic status, psychiatric disorders, social issues, and 
physical and sexual abuse can all be involved and affect the 
future development of the child.
Putting knowledge into practice
Although much progress has been made in the field of addiction 
medicine over the past few decades, the latest scientific 
advances have not yet been fully translated into real-world 
practice, where they are needed most. Continued attention 
to the most recent evidence-based studies is essential to 
providing the best possible care and support for women who 
are addicted and to assessing the overall immediate and long-
term effects of in utero drug exposure in their children. We 
also need to increase funding as well as research and clinical 
capacity in the field to further define this complex issue.
TERMINOLOGY NOTES
Several of the terms used in this document have specific and distinct clinical significance, but to avoid repetition have been used as equivalents. 
Unless otherwise noted, the definitions below are based on those provided in the fourth edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV-TR).
• Addiction: Generally applied to patterns of heavy use of psychoactive drugs. While addiction has been replaced technically by the more 
specific term “substance dependence,” it continues to be used widely. Addiction is generally thought of as compulsive use leading to 
physical symptoms of withdrawal when use is discontinued. For that reason, it is often equated with physical dependence.
• Substance dependence*: Also referred to as “drug dependence,” this constitutes a cluster of cognitive, behavioural and physiological 
symptoms indicating continued substance use despite the occurrence of significant substance-related problems. It involves a pattern of 
repeated self-administration that usually results in tolerance, withdrawal and compulsive drug-taking behaviour.
• Substance abuse*: Also known as “drug abuse,” this term refers to a maladaptive pattern of substance use resulting in recurrent and 
significant adverse consequences related to the repeated use of a drug. Substance abuse is not characterized in terms of tolerance 
and withdrawal; instead, it includes only the harmful consequences of repeated use (for example, when such use becomes physically 
hazardous; causes failure to fulfill obligations at work, school or home; or creates legal, social or interpersonal problems). Although it is 
often taken to also mean substance use, Jaffe (1985) clarifies that “drug abuse refers to the use, usually by self-administration, of any 
drug in a manner that deviates from the approved medical or social patterns within a given culture.”
• Withdrawal: Withdrawal occurs when the chronic intake of a substance is abruptly discontinued.
• Tolerance: The need to use an increasing amount of a drug to attain the desired effects, or the decreased intensity in effects 
experienced with the continued use of the same amount of the substance.
• Intoxication: The development of a reversible, substance-specific syndrome during or after substance use. It becomes a clinical 
problem when significant maladaptive patterns of behaviour lead to distress and impairment.
• Morbidity: From the Latin word “morbidus” (meaning “sick” or “unhealthy”), this term refers to a state of disease or disability from any 
cause. It can be used to refer to the existence of any form of disease as well as the degree to which a disease affects an individual.
* The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) combines the DSM-IV-TR categories of “substance abuse” 
and “substance dependence” into a single disorder measured on a continuum from mild to severe (American Psychiatric Association, 2013).
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As this report outlines, the best public health result for 
women who are pregnant and using substances and babies 
exposed to maternal drug use  can be obtained only once the 
barriers to effective intervention have been removed, allowing 
women to finally receive the services they need in supportive, 
nonjudgmental and multidimensional treatment settings.
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1.1 Prevalence of drug use in 
pregnant women
1.1.1 Canada
Details on the epidemiology of drug use among pregnant 
women can be gleaned from a variety of sources. For example, 
there is the 2006–2007 Maternity Experience Survey, which 
surveyed Canadian women aged 15 and older who had a 
singleton live birth during a three-month period preceding the 
2006 Census of Population. Its results revealed that 10.5% of 
women smoked cigarettes daily or occasionally during the last 
three months of pregnancy; 10.5% reported drinking alcohol 
during their pregnancy; and 1% used street drugs during 
pregnancy (Public Health Agency of Canada, 2009). 
Epidemiology is the study of the distribution and determinants of health-related states or incidents—and is extremely important to consider when examining the issue of substance use and addiction. The epidemiology of drug use has typically 
focused on identifying specific risk factors at the following levels: individual (e.g., genetic 
factors, high-risk behaviours), family (e.g., child abuse), community (e.g., availability of 
drugs) and societal (e.g., policies, laws). Through the data gathered from this research, 
which includes cross-sectional studies, longitudinal studies and clinical experiments, a 
foundation has been created for better understanding the extent of drug use, abuse and 
dependence; informing basic, clinical, treatment and services research; and developing 
drug-prevention strategies (Compton et al., 2005).
Data at the national level was also provided by the 2008 
Canadian Perinatal Health Report, which found that 11% of 
pregnant women consumed alcohol and 13% smoked cigarettes 
during the past month. An additional 5% of pregnant women 
also reported illicit drug use during pregnancy. However, given 
the systematic under-reporting of substance abuse, the actual 
prevalence rates are probably higher (Ordean & Kahan, 2011).
The Canadian Community Epidemiology Network on Drug Use 
(CCENDU) is a surveillance project that promotes networking 
among Canadian agencies with common interests in local, 
national and international drug trends. In 2010, CCENDU 
partner agencies collected data on alcohol and drug use in 
seven cities across Canada, examining rates of substance use 
1
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prevalence, treatment, enforcement, prevention, morbidity and 
mortality. Although information on pregnant women represented 
just a fragment of the data collected, the 2010 CCENDU site 
reports did include the following highlights:
• In Saskatoon, respondents reported observing an 
increase in the number of women using various 
substances (namely alcohol, cocaine/crack and 
cannabis) during pregnancy. Survey respondents 
also indicated a lack of services to support pregnant 
women with substance use issues. 
• In Winnipeg, the rate of maternal alcohol consumption 
during pregnancy ranged from 10.7% to 12.5% for the 
years 2003 through 2006. During this same period, 
the average rate of maternal smoking during pregnancy 
was 21% (and as high as 43% in some of Winnipeg’s 
12 Community Areas).
In addition, a report from the Reproductive Health Working Group 
in Alberta indicated that 2.3% of women who gave birth to live 
infants in 2006 reported using street drugs while pregnant, with 
cannabis being the most commonly used substance (Porath-
Waller, 2009).
At a Glance
• Epidemiology is the study of the factors related to and distribution of health-related states or 
incidents among different groups of people.
• Tobacco and alcohol are the most common substances used by pregnant women in Canada and 
the United States.
• The use of illicit drugs by pregnant women is comparatively lower than for tobacco and alcohol, 
yet still represents a significant percentage of use in Canada and the United States. 
• Cannabis is the most common illicit substance used among pregnant women.
• Substances used during pregnancy vary by the race and ethnicity of women.
• Children of parents with untreated substance use disorders are at greater risk of developing their 
own substance-related problems later in life.
Canadian Centre on Substance Abuse10
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With regard to the country’s population as a whole, the 2011 
edition of the Canadian Alcohol and Drug Use Monitoring 
Survey found that among Canadian women of childbearing age 
(i.e., 15–44 years), 76.7% reported past-year consumption of 
alcohol, nearly 11% reported past-year use of cannabis, and 
2.1% reported past-year use of illicit drugs such as cocaine, 
ecstasy, speed, hallucinogens (including salvia) and heroin 
(Health Canada, 2012).
1.1.2 United States
In the United States, the 2010 National Survey on Drug Use and 
Health (NSDUH) found that 4.4% of pregnant women aged 15–
44 reported illicit drug use1 during the past 30 days. In contrast, 
the prevalence of illicit drug use among non-pregnant American 
women in the same age group was 10.9% (Substance Abuse 
and Mental Health Services Administration [SAMHSA], 2011).
In addition, the 2010 NSDUH also found that among pregnant 
women aged 15–44: 
• 10.8% reported past-month alcohol use;
• 3.7% reported past-month binge drinking;2
• 1.0% reported past-month heavy drinking;3
• 10.1% reported binge drinking in the first trimester of 
pregnancy (i.e., during the embryonic and early fetal 
stages); and
• 16.3% reported past-month cigarette smoking (with 
even higher rates among pregnant women in the 15–
25 age group, where 22.7% smoked cigarettes). 
Marijuana is the most commonly used illicit drug among 
pregnant women. A review of NSDUH data from 2002 to 2007 
found that 4.6% of women aged 18–44 reported past-month 
marijuana use during the first trimester, 2.9% reported use in the 
second trimester and 1.4% used marijuana in the third trimester 
of pregnancy (SAMHSA, 2009). 
Data collected from NSDUH surveys conducted between 2002 
and 2010 also indicate that substance use during pregnancy 
varies by race and ethnicity (SAMHSA, 2012a). Reviewers 
found that pregnant white women had higher rates of cigarette 
smoking (21.8%) than both pregnant African-American women 
(14.2%) and pregnant Hispanic women (6.5%). Levels of self-
reported alcohol use were fairly similar between pregnant white 
women and pregnant African-American women (12.2% and 
12.8%, respectively), while Hispanic women had the lowest 
rates of alcohol use during pregnancy (7.4%). Finally, African-
American women were found to have the highest rates of illegal 
drug use during pregnancy (7.7%), followed by pregnant white 
women (4.4%) and pregnant Hispanic women (3.1%). 
1.2 Prevalence of drug use in non-
pregnant women with children
The children of parents with untreated alcohol use disorders 
are at far greater risk of developing their own problems with 
alcohol and other substances later in life (SAMHSA, 2012b). 
Therefore, for the purposes of developing appropriate 
prevention and treatment strategies, it is also important to look 
into the prevalence of drug use among women who are no 
longer pregnant but still have children living in their households.
According to a review of NSDUH from 2005 to 2010, 
approximately 7.5 million American children under the age 
of 18 (or 10.5% of all children) lived with a parent who had 
experienced an alcohol use disorder in the past year (SAMHSA, 
2012b). Of these children, 6.1 million lived with two parents 
(with either one or both experiencing an alcohol use disorder in 
the past year) and the remaining 1.4 million children lived in a 
single-parent household.
Using data from the 2003 NSDUH, Simmons and colleagues 
(2009) sought to identify maternal risk factors by examining the 
prevalence of past-year illicit drug abuse or dependence among 
American women with children less than 18 years of age. They 
found that approximately 2% of the mothers reported illicit drug 
abuse or dependence, with these women more likely to be 
unmarried, have stress in their lives, have poorer health status 
and meet criteria for mental illness. Similarly, studies on female 
substance abuse treatment patients have found that women 
tend to have lower education levels and employment rates than 
men as well as a lower average age at admission into treatment. 
These characteristics generally lead to a lack of preventive and 
treatment services (Gomberg, 1993; Chou, 1994).
1 Illicit drugs include marijuana, cocaine (including crack), heroin, hallucinogens, inhalants and the non-medical use of prescription psychotherapeutics.
2 Binge drinking is defined as having five or more drinks on the same occasion at least once during the past 30 days.
3 Heavy drinking is defined as having five or more drinks on the same occasion five times or more during the past 30 days.
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LAUREN 
Lauren is 17 and lives in Toronto. She has a younger 
brother and sister, both by different fathers. Her mother 
is addicted to crack cocaine. When Lauren was 10, 
her stepfather began sexually abusing her. He was also 
physically abusive of Lauren and her mother. It took 
Lauren a long time to summon the courage to tell her 
mother about her stepfather’s late-night visits to her 
bedroom—and when she did, her mother did nothing 
about it. At just 12, she started drinking alcohol and 
smoking cigarettes as a way to escape. At 14, she ran 
away. Without a job, and resolved not to return home, 
she ended up living on the street. That’s where she met 
25-year-old Eric. 
Lauren felt he genuinely cared for her: he provided her 
with food and clothes, and would listen to the stories of 
her abusive home life. As their relationship deepened, 
he convinced her to let him rent her a room at a hotel. 
Lauren became very attached to Eric. She believed they 
loved each other and felt indebted to him, so when he 
asked her to help pay for the room through prostitution, 
she agreed. That began years of working on the street, 
accompanied by cycles of abuse. Lauren became 
addicted to heroin and cocaine, and also used marijuana 
and amphetamines. She continues to depend on drugs 
to cushion the pain of her daily life.
Canadian Centre on Substance Abuse12
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of Drug Use   
in Women
When non-medically prescribed drug use or abuse occurs in pregnant women, considerable morbidity can be expected for both the mother and her offspring. In particular, illicit drug use during pregnancy places the mother at increased 
risk of a variety of obstetrical complications, which are listed below according to time in 
the pregnancy:
This chapter outlines the specific medical and obstetrical outcomes associated with the use of several different types of drugs, 
including opioids, cocaine, amphetamines, methamphetamines, cannabis, tobacco and alcohol.
• Early pregnancy loss;
• Abruptio placentae (premature detachment of the 
placenta from the wall of the uterus); 
• Amnionitis (inflammation of the amnion, the thin 
membrane surrounding the fetus that contains the 
amniotic fluid);
• Intrauterine growth restriction;
• Placental insufficiency;
• Septic thrombophlebitis (a condition characterized by 
a venous clot, inflammation and infection);
• Pre-eclampsia (a sudden rise in blood pressure, 
excessive weight gain, generalized edema, 
proteinuria, severe headache and visual 
disturbances); 
• Eclampsia (convulsions or coma occurring with 
pregnancy-associated high blood pressure); 
• Late intrauterine death; 
• Premature labour;
• Premature rupture of membranes; and 
• Postpartum hemorrhage.
2.1 Opioids
Opioids generally refer to morphine-like synthetic narcotics (e.g., 
heroin, methadone, oxycodone, propoxyphene) that produce 
the same effects as drugs naturally derived from the opium 
poppy (e.g., opium, codeine, morphine), which are collectively 
referred to as opiates. As pain relief is among these effects, 
opioids are some of the most common drugs taken during 
pregnancy. Although the onset and intensity of the effects will 
vary based on how the drug is taken and its formulation, all 
opioids have the potential for overdose, abuse, dependence 
and addiction. 
Incidence of opioid abuse has been increasing at an alarming rate, 
especially among teens and young adults. In fact, the number 
of Americans abusing prescription medications has more than 
2
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At a Glance
• Women generally progress more quickly than men into alcohol dependence and other related 
medical problems, such as circulatory disorders, cirrhosis of the liver and hypertension, and 
have a higher rate of premature death.
• Women are also at greater risk of experiencing severe cocaine-related health problems 
compared to men.
• Women who abuse opioids may progress more quickly to addiction than men.
• Pregnant women with opioid addictions tend to seek out prenatal care late in pregnancy or 
not at all.
• Substance use during pregnancy increases the risk of various medical and obstetrical 
complications, such as early pregnancy loss, premature labour and postpartum hemorrhage.
• Amphetamines may reduce the production of breast milk and can be transmitted to the baby 
by nursing mothers.
• Heavy use of cannabis has been linked to decreased fertility among both women and men 
and an increased risk for a failed pregnancy.
• Tobacco smoking is associated with cancers of the ovaries and cervix, which may cause 
concern for a woman’s reproductive health. 
• Smoking can cause significant health risks for an infant and child, both in utero and 
postnatally through exposure to second-hand smoke.
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doubled over the past decade, with more than 1.9 million new 
non-medical users aged 12 years or older of prescription pain 
relievers reported in 2012 alone (Substance Abuse and Mental 
Health Services Administration, 2013). Research has also shown 
that women who abuse opioids may progress more quickly to 
addiction than men. For instance, women are more likely than 
men to become addicted to heroin within one month of initial 
exposure (Hernandez-Avila, 2004). Women also escalate their 
use of heroin more rapidly and tend to become addicted within a 
shorter period of time (Anglin et al., 1987).
Opioid abuse can have a number of severe neurological 
consequences. Heroin, for example, has been shown to have 
negative effects on brain function, affecting attention span, 
memory and verbal fluency (Guerra et al., 1987; Kamboj et 
al., 2005). Studies have also found that heroin abusers exhibit 
impaired verbal function, visual-spatial analysis, impulse control 
and mental planning (Lee & Pau, 2002; Prosser et al., 2006; 
Davydov & Polunina, 2004). Such effects can seriously affect a 
person’s ability to care for his or her own health and, in the case 
of pregnant women, for newborn children. 
The chaotic lives of opioid-abusing women (e.g., sharing 
unclean needles for injection, turning to theft or prostitution to 
support their addictions) and the frequent lack of consistent 
prenatal care put them at risk of a variety of medical problems 
during pregnancy. In particular, heroin-abusing women may 
suffer from conditions such as anemia, bacteremia, septicemia, 
bacterial endocarditis, cellulitis, endocrinopathies, hepatitis, 
phlebitis, pneumonia, tetanus, tuberculosis, urinary tract 
infections and a number of sexually transmitted infections. 
Miscarriages are also prevalent in untreated heroin-addicted 
women. As well, the nutritional deficiencies resulting from 
the many medical complications associated with opioid use, 
overdose and withdrawal can be problematic for the developing 
fetus (Finnegan, 1976, 1981; Finnegan & Kandall, 1992, 
2008, 2010). For example, intrauterine passage of meconium 
(a substance in the fetal gastrointestinal tract composed of 
mucous, bile salts and cellular debris) can occur as a sign of 
fetal distress. This distress might be related to the repeated 
exposure of the fetus to opioid withdrawal as well as the effects 
of withdrawal on placental function (Center for Substance 
Abuse Treatment, 2005; American Congress of Obstetricians 
and Gynecologists [ACOG], 2012).
Pregnant women with opioid addictions tend to seek prenatal 
care late in pregnancy (or not at all, arriving at the emergency 
department already in labour); miss their appointments; 
experience poor weight gain; or exhibit signs of sedation, 
intoxication or erratic behaviour. On physical examination by the 
physician, signs of opioid use might include track marks from 
intravenous injection, lesions from subcutaneous injections 
(“skin popping”), abscesses or cellulitis. Positive results of blood 
tests for human immunodeficiency virus (HIV) or hepatitis can 
also indicate substance abuse (ACOG, 2011a, 2012). 
Additional risk factors that can alert obstetricians or family 
physicians to maternal drug abuse include an unexplained 
history of obstetrical or neonatal problems, homelessness, 
having a partner who is a drug user, a family history of drug 
abuse and a history of treatment with prescription drugs for 
chronic pain (Alto & O’Connor, 2011).
2.2 Cocaine
Cocaine use appears to affect women in different ways 
than men. First, women tend to use cocaine earlier in their 
patterns of concurrent addictions and move more quickly from 
their introduction to cocaine into abuse (Griffin et al., 1985; 
Mendelson et al., 1991; Haas & Peters, 2000). Women are 
also more likely than men to experience severe health problems 
related to cocaine use. It has been shown that chronic cocaine 
use can lead to potentially fatal myocardial alterations such as 
cardiac hypertrophy, fibrosis (scarring) and microangiopathy 
(Karch, 2005). Smoking crack cocaine produces more 
prolonged cardiovascular effects as well as higher cocaine 
plasma concentrations in women than in men (Evans et al., 
1999). Women are also more likely to report headaches and 
trips to the emergency room following crack cocaine use 
(Dudish & Hatsukami, 1996).
Women’s menstrual cycles affect how they experience the 
subjective effects of cocaine. The mood-altering effects of 
cocaine are experienced more strongly during the follicular 
phase of their menstrual cycle, when estrogen is high but 
progesterone is low. Later, in the luteal phase of the cycle when 
progesterone is higher, the effects of cocaine are not felt as 
strongly. It is suggested that progesterone plays a significant 
role in dampening the physical reaction to cocaine (Sofuoglu 
et al., 1999). 
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Cocaine use during pregnancy is associated with many adverse 
outcomes. For example, cocaine use can cause miscarriages 
in up to 38% of early pregnancies—most likely because of an 
increase in maternal plasma norepinephrine, which increases 
uterine contractility, constricts placental vessels and decreases 
blood flow to the fetus (Schempf & Strobino, 2008). In addition, 
placental abruption (the separation of the placenta from the 
uterus wall) accounts for up to 15% of the adverse effects 
experienced when cocaine is used during pregnancy—and is 
the primary reason why the incidence of stillbirth in cocaine-
abusing mothers is 8% greater than that of the general 
population. More common with cocaine binging than with 
regular use, placental abruption is thought to be caused by 
vasospasm (the constriction of blood vessels) and hypoxia 
(decreased oxygen transfer to the tissues) of the placental bed 
(Bhuvaneswar et al., 2008; Schempf & Strobino, 2008).
Because cocaine stimulates uterine contractility, there is also an 
increased risk of premature rupture of membranes and preterm 
labour or delivery, conditions that affect 17–29% of pregnancies 
of cocaine-abusing women. Intrauterine growth restriction and 
low birth weight can be found in 22–34% of all infants exposed 
to cocaine in utero, secondary to the constriction of the uterine 
blood vessels that leads to intermittent hypoperfusion (a 
decrease in circulation of blood to the tissues) of the uterus 
and placenta. In addition, appetite is significantly suppressed 
by cocaine, contributing to poor maternal and fetal nutrition 
(Schempf & Strobino, 2008).
Clinicians should observe pregnant cocaine users for 
hypertension, hyperthermia (greatly increased body 
temperature), abdominal pain and increased heart rate—and 
in the case of heavy cocaine use, arrhythmias, myocardial 
infarction, respiratory failure, stroke and seizures (National 
Institute on Drug Abuse, 2010). Hyperthermia mediated by 
vasoconstriction (constricted blood vessels) or the hyper-
metabolic state of cocaine use may also be observed; this 
should be considered an effect that might counteract the 
expected physiologic vasodilatation (and normal lowering 
of blood pressure) from increased levels of progesterone. 
Hyperthermia from multiple causes (including pyelonephritis 
and other infections) has been linked with prematurity, low 
birth weight and, in rare cases, fetal death (Bhuvaneswar 
et al., 2008).
Migraine headaches, which become more prevalent during 
pregnancy generally, are also more common among cocaine 
users. Dyspnea (shortness of breath) during pregnancy, owing 
to a decreased lung tidal volume from the compression of the 
lower lung fields by the expanding uterus, can also be indicative 
of so-called “crack lung” or pneumonitis in a cocaine user—a 
condition characterized by fevers, pulmonary infiltrates and 
leukocytosis (Bhuvaneswar et al., 2008).
2.3 Amphetamines
Commonly used as drugs of abuse, amphetamines are powerful 
central nervous system stimulants with a profound ability to 
increase wakefulness and focus. Amphetamines also increase 
the rate of release of neurotransmitters such as norepinephrine, 
serotonin and dopamine. (At the same time, they also inhibit re-
uptake of these neurotransmitters.) Drugs in the amphetamine 
family can serve a variety of traditional medicinal purposes; 
methylphenidate, for example is a very effective treatment for 
attention deficit hyperactivity disorder.
As with cocaine, women experience the euphoric and addictive 
effects of amphetamines more strongly during the early follicular 
phase of their menstrual cycles. Women in one study also 
reported craving and enjoying the effects of amphetamines 
more during the early phases of menstruation, particularly in 
times of high estrogen levels (Justice & deWit, 1999).
Amphetamine use, particularly among young pregnant patients, 
appears to be increasing (Cox et al., 2008). However, it does 
not seem to be associated with any consistent increase in 
congenital abnormalities above the background 3% population 
risk. Furthermore, there is no evidence of a consistent syndrome 
associated with first trimester amphetamine use (Smith et al., 
2006; Briggs et al., 2008).
That said, amphetamines have been found to inhibit the 
release of prolactin, potentially reducing a mother’s supply of 
breast milk (Anderson, 2010). In addition, the concentration of 
amphetamines found in breast milk is 2.8 to 7.5 times higher 
than those found in maternal plasma, with infants who ingest the 
breast milk of women using amphetamines exhibiting increased 
irritability and agitation (Briggs et al., 2008; American Academy 
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of Pediatrics Committee on Drugs, 2001). Amphetamines 
purchased illegally often contain a mixture of substances with 
unpredictable harmful effects on the woman and her infant; 
therefore, women who are actively using amphetamines should 
not breastfeed.
2.4 Methamphetamines
Methamphetamine is a more potent stimulant drug than its 
parent compound, amphetamine. It is the only illegal drug that 
can be easily made from legally obtained ingredients such as 
pseudoephedrine. Its widespread availability is fuelled by a 
lower cost compared to other illicit drugs of abuse as well as 
its ability to be produced in both large and small clandestine 
laboratories (Good et al., 2010; ACOG, 2011b). 
The consequences of long-term abuse of methamphetamines—
in particular, crystal meth and speed—include addiction, 
anxiety, confusion, insomnia, memory loss, weight loss, severe 
dental problems, depression and violent behaviour (Winslow 
et al., 2007). Long-term users can also display psychotic 
symptoms such as paranoia, delusions, and visual and auditory 
hallucinations—and these symptoms can persist for months or 
years after a person has stopped using the drug. Brain-imaging 
studies of long-term methamphetamine users have shown 
severe structural and functional changes in the areas of the 
brain associated with emotion and memory (ACOG, 2011b).
Methamphetamine addiction can be especially harmful to 
the pregnant woman and her baby, with a 2005 study by 
the University of Toronto finding that taking just one dose 
of methamphetamine during pregnancy can have dire 
consequences for the baby (Adlaf et al., 2005).
Of the various conditions associated with methamphetamine 
use, most worrisome for pregnant women are increased blood 
pressure and heart rate; exhaustion; poor personal and dental 
hygiene; mental disorders such as psychosis and depression; and 
decreased cognitive abilities (e.g., memory, judgment, reasoning, 
verbal learning). Pregnant methamphetamine users also tend to 
have a decreased appetite, which can lead to poor nutrition.
A study conducted by Good and colleagues (2010) in California 
examined the demographic characteristics and clinical morbidity 
of 276 methamphetamine-exposed pregnancies compared to 
34,055 control patients in the general obstetric population in 
a tertiary care, academic medical centre. Factors that were 
significantly associated with methamphetamine use were:
• Age younger than 20 years;
• Non-Hispanic white ethnicity;
• Married;
• Preterm delivery;
• Low Apgar scores; and 
• Caesarean delivery. 
The women using methamphetamines were also more likely 
to be unemployed, use other abusive substances and have 
higher rates of domestic violence when compared with the 
control population.
2.5 Cannabis
Three products can be derived from the cannabis plant 
(cannabis sativa): marijuana, which is made from dried flowers 
and leaves; hashish, which is made by drying and pressing the 
plant’s resin into small blocks; and hash oil, the most potent of 
the three, which is a thick oil obtained from hashish. 
The terms “marijuana” and “cannabis” are most frequently used 
to refer to this drug, which is used to heighten perception and 
affect a person’s mood. Its pharmacologically active ingredient, 
delta-9-tetrahydrocannabinol (THC), influences brain chemistry 
in a way similar to alcohol, affecting memory while slowing 
thinking and reflexes. Long-term effects of marijuana use may 
include decreased motivation as well as harmful effects on the 
brain, heart, lungs and reproductive system. People who smoke 
marijuana are also at increased risk of developing cancer of the 
head and neck (Diplock & Plecas, 2009). 
Heavy use of marijuana has been linked to decreased fertility 
in both men and women. In females, there is evidence that 
cannabis use might disrupt the menstrual cycle. In males, 
cannabis is thought to decrease sperm quality and testosterone 
levels. These factors can make it difficult for a woman to become 
pregnant when either partner is using marijuana (National 
Cannabis Prevention and Information Centre [NCPIC], 2011).
More alarmingly, a number of studies suggest that marijuana is 
a teratogen (i.e., something that can hinder the normal growth 
and development of a fetus) and that intrauterine exposure to 
cannabis might result in risks for the fetus. THC is known to pass 
from the mother to the fetus through the placenta and can be 
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DIANE 
Diane’s parents often fought, not only verbally but physically 
as well. One night during a particularly intense confrontation, 
Diane’s father accidentally killed her mother. Diane was 
two. She and her sisters were entrusted to the care of their 
maternal grandmother, who lived in a small house with Diane’s 
aunts. Growing up, Diane gradually became aware that her 
grandmother and aunts engaged in prostitution; her older 
sisters were eventually recruited as well. When Diane was 12, 
her sisters began grooming her to follow in their footsteps, 
assuring her she could make lots of money. Afraid and anxious, 
Diane ran away from home. She lived on the streets, stealing 
to subsist and getting clothes and food from friends when 
they were able to provide them. More than once, guys tried to 
convince her to engage in prostitution, but she resisted. 
Vaughn, a 27-year-old in the periphery of her social circle, was 
especially persistent. One night after Diane had been binge 
drinking with her friends, he injected her with heroin and posted 
explicit pictures of her on the Internet. After that episode, he 
used threats and humiliation to force her to perform sexual 
acts, keeping her locked up in an apartment for several months 
until she finally relented and agreed to work the streets. 
Today, Diane is addicted to heroin and pregnant, unsure who is 
the father. She has ulcers and abscesses from injecting heroin 
under her skin, and she has been treated for gonorrhoea. She 
is very worried about how her drug addiction will affect her 
unborn baby—and feels hopeless about ever escaping the life 
she’s caught in.
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found in the newborn’s body for up to a month after a single use. 
As such, the fetus is affected by any amount of marijuana taken 
by the pregnant woman, placing it at greater risk for potential 
complications. In addition, any form of smoking can disrupt the 
supply of oxygen and nutrients to the fetus, which can result in 
restrictions to the growth of the fetus (including overall length, 
foot length, head size and body weight) and, in rare cases, 
premature birth, miscarriage and stillbirth (NCPIC, 2011). 
A study conducted by El Marroun and colleagues (2009) 
examined the relationship between maternal cannabis use 
and fetal growth until birth in a population-based sample. 
Approximately 7,452 mothers in the Netherlands had fetal 
growth determined by ultrasound measures during the 
early, middle and late stages of pregnancy. Birth weight was 
also recorded. This study showed that, compared to non-
exposed fetuses, maternal cannabis use during pregnancy 
was associated with growth restriction during mid- and late 
pregnancy as well as newborns with lower birth weights and 
smaller head circumferences. The growth reduction was 
most pronounced for fetuses exposed to continued maternal 
cannabis use during pregnancy, suggesting a dose-response 
relationship. Paternal cannabis use was not associated with 
fetal growth restriction.
A large international study of more than 3,000 pregnant women 
in Australia and New Zealand detailed the most common risk 
factors for preterm birth. Among the factors delineated was 
that women who used marijuana prior to pregnancy more than 
doubled their risk of premature birth (Dekker, 2012). Similarly, a 
2006 study conducted by Vanderbilt University Medical Centre 
in Tennessee showed that women who smoke marijuana are at 
greater risk for a failed pregnancy because the drug can upset 
the chemical balance necessary for the safe passage of the 
embryo from the fallopian tube down to the uterus, potentially 
resulting in an ectopic (tubal) pregnancy or miscarriage (Dey 
et al., 2004). 
2.6 Tobacco
The causal link between cigarette smoking and lung cancer has 
been well established: almost 80% of all lung cancer deaths in 
female smokers are attributable to smoking and, by 1987, lung 
cancer had surpassed breast cancer as the leading cause of 
cancer-related deaths in American women (Office on Smoking 
and Health, 2001; Parkin et al., 2005; Centers for Disease 
Control and Prevention, 2006). 
Research also suggests women are more susceptible than 
men to the cancer-causing compounds found in tobacco 
smoke. A study of lung cancer patients in Poland revealed 
that women developed lung cancer at younger ages despite 
consuming fewer cigarettes per day and smoking for a 
shorter duration than men (Radzikowska et al., 2002). This is 
supported by the finding that the gene for the gastrin-releasing 
peptide receptor (which, when activated, has a demonstrated 
association with the proliferation of bronchial cells) is located 
on the X chromosome (Shriver et al., 2000). Similarly, females’ 
pulmonary systems may be more swiftly compromised by 
long-term smoking, putting women smokers at greater risk of 
death due to chronic obstructive pulmonary disease (Jonas 
et al., 1992).
For women who are pregnant or planning to become 
pregnant, cancers of the reproductive system associated with 
smoking must be considered a significant health concern. 
Studies have suggested that tobacco use is associated with 
a higher incidence of both ovarian and cervical cancers. 
Cigarette smoking, however, also appears to interact with 
women’s systems in unique ways, possibly reducing the risk 
of endometrial cancer and causing other estrogen-associated 
effects (Kay et al., 2010). In studies that controlled for the effect 
of human papillomavirus (HPV) infection (a recognized cause 
of the majority of cervical cancers), tobacco use was found to 
increase the risk of cervical cancer among women who were 
already HPV-positive. Tobacco use was also a more significant 
risk factor for cancer of the cervix than other environmental risk 
factors such as diet, sexual history and oral contraceptive use 
(Plummer et al., 2003).
A direct relationship between cigarette smoking and breast 
cancer has not been clearly established, with many studies 
failing to find tobacco use to be a significant risk factor for the 
disease (International Agency for Research on Cancer, 2004). 
Other evidence, however, suggests such as association may 
exist; in four of eight case-control studies reviewed in Japan, 
moderate or strong associations between smoking and breast 
cancer risk were observed (Nagata et al., 2006). More recently, 
Gaudet and colleagues (2013) analyzed data from a large 
cohort of American women and conducted a meta-analysis of 
their results with those published from 14 other cohort studies. 
Their findings suggest that active smoking is associated with 
increased risk for breast cancer among women who initiated 
smoking before their first birth. 
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Overall, women who begin smoking at an early age and 
continue at high doses throughout their childbearing years 
are not only at higher risk for smoking-related diseases—their 
smoking could also result in significant health implications for 
the infant and child (both in utero and through exposure to 
second-hand smoke).
2.7 Alcohol
In general, women tend to progress more quickly than men 
into alcohol addiction and the development of the physiological 
consequences of alcohol abuse (Orford & Keddie, 1985; 
Randall et al., 1999; Diehl et al., 2007). There is also 
considerable evidence that women move more quickly from 
first use to addiction (Kay et al., 2010).
In addition, medical problems associated with alcohol use 
progress more swiftly in women. Female alcoholics have 50–
100% higher rates of premature death than male alcoholics, 
with more female alcoholics dying from circulatory disorders and 
cirrhosis of the liver than their male counterparts (Ashley et al., 
1977; Hill, 1982). Even with shorter durations of heavy drinking 
than their male counterparts, women have comparable incidence 
rates of diseases associated with alcoholism such as ulcer 
disease, gastrointestinal hemorrhage, liver disease, hypertension, 
obesity, anemia and malnutrition (Ashley et al., 1977).
Many women begin to use and abuse alcohol starting in 
their teenage years. By the time they reach the end of their 
childbearing years they will have caused considerable damage 
to their bodies and, potentially, those of their unborn children.
For more details on the obstetrical effects and early childhood 
outcomes of alcohol use during pregnancy, please refer to the 
section on fetal alcohol spectrum disorder in Chapter 4.
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It is estimated that two-thirds of women with substance abuse 
problems also have concurrent mental health problems, with 
drug-dependent and alcohol-using women often manifesting 
psychiatric conditions such as anxiety, depression, post-
traumatic stress disorder (PTSD) and panic disorder. And 
because pregnant women are susceptible to tremendous 
emotional changes, pregnancy is a time of heightened 
vulnerability to the exacerbation of pre-existing psychiatric 
condition (Cox et al., 1979; Evans et al., 2001). 
Numerous studies in medical literature describe the co-
occurrence of substance abuse and psychiatric disorders; for 
instance, the 2009 volume of this Substance Abuse in Canada 
series, Concurrent Disorders, describes the many ramifications 
of concurrent disorders.
3.1.1 Depression and anxiety
Based on the available data, affective disorders such as 
depression and anxiety are among the most common forms of 
To address the issue of substance abuse in pregnant women, it is first necessary to understand why these women turn to alcohol and other drugs in the first place. The reasons, not surprisingly, are many. Among them are psychosocial issues and 
histories of victimization, both of which can prevent or make it extremely difficult for 
women to access the services and supports that would otherwise help them and prevent 
adverse consequences for their developing children. 
mental illness in substance-abusing women. In a retrospective 
chart review of 276 opioid-dependent pregnant women, 
42% had a diagnosis of depression and 42% had an anxiety 
disorder (Wachman et al., 2010). Another study of 174 opioid-
dependent pregnant women conducted by Benningfield and 
colleagues (2010), who used cross-section data collected as 
part of the Maternal Opioid Treatment: Human Experimental 
Research (MOTHER) Study, found that more than 60% exhibited 
symptoms that resulted in a positive screen for one or more 
psychiatric diagnoses. Specifically, 48.6% endorsed symptoms 
of a mood disorder and 40% endorsed symptoms of an anxiety 
disorder at some point in the past 30 days. In addition, nearly 
one-third (32%) of the women reported symptoms consistent 
with major depressive disorder and 16% reported symptoms 
consistent with PTSD.
The study by Benningfield (2010) also found that the women 
with psychiatric co-morbidities had higher degrees of 
medical and social impairment than those without additional 
psychiatric diagnoses.
3
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At a Glance
• About two-thirds of women with substance abuse problems have co-occurring mental health 
problems, such as depression, anxiety and post-traumatic stress disorder.
• A large proportion of women with substance abuse problems are also victims of physical abuse 
and sexual assault. Such victimization has been linked with various mental health outcomes, suicide 
and low self-esteem.
• Untreated psychiatric and substance use disorders can have negative health consequences for 
both the mother and child and can result in poor parenting, and child neglect or abuse.
Unless promptly and appropriately diagnosed and treated, 
depression can increase a pregnant woman’s risk of: 
• Pre-eclampsia (Kurki et al., 2000);
• Low infant birth weight and delivery complications 
(Steer et al., 1992); 
• Poor weight gain and postpartum depression (Gotlib 
et al., 1989);
• Suicide (Lindahl et al., 2005); and 
• Decreased maternal responsiveness, resulting in 
impairment of the infant’s socio-emotional functioning 
and development (Weinberg & Tronick, 1998). 
Women with low self-esteem who lack attachment to their unborn 
children during pregnancy also have a higher risk of developing 
postnatal depression (Priel & Besser, 1999), while women who 
suffered from depression during or after pregnancy have a 
greater prevalence of future depressive episodes (Beck, 2001). 
It has also been shown that women suffering from depression 
tend to seek prenatal care on a less frequent basis (Kelly et 
al., 1999) and are more likely than non-depressed women 
to use alcohol, cigarettes and other drugs during pregnancy 
(Zuckerman et al., 1989).
A study by Cormier and colleagues (2004) looked at the physical 
and mental health consequences of alcohol and drug use by 
Canadian women and several subgroups of women, including 
elderly women, Aboriginal women and pregnant women. Among 
those who reported heavy drinking, 25.7% had felt sad or 
depressed in the previous two weeks. In addition, 15% of heavy-
drinking women reported visiting a mental health professional in 
the previous 12 months and 18.6% had seriously considered 
committing suicide. Of the women who had considered suicide, 
37.3% had attempted to take their own lives.
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Exacerbation of such psychological problems can occur with 
the use of stimulants, especially among women. A study by 
Wisniewski and colleagues (2006) established an association 
between illicit drug use and higher concentrations of cortisol, 
which may lead to more depressive symptoms. This study 
found that among heroin and cocaine users, the association 
was more pronounced in women—and that female users 
with elevated cortisol concentrations were significantly more 
depressed than other participants in the study. (It should be 
noted that this mechanism is not yet fully understood because it 
is unknown whether high cortisol levels precede depression or 
are an associated effect.)
3.1.2 Other disorders
Depression and anxiety are not the only psychiatric conditions 
linked to substance-using women. The U.S. National Violence 
Against Women Survey (Tjaden & Thoennes, 2000) found that 
female crime victims suffering from PTSD are 17 times more likely 
to have major drug abuse problems than the general population. 
The study also revealed that individuals with a history of PTSD 
symptomatology make use of substance abuse inpatient 
services more frequently than their non-PTSD counterparts. The 
co-occurrence of substance abuse and PTSD can therefore 
predict a more severe course than would ordinarily be the case 
with either disorder alone (Tjaden & Thoennes, 2000). 
A high correlation also appears to exist between eating disorders 
and substance abuse. As many as 55% of bulimic women are 
reported to have drug and alcohol use problems, while 15–40% 
of women with drug abuse or alcohol problems have been 
reported to have eating disorder syndromes, usually involving 
binge eating (Gosnell & Krahn, 2010).
3.1.3 Detection and treatment of 
psychosocial issues
Using a medical record review in conjunction with validated 
psychiatric screening instruments, Kelly and colleagues (1999) 
assessed the detection and treatment of psychiatric disorders 
and at-risk substance use among pregnant women receiving 
prenatal care in California. They found that nearly 40% of the 
women had high levels of symptoms associated with psychiatric 
disorders or substance use (or both at the same time). 
Approximately 20% of the women met screening criteria for drug 
or alcohol use either before or during pregnancy, and among 
the women who screened positive for alcohol or substance use, 
more than half met the criteria for a depressive disorder.
That said, Kelly’s team cautioned that the population studied, 
which was derived from a university-based obstetrics clinic 
serving low-income minority women, may not accurately reflect 
the prevalence of mental illness and substance use among the 
general population of pregnant women. Despite this caveat, the 
data from Kelly’s team do suggest that a substantial number 
of women cared for in an obstetrical setting suffer psychiatric 
or substance use disturbances during pregnancy. Their results 
also demonstrate that under-recording of such disturbances is 
not limited to hospital discharge records: it exists throughout 
prenatal care and is accompanied by low documented rates 
of mental health and substance use evaluation and treatment. 
Given that untreated psychiatric and substance use disorders 
during pregnancy can have negative consequences for both 
maternal and infant health (Zuckerman et al., 1989; Steer et 
al., 1992; Weinberg & Tronick, 1998), the high frequency of 
such disturbances, combined with the low rate of detection 
and treatment by healthcare providers, is a serious concern for 
pregnant women in obstetrical settings (Kelly et al., 1999).
3.2 Victimization
Many addicted women share a history of past or current 
physical abuse and sexual assault, with numerous reports in 
the United States and Canada linking victimization and drug 
abuse (Zilberman et al., 2003; Finnegan & Kandall, 2008). 
A review by Cormier and colleagues (2004) reported that 
a large proportion of women with substance use problems 
are victims of domestic violence, incest, rape, sexual assault 
and childhood physical abuse (Ouimette et al., 2000; Brems 
et al., 2002; Freeman et al., 2002; Simpson & Miller, 2002). 
Among women in the general population, such victimization has 
been associated with a number of adverse health outcomes, 
including PTSD, depression, anxiety, suicidal behaviour and 
low self-esteem (Briere & Runtz, 1993; Kolko, 1996). Among 
those in treatment for substance use problems, women who 
have been abused are more likely than non-abused women to 
suffer from depression, suicidal ideation, low self-esteem and 
PTSD (Gil-Rivas et al., 1996; Daley & Argeriou, 1997; Guitierres 
& Todd, 1997; Najavitis et al., 1997; Kang et al., 1999; Coker 
et al., 2002).
In a study of women entering a Philadelphia drug abuse 
treatment centre, 83% came from households in which parents 
used drugs, 67% had experienced sexual assault and 60% 
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BRIDGET 
Bridget was born to an alcoholic mother, Maggie, who had 
been abused as a child and did not want a daughter of her own. 
Exasperated with Maggie’s bitterness and drinking, Bridget’s 
father eventually left the family. Bridget wasn’t fed or bathed 
regularly by her mother, though she did receive caring treatment 
from her grandmother, who took Maggie in whenever she went 
on a prolonged binge. 
Bridget was naturally pretty and grew into a beautiful girl, 
but remained introverted and unhappy. She was never very 
interested in her studies and fell in with the wrong crowd at 
school. She began to smoke cigarettes and marijuana at the 
age of 12, and was drinking excessively by 14. A year later she 
had a baby. The infant seemed fine at birth, though somewhat 
small—likely because of Bridget’s drug and alcohol use during 
pregnancy. Because of Bridget’s drug history and inability to care 
for her child, the baby was placed in foster care. Bridget was 
allowed occasional visits but seldom made them because of her 
addicted lifestyle. 
Bridget’s ongoing victimization, psychosocial disturbances 
and substance abuse prevented her from ever holding a job or 
building a stable environment around herself. By the time she 
was 26 she had had four miscarriages, a second baby—born 
preterm—and a stillbirth. Her second surviving child was also 
placed in foster care. As a result of her life experience, Bridget 
now suffers from depression and post-traumatic stress disorder, 
and is unaware of any supports or services that could help.
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had been physically assaulted (Finnegan et al., 1991). Another 
U.S.-based study compared the characteristics of out-of-
treatment, homeless, crack-using, African-American women 
with those of women who were not homeless to determine 
the risks and protective factors differentiating the two groups 
(Wechsberg et al., 2003). Its results showed that homeless 
women not only reported psychologically painful histories 
and currently stressful lives, but were also more likely to have 
experienced childhood abuse and to use additional drugs 
besides crack.
Data collected from substance use treatment centres in 
Canada corroborate the high rates of victimization among 
substance-abusing women reported in the United States. In a 
sample of 98 substance-abusing women from nine treatment 
centres across Ontario, Cormier (2000) found that 85.7% had 
been victimized. Specifically:
• 56.1% reported current physical abuse;
• 45.4% reported current sexual abuse;
• 56.1% reported childhood physical abuse; and
• 56.3% reported childhood sexual abuse.
Similarly, a treatment facility for substance-abusing women in 
Vancouver reported that 65% of its patients had been physically 
assaulted as adults and 38% had been sexually assaulted 
as adults, while 47% had experienced physical violence 
during childhood and 53% reported childhood sexual abuse 
(Poole, 2000).
3.2.1 Intimate partner violence
In 2000, women in the United States experienced 4.8 million 
instances of intimate partner-related physical assaults and 
rapes (Tjaden & Thoennes, 2000). In 2005, a total of 1,181 
women were murdered by an intimate partner (Bureau of 
Justice Statistics, 2005). An association between alcohol 
abuse and intimate partner violence exists, with considerable 
evidence linking intimate partner violence and alcohol use by 
the perpetrator (Kantor & Straus, 1989; Miller et al., 1989; 
Leonard & Senchak, 1996; Kyriacou et al., 1999; O’Farrell, 
1999; Caetano et al., 2001). 
At the same time, a correlation between intimate partner violence 
and alcohol use by the victim has also been identified (Kantor 
& Straus, 1989; Toman & Rosen, 2001). For example, Miller 
and colleagues (1989) surveyed alcoholic and non-alcoholic 
women and found that alcoholic women had higher levels of 
spousal violence in their lives. In addition, an analysis of forensic 
data from intimate partner-related homicides detected alcohol 
in 45% of victims and in 70% of suspects (Slade et al., 1991). 
It is important to be aware of this association so that signs of 
possible intimate partner violence among women who abuse 
alcohol—as well as signs of alcohol abuse in women who have 
experienced intimate partner violence—can be identified (Kay 
et al., 2010).
Tuten and colleagues (2004) evaluated the impact of partner 
violence on psychosocial and psychiatric functioning in 
pregnant, drug-dependent women at treatment enrolment. 
Abused pregnant women presented with more severe alcohol, 
family and social problems as well as greater rates of psychiatric 
problems and medical co-morbidity than those who were not 
abused. The partners of the abused women also had greater 
rates of alcohol and illicit drug use in comparison to the partners 
of non-abused women. These data suggest that treatment 
protocols should address the women’s relationships with 
their partners, especially when substance abuse and violence 
issues surface.
3.2.2 Sexual abuse
Sexual abuse (in particular, childhood sexual abuse) is also 
common among women seeking treatment for drug abuse, with 
some studies indicating that up to 70% of women in treatment 
report victimization prior to the age of 11. One such study of 
drug use among women who became pregnant before reaching 
the age of 18 found that 32% had a history of rape or incest and 
that those women had lower self-esteem and used more drugs 
than non-victims (National Institute on Drug Abuse, 2010).
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4.1 Drug-related medical 
complications in newborns
Approximately 3% of the 4.1 million women in the United States 
of childbearing age who abuse drugs are believed to continue 
their drug use during pregnancy (Iqbal et al., 2002). Clearly, 
drug abuse among pregnant women and the resulting neonatal 
morbidity are very significant clinical and social problems. 
4.1.1 Heroin
Low birth weight and prematurity are the two most prominent 
medical issues seen in the newborns of heroin-abusing women. 
Conditions such as asphyxia neonatorum (respiratory failure due 
to inadequate intake of oxygen before, during or just after birth), 
intracranial hemorrhage, nutritional deprivation, hypoglycemia 
The key to having a healthy baby is a healthy pregnancy without medical or obstetrical complications. Unfortunately, such an outcome is unlikely if the mother uses substances while pregnant and does not receive treatment.
As stated in Chapter 2, illicit drug use during pregnancy places the mother at increased 
risk of a variety of complications, most of which can have adverse effects on the health 
of the newborn. In addition, the psychosocial and victimization issues discussed in 
Chapter 3—mental illness, physical and sexual abuse, family dysfunction—can all have 
serious outcomes for the newborn, including poor parenting, failure to thrive, child neglect, 
child abuse, abandonment and even death. These complex issues must be addressed to 
effectively help pregnant women using drugs and their unborn children.
(low blood sugar), hypocalcemia (low blood calcium), septicemia 
(blood-borne infection) and hyperbilirubinemia (jaundice) should 
also be anticipated in heroin-exposed babies. 
Infants born to women undergoing methadone treatment for 
heroin addiction, however, are more likely to have higher birth 
weights and a decreased incidence of premature birth. Medical 
issues in infants born to heroin-abusing women generally reflect 
the amount of prenatal care received by the mother; whether the 
mother suffered obstetrical or medical complications during the 
pregnancy; and whether the fetus was exposed to multiple drug 
use, which can produce an unstable intrauterine milieu that can 
be further complicated by symptoms of withdrawal and overdose 
in both the woman and the fetus (Finnegan & Kandall, 2005).
4
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At a Glance
• The use of drugs during pregnancy can lead to fetal growth restrictions such as reduced  
length, head circumference and birth weight, and medical complications such as preterm birth  
and infections.
• Pregnant women with opioid dependence who are undergoing methadone maintenance treatment 
are more likely to give birth to infants with higher birth weights and are less likely to experience 
premature birth than opioid dependent women who are not under methadone maintenance. 
• Smoking tobacco during pregnancy can have harmful effects on fetal development and can result in 
reduced birth weight and sudden infant death syndrome. Smoking can also be linked to behavioural 
disorders such as attention deficit hyperactivity disorder, conduct disorders, and externalizing and 
internalizing behavioural problems.
• Exposure to alcohol in utero can result in a wide range of negative outcomes collected under the 
umbrella term fetal alcohol spectrum disorder, including fetal alcohol syndrome (FAS). FAS can be 
categorized by facial abnormalities, growth deficiencies and damage to the central nervous system. 
It is estimated that FAS occurs at a rate of one to two cases per 1,000 live births in Canada.
• Infants born to chronic opioid users are frequently born with a dependency to such drugs and 
experience withdrawal after the opioids cease to be administered following birth. The resulting 
effects are known as neonatal abstinence syndrome (NAS), which has a negative impact on vital 
bodily functions such as feeding, elimination and sleeping. Recent Canadian estimates suggest that 
0.3% of infants are born with NAS.
• NAS caused by exposure to opioids can be treated using a number of different medications, 
although most UK and US physicians use morphine or methadone. Accompanying measures can 
be used to create a supportive, comforting environment for the infant and enhance the relationship 
between the mother and baby.
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The general consensus is that maternal cocaine use can lead to 
shortened gestation as well as restricted fetal growth. It has been 
shown that cocaine intake can cause a rise in norepinephrine,4 
which can cause contractions of the uterus that, in turn, increase 
the incidence of precipitous labour and preterm births. Cocaine 
also causes constriction of blood vessels in the uterus and 
placenta, which can lead to reduced fetal nutrition resulting in 
poor fetal growth (Finnegan et al., 1992). In studies conducted 
during the surge of cocaine use in the United States in the 
1980s, babies exposed to cocaine were commonly reported to 
have low birth weight, premature gestation or intrauterine growth 
restriction (Livesay et al., 1987; Chouteau et al., 1988; Handler 
et al., 1991; Kliegman et al., 1994).
Because a wide range of factors can contribute to decreased 
fetal growth and gestation, it is important for studies to control 
for concurrent use of other substances as well as other medical 
and socio-demographic factors. With this in mind:
• Eyler and colleagues (1998) controlled for associated 
substance use (alcohol, marijuana and tobacco) and 
documented a reduction in head circumference in 
cocaine-exposed newborns;
• Bandstra and colleagues (2001) studied 253 infants 
born to African-American women in Miami and found 
evidence supporting a pattern of cocaine-associated 
symmetric intrauterine growth restriction (i.e., affecting 
both birth weight and head circumference); and
• Scafidi and colleagues (1996) looked at reduced 
head circumference in preterm infants, with the data 
suggesting maternal cocaine use is associated with 
symmetric growth restriction. 
Data on the relationship of cocaine to human malformations 
can be characterized as inconsistent. Numerous studies have 
reported on a variety of abnormalities in infants exposed to 
cocaine in utero (Bingol et al., 1987; Chasnoff et al., 1988; 
Hoyme et al., 1990; Lipshultz et al., 1991). However, Martin 
and colleagues (1992) did not find an increase in congenital 
malformations attributable to vascular disruption based on 
1968–1989 data from the Metropolitan Atlanta Congenital 
Defects Program. Similarly, Rajegowda and colleagues (1991) 
In another study, women with positive urine toxicology for either 
heroin or methadone (mostly women receiving methadone 
treatment and prenatal care) were compared to non-drug-
using women. Its results showed a non-significant birth weight 
decrement of 130 grams but no statistical difference in low birth 
weight, preterm birth or gestational age (Gillogley et al., 1990).
During a study of pregnant women using drugs in Philadelphia 
conducted by Connaughton and colleagues (1977), neonatal 
morbidity was experienced by approximately 75% of the 
infants born to heroin-using women without prenatal care and 
methadone-treated women with suboptimal prenatal care. 
Neonatal problems were somewhat decreased in infants born 
to methadone-treated women, with hospitalizations averaging 
17 days compared to the 27-day stays seen with the infants 
of heroin-abusing mothers. The main reason for prolonged 
hospitalization among methadone-exposed babies was neonatal 
abstinence syndrome. Babies exposed to heroin, meanwhile, 
suffered from a variety of medical problems primarily related to 
premature birth.
Infants of heroin-abusing women also have an increased risk 
of mortality owing to the absence of prenatal care and the 
concomitant complications resulting from that lack of care. For 
example, in a sample of 10 preterm heroin-exposed babies 
whose mothers did not attend prenatal care or addictions 
services, postmortem examinations revealed lesions in the 
infants’ brains. These lesions were postulated to have occurred 
during maternal episodes of withdrawal or overdose, which 
caused a lack of oxygen to the fetal brains (Rorke et al., 1977). 
Mortality rates can be decreased if mothers enrol in methadone 
treatment, receive prenatal care and seek out comprehensive 
services for their opioid addictions (Finnegan et al., 1977).
4.1.2 Cocaine
Although in utero exposure to stimulants such as cocaine has 
been widely studied, confounding variables such as a lack of 
prenatal care and the mother’s use of marijuana, opioids or 
alcohol have caused opposing opinions as to their effects upon 
newborn babies. 
4 Both a hormone and a neurotransmitter, norepinephrine is secreted by the adrenal medulla and the nerve endings of the sympathetic nervous system to cause 
blood vessel constriction and increases in heart rate, blood pressure and blood-sugar level. Its primary function is to help maintain a constant blood pressure by 
stimulating certain blood vessels to constrict when blood pressure falls below normal.
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wanted pregnancies. Counselling of pregnant women as to the 
actual risk of congenital malformations resulted in a decrease 
in both risk perception and the tendency to terminate the 
pregnancy (Koren et al., 1993). At the present time, mothers 
should be informed that cocaine use might increase the risk of 
congenital malformations in their fetuses; however, confirmatory 
studies looking at cause and effect are needed.
4.1.3 Amphetamines and methamphetamines
Amphetamine use during pregnancy has been associated with 
a high perinatal mortality rate; reductions in birth weight, length 
and head circumference; associated congenital malformations; 
poor feeding; seizures; and abnormal neurological signs, 
muscle tone, drowsiness and cry patterns (Eriksson et al., 
1978, 1981; Oro & Dixon, 1987; Smith et al., 2003). 
The Infant Development, Environment and Lifestyle (IDEAL) 
Study looked at the effects of prenatal methamphetamine 
and poly-drug exposure on neonatal growth (Smith et al., 
2006). It included 1,618 infants, 84 of whom were exposed 
to methamphetamine and 1,534 who were unexposed. Both 
groups included infants prenatally exposed to alcohol, tobacco 
or marijuana. In general, mothers in the methamphetamine 
group tended to be younger, poorer and less educated than 
those in the unexposed group. They also drank and smoked 
more frequently, were more likely to have no partner, had 
fewer prenatal care visits and began prenatal care at a later 
gestational age.
After adjusting for covariates, infants in the methamphetamine-
exposed group were 3.5 times more likely to be small for 
gestational age (SGA) compared to the unexposed group. 
(SGA is usually defined as having a birth weight below the 
tenth percentile, which puts the newborn at increased risk of 
morbidity and mortality.) In addition, mothers who used tobacco 
as well as methamphetamine were nearly two times more likely 
to deliver SGA babies (Smith et al., 2006).
found no increase in congenital urogenital abnormalities in 
1,324 cocaine-exposed infants when compared to 18,028 
reportedly drug-free controls. The same lack of association was 
also found by Hadeed and Siegel (1989) and Zuckerman and 
colleagues (1989). 
In general, there is a lack of definitive evidence linking cocaine 
to any effects on the developing fetus apart from the growth 
restriction mentioned above. A Canadian research team 
(Graham et al., 1991) reported that despite a growing number 
of studies investigating the effects of maternal cocaine use, a 
homogeneous pattern of fetal effects has not been established 
and there is little consensus on the adverse effects of the drug. 
In their meta-analysis of 20 studies of cocaine-using pregnant 
women, very few adverse reproductive effects could be shown 
to be significantly associated with cocaine use by poly-drug 
users when compared to control groups of poly-drug users 
who did not use cocaine. When the control groups consisted 
of women who did not use any drugs, the poly-drug users 
who also abused cocaine had a comparatively higher risk of 
miscarriage. Comparisons between women who only used 
cocaine to those who did not use drugs also revealed a higher 
risk for in utero death and genito-urinary tract malformations in 
the cocaine-exposed infants, most likely because of cocaine-
induced constriction of the placental blood vessels. However, 
no statistical link could be found between prenatal cocaine 
use and premature delivery, low birth weight or congenital 
heart defects. 
The results from the meta-analysis by Graham and colleagues 
(1991) also suggest that confounding factors such as the use 
of alcohol, tobacco or other drugs might actually account for 
the fetal growth restriction and prematurity commonly ascribed 
to cocaine. Women who use cocaine tend to smoke more 
cigarettes than those who use other illicit drugs and are also 
more likely to drink alcohol and take other drugs. As such, it can 
be difficult to determine which specific drug or combination of 
drugs causes these medical complications.
As part of the Motherisk program at Toronto’s Hospital for Sick 
Children, women are counselled on pharmacological risks during 
pregnancy. Koren and colleagues (1992) reported that although 
cocaine exposure early in pregnancy was not associated 
with a markedly increased risk of congenital malformations, 
the physician’s perception of a high risk of cocaine-related 
abnormalities resulted in the termination of many otherwise 
FETAL GROWTH RESTRICTION
Why does methamphetamine cause fetal growth restriction? 
One reason is that it can cause both maternal and fetal 
blood vessel constriction, restricting nutrient delivery to the 
fetus and contributing to high fetal blood pressure that can 
result in decreased hemoglobin oxygen-carrying capacity. 
Sources: Burchfield et al., 1991; Stek et al., 1995.
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GABRIELLE AND BABY JACQUES
Gabrielle and Jean-Paul met at university in Vancouver. They 
were relatively good students, though their weekends were 
usually a blur because of excessive drinking and some drug 
use at parties. For both of them, alcohol was their drug of 
choice. Shortly after graduating, the two were married and 
they each obtained good jobs as a result of the influence 
of Gabrielle’s father, a well-connected politician. Jean-Paul 
became a junior architect and Gabrielle an assistant in a major 
advertising firm. As at school, they performed well during the 
week, but their weekends were occupied with binge drinking. 
While they’d planned to get established before having a baby, 
Gabrielle was pregnant by age 25. She knew alcohol was 
incompatible with a healthy fetal outcome, but her nine-year 
habit of weekend binge drinking was well established. Jean-
Paul did not want to stop drinking or be forced to drink alone, 
so Gabrielle convinced herself that the risk was greatest with 
daily consumption and reserved her drinking for weekends. 
Baby Jacques was delivered at 38 weeks. Gabrielle was 
surprised by his small size. He was jittery, he didn’t nurse 
well and he didn’t look like either Gabrielle or Jean-Paul: he 
had a small head with thin lips, an upturned nose and small, 
wide-set eyes. A doctor explained to Gabrielle and Jean-Paul 
that these were all signs of fetal alcohol spectrum disorder, of 
which Jacques had an extreme form. He said Jacques would 
most likely have decreased intellectual functioning in addition 
to vision, hearing and behavioural problems as a result of his 
exposure to alcohol in utero.
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4.1.4 Cannabis and tobacco
The effects of heavy cannabis smoking include reduced fetal 
growth, preterm birth and an increase in neonatal tremors and 
startle responses. The Ottawa Prenatal Prospective Study, a 
major Canadian study that collected data on a wide range of 
pre- and postnatal outcomes following exposure to cannabis 
and tobacco smoke, also showed that in utero exposure to 
marijuana can affect an infant’s ability to respond to visual 
stimulation (Fried, 1995; Fried et al, 1983).
With regard to maternal tobacco smoking, a study by Godding 
and colleagues (2004) demonstrated the following outcomes: 
• Birth weight is reduced by approximately 150–200 
grams for every pack of cigarettes smoked during 
pregnancy;
• Maternal tobacco smoking of long duration is linked to 
increased rates of abruptio placentae, placenta previa 
(where the placenta is inserted partially or wholly in the 
lower part of the uterus), placental infarcts (interrupted 
blood supply to the placenta) and other placental 
changes caused by blood vessel constriction; and
• Delivery of oxygen to the fetus is adversely affected by 
the elevated levels of carbon monoxide in the mother’s 
blood.
In addition, hypertonia (increased muscle tone) has been 
reported in infants born to tobacco-smoking mothers. Increased 
rates of hospitalization and death in children up to five years of 
age, primarily from respiratory disorders such as bronchiolitis 
and pneumonia, have also been reported in infants born to 
smokers. Mild neonatal abstinence syndrome can also occur in 
infants exposed to heavy maternal smoking during pregnancy 
(Godding et al., 2004). 
As reviewed by Abbott and Winzer-Serhan (2012), maternal 
smoking during pregnancy can have deleterious effects on 
fetal development as well as long-term adverse consequences 
on postnatal development and maturation of several organ 
systems. Low birth weight, sudden infant death syndrome 
(SIDS), behavioural disorders including attention deficit 
hyperactivity disorder (ADHD), externalizing and internalizing 
behavioural problems, and conduct disorders in children have 
all been linked to prenatal exposure to tobacco smoke.
Because preliminary growth data after one year of the study 
reported an increased incidence of SGA in methamphetamine-
exposed infants, the IDEAL team continued to enrol subjects after 
its initial report was published in 2006. A second report on the 
complete data set was released in 2010, this time including 204 
infants exposed to methamphetamine and 3,501 who were not. 
One of the more surprising findings was that methamphetamine-
using mothers gained more weight than those in the unexposed 
group. To further study this point, the IDEAL team compared 
weight gain between mothers who reported methamphetamine 
use during the first or second trimester only to those who 
also reported use during the third trimester. It was found that 
women who quit using the drug earlier in gestation gained 10.4 
pounds more than those who continued to use throughout their 
pregnancy, suggesting the anorexic effects typically associated 
with methamphetamine occur only with continuous use and that 
a rebound in maternal weight might be possible if the mother 
discontinues use. 
In its expanded study (Nguyen et al., 2010), the IDEAL researchers 
found that although the infants in the methamphetamine group 
were born slightly earlier than those in the unexposed group, both 
groups had a term mean gestational age. While no significant 
differences were found in birth weight, the incidence of SGA was 
higher in the exposed group. They also reported a low incidence 
of the maternal complications known to cause SGA; of the 204 
women in the exposed group, none of the nine mothers diagnosed 
with diabetes or chronic hypertension delivered SGA infants, while 
only two of the 10 diagnosed with pre-eclampsia delivered SGA 
infants. Finally, in contrast with the initial study, the team did not 
find that co-exposure to methamphetamine and maternal smoking 
resulted in significantly decreased neonatal growth.
It should also be noted that the increased incidence of 
SGA and fetal growth restriction associated with prenatal 
methamphetamine exposure might pose long-term health risks 
for the newborn, including coronary heart disease, stroke, 
diabetes and hypertension during adulthood (Barker et al., 
1993). Nguyen and colleagues (2010) therefore recommended 
further longitudinal studies of the methamphetamine-exposed 
infants involved in the IDEAL Study to fully ascertain whether 
they are at increased risk for future growth abnormalities or other 
medical problems.
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4.2.1 Prevalence of FASD
In Canada, it is estimated that FAS occurs at a rate of one to 
two cases per 1,000 live births (Roberts & Nanson, 2000) and 
that an FASD occurs in approximately nine of every 1,000 live 
births (Public Health Agency of Canada, 2003). These rates are 
believed to be even higher in Canada’s Aboriginal communities 
(Canadian Paediatric Society, 2002), with some statistics 
suggesting rates anywhere from 25 to 200 instances of FAS 
or FASD per 1,000 live births in isolated northern communities 
(Masotti et al., 2003). It has been noted, however, that Canadian 
studies of the prevalence of FAS/FAE have focused primarily on 
Aboriginal communities where alcohol abuse and dependency 
are known to be high, raising concern that the high prevalence 
rates of FAS/FAE found in these communities will be used 
to describe rates in the general Aboriginal population (Tait, 
2003a; Dell & Roberts, 2006). The lack of epidemiological data 
regarding other populations in Canada also makes it difficult to 
determine whether or not Aboriginal women are at greater risk 
than other groups (Dell & Roberts, 2006).
In the United States, the prevalence of FAS is estimated at 0.5 
to two cases per 1,000 live births. Other FASD disorders are 
believed to occur approximately three times as often as FAS, 
with signs of FASD present in 2–5% of young children across 
the U.S. school population (Department of Health and Human 
Services, 2005). A slightly lower rate was found by May and 
Gossage (2001), who showed that FASD is estimated to affect 
at least 1% of all live births in the United States. 
FASD has been linked to patterns of alcohol consumption 
that produce high blood-alcohol concentrations. In particular, 
studies conducted on animals have found that binge drinking 
(for women, this is typically defined as four or more drinks 
on a single occasion) is especially dangerous to fetal brain 
development, even if the total amount of alcohol consumed is 
less than the amount consumed in a more continuous drinking 
pattern (Maier & West, 2001). 
Data from the 2007–2008 Canadian Community Health Survey 
indicated that the national prevalence of alcohol consumption 
during pregnancy was 5.8% (Thanh & Jonsson, 2010). In the 
United States, rates of alcohol use and binge drinking among 
women aged 18–44 were derived from self-reported data 
taken from the 2006–2010 Behavioral Risk Factor Surveillance 
System. Overall, 7.6% of pregnant women reported past-
4.2 Fetal alcohol spectrum 
disorder
Alcohol use during pregnancy is one of the leading preventable 
causes of birth defects and developmental disabilities (Centers 
for Disease Control and Prevention [CDC], 2012). Yet while the 
effects of prenatal exposure to alcohol have been known for 
centuries, they were not actually documented in the medical 
literature until 1968, with fetal alcohol syndrome (FAS) first 
identified in 1973 (Calhoun & Warren, 2007). 
A diagnosis of FAS requires the presence of all three of the 
following diagnostic criteria: 
• Facial anomalies or abnormalities;
• Growth deficiency; and
• Central nervous system (CNS) damage or 
dysfunction.
It should be noted that while confirmed prenatal alcohol 
exposure can strengthen the evidence for diagnosis, it is not 
necessary in the presence of the above criteria.
In the decades following the identification and definition of FAS, 
it has since become clear that even if a person does not meet 
all of the FAS criteria listed above, he or she can still experience 
a vast spectrum of physical, mental, behavioural and learning 
disabilities, all with potential lifelong implications. As a result, 
the term “fetal alcohol spectrum disorder” (FASD) is now used 
as a non-diagnostic umbrella term to include the wide range 
of negative outcomes that can occur in individuals exposed to 
alcohol during pregnancy, including FAS (Bertrand et al., 2004).
Although the term FASD is not intended for use as a clinical 
diagnosis, diagnostic guidelines have been developed to 
describe many of the effects of prenatal exposure to alcohol. 
For example, designations have been defined for many of 
the disorders that fall under the FASD umbrella, including 
FAS, partial fetal alcohol syndrome (PFAS), fetal alcohol 
effects (FAE), alcohol-related birth defects, alcohol-related 
neurodevelopmental disorder (ARND), static encephalopathy/
alcohol exposed and neurobehavioural disorder/alcohol 
exposed (Bertrand et al., 2004; Hoyme et al., 2005; Astley, 
2006; Astley et al., 2009; Olson et al., 2009). In general, 
individuals diagnosed with FAS are typically more impaired than 
those with other disorders under the FASD umbrella (Fryer et al., 
2007; Olson, King & Jirikowicz, 2008; Chasnoff et al., 2010).
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• Structural, including reduced head circumference 
or brain abnormalities such as reduced size of the 
corpus callosum (the thick band of nerve fibres 
dividing the left and right sides of the brain);
• Neurologic, including motor problems or seizures not 
resulting from postnatal insult; and
• Functional, including substandard cognitive 
functioning in various domains.
General mental ability
Prenatal exposure to alcohol can result in impairments to an 
individual’s general mental ability, including a lack of general 
proficiency in learning, reasoning, abstract thinking and the 
processing of complex information efficiently and accurately 
(Gottfredson, 2008). In fact, impaired general mental ability 
constitutes the central cognitive impairment related to—and the 
most devastating consequence of—prenatal alcohol exposure 
(Kodituwakku, 2007; Riley, Mattson & Thomas, 2009). 
Intellectual disability is seen in approximately 25% of individuals 
with an FASD (Bertrand et al., 2004; Streissguth et al., 2004). 
While FASD is fully compatible with average and above-average 
intellectual functioning—IQs as high as 126 have been found in 
people with FASD (Streissguth et al., 2004)—it does not mean 
there is no impairment in cognitive functioning. And because 
general mental ability does not include the full spectrum of 
cognitive abilities (Gottfredson, 2008; McGrew, 2009), it does 
not capture the full range of cognitive deficits caused by an 
FASD (Bertrand et al., 2004; Hoyme et al., 2005).
Non-verbal learning disability, for example, is among the 
cognitive deficits not accounted for by general mental ability. A 
number of studies (Don & Rourke, 1995; Tsatsanis & Rourke, 
2008; Rasmussen & Bisanz, 2009) have shown that the non-
verbal learning disabilities commonly found in individuals with 
FASD include:
month alcohol use. Although the prevalence of binge drinking is 
much lower among pregnant women (1.4% compared to 15.0% 
of non-pregnant women), pregnant women who did report past-
month binge drinking did so with similar frequency (an average 
of three times per month) and intensity (an average of six drinks 
on a single occasion) as non-pregnant women (CDC, 2012).
4.2.2 Outcomes of FASD
Multiple studies have shown that even low levels of prenatal 
exposure to alcohol can have adverse effects on fetal 
development. What’s more, these effects are dose-dependent, 
meaning heavier maternal alcohol consumption is associated 
with more severe outcomes (Olson, King & Jirikowicz, 2008; 
Olson et al., 2009; Riley, Mattson & Thomas, 2009). Although 
there is consensus on the adverse effects of heavy maternal 
drinking over an extended period of time during pregnancy, 
the issue of whether adverse effects are associated with low 
to moderate levels of drinking continues to be controversial 
(Abel, 2006). 
There is also a marked variability in FASD-related outcomes, 
even among heavy drinkers. This variability can be explained 
by differences in consumption patterns and timing of exposure 
in addition to other factors such as maternal health, genetic 
background and interactions with other substances (Abel, 2006; 
Olson, King & Jirikowicz, 2008; Guerri, Bazinet & Riley, 2009).
The three most prominent outcomes of FASD are facial 
abnormalities, growth deficiencies and damage to the CNS. 
Facial abnormalities associated with FASD include a shorter 
distance between each end of the eye-socket opening, a thin 
upper lip and a lack of skin-fold indentation between the nose 
and upper lip (also known as smooth or indistinct philtrum) (Astley, 
2006; Astley et al., 2009). FASD-related growth deficiencies are 
considered to exist if pre- or postnatal height or weight is at 
or below the 10th percentile at any point in time (Bertrand et 
al., 2004). 
Damage to the CNS, however, represents the most devastating 
consequences of prenatal alcohol exposure (Astley, 2006; Guerri 
et al., 2009; Riley, Mattson & Thomas, 2009) and generally 
persists throughout the affected person’s lifespan (Bertrand 
et al., 2004). FASD-related CNS dysfunction can include any 
combination of the following abnormalities:
THE EFFECTS OF PRENATAL ALCOHOL 
EXPOSURE ON INTELLECTUAL FUNCTIONING
The mean IQ in individuals with FAS is in the low 70s for 
those with facial anomalies and in the low 80s for those 
without facial anomalies.
Source: Riley, Mattson & Thomas, 2009.
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substance use and mental health problems typically faced by 
individuals with FASD (Vaurio et al.,  2009).
4.2.3 Diagnosis, treatment and prevention  
of FASD
Although its consequences are devastating, FASD is a 
completely preventable condition. According to Dr. Ann 
Streissguth, a researcher who has dedicated her life to the 
effects of alcohol on fetuses, newborns, children and adults, 
“the most outstanding characteristics of [FASD] are bad 
judgment and the inability to make the connection between an 
act and its consequences” (Streissguth et al., 2004). There is a 
pressing need to foster greater public awareness of FASD and 
its effects, part of which involves the development of practical 
guidelines for diagnosis, treatment and prevention. Fortunately, 
medical professionals, parents, educators, advocates and 
government agencies have all worked to produce such material 
in recent years.
Published in 2003 through funding from the Alberta FAS 
Initiative, the Alberta Clinical Practice Guidelines contain a 
number of recommendations to help physicians, midwives 
and other healthcare professionals reduce the incidence of 
FASD. In particular, they call for increased screening for alcohol 
consumption during pregnancy, greater awareness of the link 
between alcohol use and FASD, and productive dialogue and 
action between practitioners and their patients (and when 
possible, their partners) (Alberta Clinical Practice Guidelines 
Program, 2003).
In 2005, a subcommittee of the Public Health Agency of Canada’s 
National Advisory Committee on FASD reviewed, analyzed and 
integrated the existing approaches to the diagnosis of FASD-
related disabilities with the aim of reaching an agreement on a 
national diagnosis standard applicable to Canadians of all ages 
(Chudley et al., 2005). Because such diagnosis necessitates 
a multidisciplinary approach, the resulting guidelines—the first 
of their kind in Canada—are organized into the following seven 
categories:
• Screening and referral;
• Physical examination and differential diagnosis; 
• Neurobehavioural assessment; 
• Treatment and follow-up; 
• Maternal alcohol history in pregnancy; 
• Poor coordination and motor slowness, often        
more marked on the left side of the body; 
• Deficiencies in visual-spatial skills and visual        
spatial memory;
• Relative deficiencies in mechanical arithmetic in 
contrast with verbal skills such as word decoding, 
spelling, vocabulary and rote verbal memory;
• Difficulty dealing with cause-and-effect relationships;
• Deficiencies in the appreciation of incongruities     
(e.g., humour); 
• Deficiencies in non-verbal problem solving, concept 
formation and hypothesis testing;
• Difficulty with more complex verbal material and 
written text (e.g., material that is abstract or inferential);
• Notable difficulty adapting to novel or complex 
situations; and
• Deficiencies in the capacity to benefit from feedback 
in novel or complex situations. 
Combined, these impairments contribute to deficits in skills 
related to social perception, judgment and interactions, making 
it practically impossible for the individual to adapt to novel 
interpersonal situations (Eme & Millard, 2012).
Executive functions
Executive functions such as response inhibition and working 
memory represent a class of higher-order cognitive abilities 
that allow for strategic planning, impulse control, cognitive 
flexibility and goal-directed behaviour (Weyandt, 2009). 
Because executive functions facilitate behavioural and affective 
regulation (Barkley, 2006; Nigg, 2006), major life problems can 
occur as a result of impaired executive functions (Vaurio, Riley & 
Mattson, 2009). 
For example, it is estimated that 95% of individuals with ADHD 
have impaired executive functioning (Barkley, 2006). Although 
individuals diagnosed with FASD account for just 2% of all 
individuals with ADHD (Nigg, 2006), ADHD is the most frequent 
neuropsychiatric presentation of an individual with FASD, with 
rates ranging from 60% to 95% (Streissguth et al., 1996; Burd et 
al., 2003; Fryer et al., 2007; O’Malley, 2007; Herman, Acosta & 
Chang, 2008; Astley et al., 2009). The impairment of executive 
functions can therefore account for many of the social, legal, 
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4.3 Neonatal abstinence 
syndrome
Infants of chronic opioid users are frequently born with a 
passive dependency on the drugs used by their mothers. With 
their low molecular weight and lipid solubility, opioids can pass 
easily from the mother to the fetus through the placenta; once 
the drugs accumulate in the fetus, equilibrium is established 
between the maternal and fetal blood. Disruption of the 
transplacental passage of drugs when the umbilical cord is 
cut at birth terminates the drug supply to the baby, potentially 
resulting in the development of symptoms of abstinence or 
withdrawal. Affecting the central nervous, autonomic nervous, 
gastrointestinal and respiratory systems, this constellation of 
symptoms constitutes a multisystem disorder called neonatal 
abstinence syndrome (NAS).6
NAS is a serious medical condition because it affects the vital 
functions that permit growth and normalcy—feeding, elimination 
and sleep, for example. Moreover, the symptoms can mimic 
other neonatal conditions such as infection, hypoglycemia, 
hypocalcemia and intracranial hemorrhage, all of which can be 
life threatening or lead to other major problems. If untreated, 
NAS can cause death because of excess fluid loss, high 
temperatures, seizures, respiratory instability, aspiration of fluid 
into the lungs or the cessation of breathing. However, with 
current medical knowledge about drug abuse during pregnancy 
and newborn care, no infant should die as a result of NAS.
4.3.1 Prevalence of NAS
In 2009–2010, 0.3% of all infants born in Canada had NAS, with 
affected newborns staying in acute care facilities for an average 
of 15 days after birth (Canadian Institute for Health Information 
[CIHI], 2012). The incidence of NAS in Ontario, as reported by 
CIHI, has increased from 1.3 cases per 1,000 births in 2004 to 
4.3 cases per 1,000 births in 2010 (Dow et al., 2012).
In the United States, a study of 7.4 million discharges from 
4,121 hospitals across the country found that between 2000 
and 2009, the number of mothers using opiates increased 
from 1.19 to 5.63 per 1,000 hospital births per year. NAS was 
diagnosed at a rate of 3.39 per 1,000 hospital births per year; 
in 2009, an estimated 13,539 newborns (or approximately 
• Diagnostic criteria for FAS, PFAS and ARND; and
• Harmonization with Institute of Medicine and 4-Digit 
Diagnostic Code5 approaches. 
These Canadian guidelines were developed in parallel and in 
consultation with a U.S.-based committee charged with the 
same task. In its report, the National Center on Birth Defects 
and Developmental Disabilities at the U.S. Centers for Disease 
Control and Prevention stated that because the challenges 
related to FASD prevention, diagnosis and intervention are 
constantly evolving, more research is needed to determine 
whether tools such as brain imaging, biomarkers and DNA 
micro-array techniques could enhance the accuracy and 
reliability of alcohol-related diagnoses and treatment (Bertrand 
et al., 2004). The guidelines featured in this report are intended 
to help facilitate the training of healthcare professionals, improve 
access to diagnostic services and facilitate referral to treatment 
for people affected by FASD.
Most recently, Canada’s Low-Risk Alcohol Drinking Guidelines 
(Butt, Beirness, Gliksman, Paradis & Stockwell, 2011) address 
alcohol use during pregnancy simply by stating that the safest 
option during pregnancy or when planning to become pregnant is 
to not drink alcohol at all. Ultimately, with greater public awareness 
and recognition of the adverse effects of FASD, it is hoped that 
pregnant women will be more likely to heed the warnings and 
choose to abstain from alcohol—not only during pregnancy, but 
also when they are planning to  become pregnant.
With respect to culturally appropriate guidelines for Aboriginal 
women, the Society of Obstetricians and Gynaecologists 
of Canada prepared a policy statement in 2001 to guide 
professionals in addressing Aboriginal health concerns, including 
FASD (Smylie, 2001). In a report prepared for the Aboriginal 
Healing Foundation, Tait (2003b) suggested best practices 
from an Aboriginal perspective, proposing alternative practices 
that are aligned with the culture and fit with the reality in which 
Aboriginal peoples live in Canada. The report gives particular 
attention to the role of residential schooling, concluding that 
the widespread use of alcohol and other substances among 
many residential school survivors can be attributed to that 
traumatic experience.
5 The 4-Digit Diagnostic Code is used for diagnosis, screening and surveillance in clinics throughout Canada and the United States (Chudley et al., 2005).
6 There are two types of NAS: prenatal, which is caused by the discontinuation of drugs taken by the pregnant mother; and postnatal, which is caused by the 
discontinuation of drugs given directly to the infant (Hall et al., 2007). Only prenatal NAS will be discussed in this report.
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Why is there so much variability in the expression of NAS? It 
has been suggested that the rate of decline in a newborn’s 
drug plasma level from the first day to the fourth day of life 
influences the severity of abstinence symptoms (Doberczak et 
al., 1993; Rosen & Pippenger, 1976). Essentially, the faster a 
baby excretes the pharmacological agent, the faster the onset 
of NAS symptoms.
As with the variability in the onset of NAS, the pattern of the 
syndrome can take several different courses. It can be mild and 
transient, delayed in onset, have a stepwise increase in severity, 
be intermittently present, or have a biphasic course that includes 
acute neonatal symptoms followed by improvement and then 
an exacerbation of the acute symptoms (Finnegan et al., 1975).
4.3.3 Symptoms of NAS caused by exposure 
to opioids
In general, NAS resulting from opioids is characterized by 
signs of CNS hyperirritability, gastrointestinal dysfunction, and 
respiratory and autonomic nervous system symptoms.
Central nervous system 
Tremors, high pitched crying, hypertonia, irritability, increased 
deep tendon reflexes and an exaggerated startle reflex are 
all characteristic of neonatal abstinence. An exaggerated 
rooting reflex and a voracious appetite manifested as sucking 
of fists or thumbs are also common, yet when feedings are 
administered the infant may have extreme difficulty because of 
an uncoordinated sucking and swallowing mechanism. Kron 
and colleagues (1976) found that both heroin- and methadone-
exposed infants showed reductions in sucking rates and 
pressures, disordered sucking organization and a reduction in 
the amounts of nutrient consumed. As a result of these issues, 
an infant affected by NAS can be challenging to feed except by 
a very skilled neonatal nurse.
Seizures represent perhaps the most dramatic CNS 
manifestation of NAS. Fortunately, they are not the most 
prominent of the symptoms. However, because they may be 
subtle or confused with exaggerated tremors, the reported 
incidence of seizures varies, ranging from 1% (Finnegan, 1986) 
to 5.9% (Herzlinger et al., 1977) to 7.8% (Kandall et al., 1983) of 
newborns exposed to heroin or methadone during pregnancy. 
Certain practices used in the treatment of NAS, such as tightly 
swaddling the infant in a darkened room, can also make it 
difficult to observe seizure movements.
one infant born each hour) showed signs of withdrawal or 
abstinence. Newborns with NAS were 19% more likely than all 
other hospital births to have low birth weight and 30% more 
likely to have respiratory complications. These babies also 
tended to have greater feeding difficulties and more frequent 
seizures (Patrick et al., 2012). 
While the length of hospital stay for NAS-diagnosed newborns 
remained relatively unchanged from 2000 to 2009 (approximately 
16 days), the charges for these stays increased from $39,400 to 
$53,400, which is nearly six times the cost of non-NAS hospital 
births (Patrick et al., 2012). These data speak to the significant 
burden drug abuse places not only on the health of the mother 
and her child but also on hospital staff and resources—not to 
mention the costs incurred at the national level.
4.3.2 Onset and severity of NAS
At birth, most infants exposed to opioids appear physically and 
behaviourally normal. Symptoms of NAS typically appear shortly 
after birth and up to two weeks later,  with the majority exhibited 
within the first 72 hours of life (Finnegan, 1988; Finnegan & 
Kandall, 2005; Hudak & Tan, 2012). This timing is because 
most opioids are short-acting and therefore not stored by the 
fetus in appreciable amounts. (Methadone, however, is longer-
acting; therefore, the occurrence, timing and severity of NAS 
symptoms for babies withdrawing from methadone are more 
variable.) Acute symptoms can persist for several weeks, 
whereas subacute symptoms (e.g., irritability, sleep problems, 
hyperactivity, feeding problems, hypertonia) can persist for up 
to four to six months (Franck & Vilardi, 1995; Coyle et al., 2002).
The type of pain medication and anesthesia received by the 
mother can also influence the onset of NAS symptoms, with 
epidural anesthesia generally resulting in fewer problems for 
both mother and child. In addition, poor nutritional status and 
illness in the baby can result in a later onset of NAS because 
the infant is slower to excrete the drugs (Finnegan et al., 1975; 
Finnegan & Kandall, 2005).
The maturity of the infant is another important factor influencing 
the onset of NAS symptoms. In full-term infants, NAS onset is 
earlier and the symptoms can be more severe. Preterm babies, 
on the other hand, tend to have a later onset and less severe 
symptoms, likely because of the developmental immaturity of 
the preterm nervous system or the reduced total drug exposure 
in shortened gestations (Doberczak et al., 1991). 
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CELESTE AND BABY SARA-ANN
Celeste is 26 years old and newly married to her husband, Chris. 
Both had lucrative jobs and were building strong careers when  
two things happened: Celeste had a serious automobile accident 
and, during her evaluation in the hospital, she was told that she  
was pregnant. 
For the severe back injury she suffered in the accident, Celeste 
was placed on oxycodone. Her pain was intense and, because 
she was in the first trimester of pregnancy, she had the discomforts 
of nausea and vomiting to contend with as well. Although she felt 
poorly, she continued to work—not only because she needed 
the money, but also because she did not want to jeopardize her 
position. She escalated her dose of medication, quickly finding that 
she had to take progressively more pills to achieve the same effect. 
Her doctor told her to wean off the medication to avoid becoming 
addicted, but did not explain how to do so safely. Celeste ended up 
with multiple prescriptions, one from her obstetrician and another 
from her family physician. 
As the pregnancy progressed Celeste’s pain worsened, so she 
continued taking oxycodone until baby Sara-Ann was born. 
Concerned about the effect her use of pain medication would have 
on the newborn, Celeste spoke to her obstetrician, who in turn 
consulted a neonatologist. By this point, Sara-Ann was already 
showing signs of neonatal abstinence syndrome, which can occur 
when newborns stop receiving doses of drugs via their mother in 
utero. She was actively monitored to determine if treatment would 
be necessary. On her second day of life, Sara-Ann’s symptoms 
reached a critical level and she was given morphine drops to relieve 
them. Because the baby was otherwise healthy, after two weeks of 
treatment the doctor was able to start weaning her off morphine. 
Celeste and Chris took Sara-Ann home by three weeks of age, 
and Celeste enrolled in a drug treatment program to deal with her 
addiction to prescription medications.
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found that approximately 40% of low-birth-weight infants born 
to heroin-addicted mothers had spontaneous generalized 
sweating. In comparison, this condition appeared in less than 
1% of healthy low-birth-weight babies.
4.3.4 Symptoms of NAS caused by exposure 
to other drugs
Even though opioid-related NAS produces the most dramatic 
effects in newborns and their mothers, anti-depressants, 
sedative-hypnotics, alcohol and tobacco have all been identified 
as causes of NAS (Finnegan et al., 1975; Finnegan & Kandall, 
2005; Weiner & Finnegan, 2010).
Cocaine
Although neurobehavioural symptoms in cocaine-exposed 
babies can include tremors, lethargy intermittent with irritability, 
abnormal cry patterns, poor sucking, hypertonia, abnormal sleep 
patterns and poor interactions with caretakers, NAS does not 
generally occur in babies exposed to cocaine in utero. Askin 
and Diehl-Jones (2001) defined these effects not as “true” NAS 
but rather neurotoxicity with under-aroused neurobehavioural 
function. Moreover, symptoms of irritability in these infants are 
difficult to separate in the context of other factors from which they 
suffer, such as prenatal exposure to other drugs used together 
with cocaine (Askin & Diehl-Jones, 2001; Bada et al., 2002).
 
Antidepressants
Selective serotonin reuptake inhibitors (SSRIs) such as 
fluoxetine, paroxetine, sertraline, citalopram, escitalopram 
and fluvoxamine are the most frequently used drugs to treat 
depression and other mood and behavioural disorders. Infants 
exposed to SSRIs during the last trimester of pregnancy can 
exhibit the full range of NAS-related CNS signs (e.g., irritability, 
seizures), respiratory signs (e.g., increased respiratory rate, 
nasal congestion), gastrointestinal symptoms (e.g., diarrhea, 
feeding difficulty) as well as motor signs (e.g., agitation, tremors, 
hypertonia), fever and hypoglycemia (Haddad et al., 2005). 
A decrease in maternal SSRI use during the third trimester 
can lower the neonatal risk of developing NAS; however, this 
needs to be balanced against the harmful effects of untreated 
depression during pregnancy, which can include a lack of 
attention to prenatal care and continued illicit drug use.
The onset of SSRI-related NAS symptoms ranges from several 
hours to several days after birth, usually resolving within two 
weeks. Symptoms are more commonly reported among infants 
exposed to fluoxetine and paroxetine.
Gastrointestinal system
Regurgitation, projectile vomiting and loose stools are all 
gastrointestinal manifestations of NAS. Dehydration because 
of poor intake, coupled with increased losses from the 
gastrointestinal tract, can cause excessive weight loss, 
electrolyte imbalance, shock, coma and even death. Babies 
with mild NAS not requiring treatment can lose about 4% of their 
birth weight, regaining it by the seventh day of life. Newborns 
displaying more severe abstinence lose more weight and do 
not regain their weight until an average of two weeks after 
birth, suggesting that timely and appropriate pharmacological 
control of abstinence, combined with the provision of extra 
fluids and calories to offset the weight loss, are important in the 
management of NAS (Weinberger et al., 1986).
Although babies that exhibit mainly gastrointestinal symptoms 
might not meet the criteria for pharmacological treatment of their 
symptoms, it is still extremely important for these babies to be 
monitored following discharge from the hospital because of the 
potential for water losses and poor intake, both of which can 
lead to dehydration.
Respiratory system
Respiratory symptoms caused by NAS can include excessive 
secretions and nasal stuffiness, sometimes accompanied 
by retractions between the ribs of the chest wall, intermittent 
cyanosis (blue colouring of the lips and fingertips) and apnea 
(cessation of breathing) (Finnegan, 1980). Severe respiratory 
distress occurs most often when the infant regurgitates, 
aspirates and develops aspiration pneumonia. Infants with acute 
heroin withdrawal were found to have increased respiratory 
rates, leading to hypocapnia (a state of reduced carbon dioxide 
in the arterial blood) and an increase in blood alkalinity during the 
first week of life (Glass et al., 1972). Surprisingly, the incidence 
of respiratory distress syndrome is actually decreased in NAS-
affected infants, possibly because of chronic intrauterine stress, 
accelerated heroin-mediated maturation of lung function or 
perhaps both (Glass et al., 1972). This decrease, however, is 
just one benefit among a long list of adverse effects resulting 
from intrauterine heroin exposure.
Autonomic nervous system
Autonomic nervous system signs seen during abstinence 
include sneezing, yawning, skin color changes (mottling) 
and water loss caused by increases in temperature and the 
shedding of tears. In addition, Behrendt and Green (1972) 
47
SUBSTANCE ABUSE IN CANADA - Licit and Illicit Drug Use during Pregnancy
Canadian Centre on Substance Abuse
this issue (Dryden et al., 2009; Lim, et al., 2009; Wouldes & 
Woodward, 2010), with some finding that the greater the dose 
of methadone, the greater the severity of NAS. However, an 
equal number of reports have found no correlation between 
methadone dose and NAS severity. Cleary and colleagues 
(2010) conducted a meta-analysis of 67 studies (29 of which 
met the criteria for inclusion) to help settle this debate. They 
concluded that the severity of NAS symptoms does not appear 
to differ according to whether mothers are on high- or low-dose 
methadone maintenance therapy.
Buprenorphine, an opioid partial agonist, is another effective 
medication for the treatment of opioid abuse, with numerous 
studies in Europe and the United States reporting its efficacy 
among pregnant women. In Canada, buprenorphine-naloxone 
is available for the treatment of opioid dependence; however, 
this formulation is contraindicated during pregnancy due to its 
naloxone component. (As discussed further in Chapter 5, although 
plain buprenorphine can be accessed through Health Canada’s 
Special Access Program, logistical issues make it impractical to 
use in pregnant opioid-dependent women in Canada.)
NAS has been reported in varying degrees and incidence in 
relation to buprenorphine use. While studies have showed 
minimal abstinence symptoms from buprenorphine alone, those 
studies that included other drug use indicated significant NAS 
occurrence. In several well-controlled studies, the occurrence, 
duration and severity of NAS from buprenorphine administration 
were found to be less than methadone-related NAS (Fischer et 
al., 1998, 2006; Fischer, 2000; Johnson et al., 2003; Lacroix 
et al., 2004; Jones et al., 2005, 2010; Lejeune et al., 2006).
For more information about the use of methadone and 
buprenorphine in the treatment of opioid dependence in 
pregnancy, please refer to Chapter 5.
Sedative-hypnotics
Sedative-hypnotics such as benzodiazepines (i.e., diazepam) 
and barbiturates can also cause NAS. Because these agents 
have a longer half-life, withdrawal might not start until after the 
infant has been discharged from hospital. In study by Seligman 
and colleagues (2008) on the maternal variables predicting 
length of treatment for NAS in methadone-exposed newborns, 
it was found that later gestational age and concomitant maternal 
benzodiazepine use is associated with longer treatment 
durations. These results indicate that maternal poly-drug abuse 
can increase the severity of NAS.
Tobacco and alcohol
Infants born to heavy cigarette smokers have been found to 
demonstrate increased signs of stress and abstinence (Law et 
al., 2003). Among babies exposed prenatally to alcohol, NAS 
symptoms are usually seen within the first 24 hours of life and 
are especially reported in those with signs of FAS. In addition, 
these newborns have also been shown to exhibit irritability, 
tremors, seizures, abdominal distension and opisthotonus 
(severe hyperextension and spasticity in which the baby’s head, 
neck and spinal column enter into an “arching” position).
Volatile substances
Volatile substances cover a wide range of easily obtained 
products such as gases, glues and aerosols that, when 
inhaled, make people feel uninhibited, euphoric and dizzy—and 
can even result in death due to these substances’ effects on 
the heart. Researchers from the University of Manitoba studied 
infants of mothers who were volatile substance abusers to 
determine if they were at risk for an abstinence syndrome 
(Tenenbein et al., 1996). They found that there is indeed an 
identifiable volatile substance abuse abstinence syndrome in 
newborns and that a characteristic chemical odour in either the 
newborn or the mother is a marker for its occurrence.
4.3.5 NAS as a side effect of opioid therapy
NAS is a potential side effect of medications provided for the 
treatment of opioid dependence in pregnant women. In general, 
when pregnant women are receiving methadone treatment for 
heroin abuse, their exposed babies have about a 60% chance 
of developing NAS (Finnegan & Kandall, 2005).
For many years, the dose of methadone was considered linked 
to the severity of NAS. Numerous studies have looked into 
AGONIST AND ANTAGONIST DRUGS
For drugs that are site-specific, actions initiated can be 
agonist, antagonist or a combination of both. Agonists initiate 
activity in the cell; the opioids with the greatest potential 
for abuse are full agonists such as morphine, heroin, and 
oxycodone. Antagonists (such as naloxone) act in the opposite 
way, blocking cellular activity. Drugs such as buprenorphine, 
meanwhile, provide a mixture of the two effects.
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while males had a significantly higher birth weight and head 
circumference, there were no significant sex-related differences 
for NAS development, severity, duration or medication 
administered. This study concluded that a similar postnatal 
vulnerability exists for both males and females, suggesting 
that factors other than sex are the major determinants of 
clinically significant NAS (Unger et al., 2011). Similarly, no 
differences were found in another study that examined the 
need for NAS treatment, length of treatment and peak dose of 
medication required in male and female newborns (Holbrook & 
Kaltenbach, 2010).
Symptom severity score sheets
Because not all drug-exposed newborns experience abstinence 
symptoms, routine prophylactic treatment is not recommended 
for NAS. Close observation of clinical symptoms is therefore 
very important; the use of a semi-objective symptom severity 
score sheet allows for the accurate evaluation of signs and 
symptoms, avoids unnecessary treatment of mildly affected 
infants and provides a methodology for the effective tapering 
of medications. 
A number of scoring tools have been developed and reported 
in the pediatric literature (Lipsitz, 1975; Green & Suffit, 1981; 
Finnegan, 1986; Zahorodny 1998). One of these is the 
Finnegan Neonatal Abstinence Score, a comprehensive tool 
recommended by the American Academy of Pediatrics for 
measuring the onset, progression and diminution of symptoms 
of abstinence (Hudak & Tan, 2012). 
The Finnegan Neonatal Abstinence Score measures 21 signs 
and symptoms that have been reported in infants with neonatal 
abstinence, including high-pitched crying, tremors, increased 
muscle tone, regurgitation, rapid respirations, poor feeding, 
poor sleep and loose stools (Finnegan, 1986). A relative 
weight based on a postulated relationship to outcomes of 
newborn morbidity is assigned to each sign and symptom, with 
pharmacological treatment provided according to the severity 
of the score. The score is then used to monitor the infant’s 
clinical response to the treatment and the amount of medication 
necessary to control the symptoms. Infants are evaluated on a 
regular basis throughout each day; with more severe symptoms, 
the infant is evaluated more frequently until stabilization of NAS 
occurs (Finnegan & Kaltenbach, 1992).
4.3.6 Assessment and diagnosis of NAS 
symptoms
Many different variables can affect the level of fetal drug 
exposure, including:
• The amount and purity of the drugs taken by the 
mother;
• The length of drug use and the mother’s drug 
metabolism; and
• The individual kinetics of placental drug transfer.
Because of these variables, it is not yet possible to predict 
at birth whether a baby will develop NAS or, if developed, 
whether that NAS will be of a mild, moderate or severe degree. 
Therefore, careful assessment and diagnosis of newborns 
exposed to drugs in utero is the only way to determine if they 
will develop symptoms and warrant subsequent treatment.
One way to identify infants at risk for NAS is through the use 
of a toxicology screening protocol at birth. In some centres, 
meconium toxicology screens are used. Meconium is the 
first intestinal discharge of the newborn infant. Consisting 
of epithelial cells, mucus and bile, it also includes any drugs 
the fetus was exposed to from about the twentieth week of 
gestation (Finnegan & Kandall, 2005).
Newborns can also be assessed for symptoms of NAS using a 
neurological examination such as the Brazelton Neurobehavioral 
Scale of Infant Development or the Neonatal Intensive Care 
Unit (NICU) Network Neurobehavioral Scale (NNNS). The 
NNNS provides a comprehensive assessment of neurological 
integrity and behavioural function, examining neurobehavioural 
organization, neurological reflexes, motor development, active 
and passive tone, and signs of stress and withdrawal in drug-
exposed infants. Yet while the Brazelton Neurobehavioral Scale 
and the NNNS can yield valuable information, both require 
specialized training and certification to be used effectively 
(Lester & Tronick, 1993).
It has been suggested that the sex of the infant might play a 
role in predicting NAS severity, with past studies showing an 
increased vulnerability to adverse outcomes among males. 
However, a study by Unger and colleagues (2011) looking 
at sex-based differences in birth weight and length, head 
circumference, and NAS duration and severity found that 
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ARLENE AND BABY ANNIE 
At the age of 13, Arlene started using heroin. Now 32, she 
continues her habit and smokes a pack of cigarettes a day. After 
a series of miscarriages and elective abortions, she recently 
became pregnant. This time she decided to keep the baby 
because she cares about the father, Derek. While Derek uses 
alcohol and cocaine excessively, he too wants to have the baby. 
Five months into her pregnancy, Arlene considered seeing a 
doctor but didn’t because she had not stopped using heroin. 
At seven months, she went into labour. Derek took her to the 
hospital and Arlene delivered Annie, a preterm and growth-
restricted baby weighing just 1,500 grams (a little over three 
pounds). Annie had difficulty breathing and very low calcium 
and sugar levels in her blood. Within the first day of life, she had 
seizures, which the doctors attributed to a brain hemorrhage 
resulting from preterm birth. Because of Arlene’s recurrent 
heroin use, which was inconsistent in both frequency and dose, 
her fetus had likely experienced equally recurrent episodes of 
abstinence (deprivation of drugs) and overdose. Baby Annie was 
very sick and needed antibiotics and treatment in the neonatal 
intensive care unit. 
After three months in hospital, Annie finally recovered. Although 
Arlene and Derek said they loved her, they did not seek 
treatment for their drug and alcohol problems. They came 
occasionally to the nursery to see Annie but were usually high 
or disruptive; on several occasions they had to be escorted out 
by security. As a result, Annie was placed in a foster home for 
medically disabled children. Her doctors believe she has little 
chance of experiencing normal growth and development.
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resulting from opioid dependence. These guidelines provide 
evidence-informed recommendations for the screening, 
assessment and medical treatment of NAS (Dow et al., 2012).
When used during treatment, morphine has been found to 
reduce bowel motility and loose stools in addition to facilitating 
feeding and interpersonal interaction. At the same time, it can 
also cause respiratory depression, hypotension, delayed gastric 
emptying, loss of bowel motility and urinary retention. The 
majority of practitioners use phenobarbital as a second drug 
if morphine treatment does not adequately control the signs of 
abstinence (Sarkar & Donn, 2006; O’Grady et al., 2009). 
Langenfeld and colleagues (2005) compared the efficacy of 
oral morphine to an alcoholic mixture of tincture of opium in 
the treatment of exposed infants. They found morphine to be 
better for treating neonatal abstinence because it avoided the 
unwanted effects of the alcoholic extracts while enabling better 
weight gain in the newborns.
In comparing the effects of phenobarbital and morphine 
hydrochloride, Ebner and colleagues (2007) found that 
infants receiving morphine required a significantly shorter 
mean duration of treatment (9.9 days) than those treated with 
phenobarbital (17.7 days), concluding that morphine is the 
preferable treatment for newborns with NAS. 
With buprenorphine being used more frequently by pregnant 
women undergoing treatment for opioid dependence, 
researchers in Philadelphia studied the feasibility of using 
buprenorphine to treat NAS. A randomized comparison trial 
of sublingual buprenorphine versus a neonatal opium solution 
showed a non-significant reduction in length of treatment and 
duration of hospitalization in the buprenorphine group. While 
buprenorphine therapy was well tolerated by the infants, 
administration was challenging because the medication is best 
absorbed when placed under the tongue (Kraft et al., 2008).
Phenobarbital
Phenobarbital is a nonspecific CNS depressant that offers the 
advantage of a broad spectrum of sedation in cases of maternal 
poly-drug abuse, controlling symptoms of irritability and insomnia 
in 50% of infants regardless of the mother’s choice of drug. 
However, its usefulness is limited because it does not control 
non-CNS signs such as loose stools, depresses sucking and, 
4.3.7 Medical treatment of NAS
A number of different medications can be used by clinicians 
to treat NAS, including opioids (e.g., morphine, methadone, 
buprenorphine), phenobarbital and clonidine. Once the infant 
is clinically stabilized on a medication (based on decreasing 
abstinence scores), the total daily dosage can be lowered by 
10% each day. Based on pharmacokinetic studies, the duration 
of treatment, although variable, is typically longer following in 
utero methadone exposure compared to heroin exposure 
(Finnegan & Kaltenbach, 1992). 
Regardless of the medication used, after cessation of treatment 
the infant should be monitored in the hospital for rebound 
abstinence symptoms for at least two days (Finnegan & 
Kaltenbach, 1992; Kandall, 1999).
Opioids
Based on numerous clinical studies and the assumption that 
opioid exposure is best treated with another opioid, preparations 
such as morphine and methadone have become the treatment 
of choice for NAS (Jackson et al., 2004). 
The American Academy of Pediatrics recommends methadone 
for the treatment of NAS and data are available regarding 
its efficacy and safety (Isemann et al., 2011). Because 
methadone’s long-acting properties can cause doses to be 
incorrectly calculated, caution must be exercised; the current 
recommendations by the American Academy of Pediatrics 
suggest carefully outlined regimens for orally administered 
methadone or morphine (Lainwala et al., 2005).
In 2012, the Neonatal Abstinence Work Group developed a 
set of clinical practice guidelines for Ontario focusing on NAS 
THE FINNEGAN NEONATAL ABSTINENCE 
SCORE
With proper training, healthcare professionals can use this 
tool to:
• Accurately assess infants for the presence of 
abstinence signs and symptoms;
• Implement appropriate examination techniques to 
evaluate infants for clinical signs and symptoms of 
abstinence; and
• Document clinical signs and symptoms of 
withdrawal.
Source: D’Apolito & Finnegan, 2010.
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and adults to reduce symptoms of autonomic overactivity such 
as rapid heart rate, hypertension, sweating, restlessness and 
diarrhea (Gold et al., 1978; Hoder et al., 1984).
Experience with clonidine as a primary or a complementary 
treatment of NAS is limited but promising. In a randomized 
controlled trial, Agthe and colleagues (2009) compared the 
efficacy and safety of treating NAS with DTO plus oral clonidine 
versus DTO plus a placebo in 80 infants with prenatal exposure 
to methadone, heroin or both. While the combination therapy 
significantly reduced the median length of treatment, more 
infants in the DTO/clonidine group required resumption of DTO 
after initial discontinuation. In addition, the mean total dose of 
morphine over the treatment course was about 60% lower in 
the DTO/clonidine group. No clinically significant differences in 
feeding, weight gain or loss, heart rate or blood pressure were 
observed (Hudak & Tan, 2012).
Naloxone
The opioid antagonist naloxone is occasionally given to 
newborns having breathing problems to reverse the acquired 
effects of pain medications typically administered to the 
mother during labour and delivery. Because of its potential for 
precipitating severe abstinence symptoms, naloxone should 
not be given to newborns exposed to opioids in utero.
4.3.8 Supporting and caring for newborns 
with NAS
When drug abuse occurs during pregnancy, disturbances in 
mother-to-infant attachment can also occur. In the mother, 
there is anxiety over the infant’s prognosis and the intervention 
of social authorities, possibly leading to further substance 
abuse. The separation of mother and infant due to the need 
for NAS treatment will also disrupt the attachment process. In 
addition, certain characteristics in the mother (e.g., difficulties 
with relationships, low self-esteem, depression, ambivalence, 
sense of guilt, problems with paternity, lack of breastfeeding) 
can all contribute to difficulties with attachment. These can 
be exacerbated when the baby displays characteristics such 
as prematurity, infections and neonatal problems like NAS, all 
of which can cause the baby to be less responsive. Infants 
exposed to drugs in utero are also more irritable and tremulous 
and may not want to be held or cuddled, behaviours the 
mother might incorrectly interpret as signs of rejection (Weiner 
& Finnegan, 2010). As such, measures to enhance the 
relationship between mother and baby are essential.
in larger doses, can depress respirations. Phenobarbital might 
also mask the severity of NAS symptoms. Infants need to be 
closely monitored for the possibility of over-sedation; however, if 
physicians properly monitor the blood level of the phenobarbital, 
there should be no cause for alarm when using this medication 
for the treatment of NAS (Weiner & Finnegan, 2010).
Coyle and colleagues (2002) tested the hypothesis that 
treatment of NAS with a combination of phenobarbital and a 
diluted tincture of opium (DTO) was superior to treatment with 
DTO alone. They found that the combined use resulted in 
shorter hospital stays and less severe symptoms. 
A study of neonatal seizures by Kandall and colleagues (1983) 
observed that 11% of infants treated with phenobarbital 
developed seizures. The authors postulated that phenobarbital 
dosages used to control abstinence were not adequate to 
protect against seizures in the face of enhanced methadone 
clearance induced by phenobarbital. Therefore, it can be 
concluded that an opioid is more effective in relieving the 
symptoms of NAS and that prompt treatment with adequate 
dosages likely adds to the success of treatment with avoidance 
of seizures (Finnegan et al., 1975; Finnegan & Kandall, 2005).
In two searches of the Cochrane Controlled Trials Register, 
Osborn and colleagues (2002, 2005) examined the 
effectiveness and safety of opioid treatment compared to 
the use of sedatives and supportive care. In the first search, 
which included five studies with 285 infants meeting inclusion 
criteria, they concluded there is no evidence that phenobarbital 
(compared to supportive care alone) reduces treatment failure; 
however, it might reduce the daily duration of supportive care 
needed. From the second search, which included seven 
studies with 585 infants meeting inclusion criteria, they 
concluded that opiates (compared to supportive care alone) 
appeared to reduce both the time needed to regain birth weight 
and the duration of supportive care, but increased the duration 
of hospital stay. When compared to phenobarbital, opiates 
might reduce the incidence of seizures but there is no evidence 
of effect on treatment failure, further illustrating the superiority of 
opioids for the treatment of NAS.
Clonidine
The American Academy of Pediatrics also recommends 
clonidine, an α2-adrenergic receptor agonist that can be used 
in combination with an opioid or other drug in older children 
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As a result of the difficulties describe above, supporting the 
mother is equally important. Because the substance-using 
mother might not have all of the parenting skills expected of her, 
frustration leading to abuse of the infant could occur. Providing 
supportive care to the mother through an appropriate treatment 
program might prevent any untoward actions by the mother 
upon the baby (Weiner & Finnegan, 2010). 
Breastfeeding enhances the infant’s immune system as well 
as maternal-infant attachment. Because opioids pass to the 
nursing infant through the breast milk in very small amounts, 
breastfeeding does not affect the severity of the NAS nor does 
it achieve sufficient concentrations to serve as treatment for 
neonatal symptoms (McCarthy & Posey, 2000). However, as 
babies with NAS have difficulties coordinating their sucking and 
swallowing reflexes, breastfeeding can be very challenging.
There is a great deal of information available for the clinicians, 
parents and others who care for newborns experiencing 
abstinence symptoms, not only in the published literature but 
also in the numerous protocols and guidelines concerning the 
assessment and management of NAS. For example, British 
Columbia’s Ministry of Children and Family Development has 
developed a resource for parents and caregivers on how to 
provide daily care for babies who have been prenatally exposed 
to alcohol or other drugs (Nelson et al., 2011). This resource is 
based on information collected from sources such as parents, 
caregivers, healthcare professionals and the published literature. 
Due to the availability of these kinds of resources and supports, 
there is no reason why babies affected by this condition should 
not be able to receive excellent care to treat and alleviate their 
symptoms. 
When a baby is born to a mother known to be using methadone 
or heroin, it is usually separated from the mother and admitted 
to an intensive care nursery for observation. Concerned that this 
separation contributes to decreased maternal attachment and 
neonatal abandonment, Abrahams and colleagues (2007) from 
the University of British Columbia conducted a retrospective 
cohort study to compare NAS treatment and discharge 
outcomes of newborns who “roomed in” with their mothers 
to those who received traditional care in neonatal intensive 
care nurseries. They found that newborns who roomed in with 
their mothers were less likely to require treatment for NAS and 
were more likely to be discharged home with their mothers, 
concluding that rooming in might promote more effective 
mothering and reduce NAS prevalence and severity.
In all cases, it is important to create a supportive environment 
for the infant experiencing abstinence. The following techniques 
recommended by Weiner and Finnegan (2010) have all been 
proven helpful in calming the baby: 
• Blanket swaddling when at rest and feeding; 
• Non-nutritive sucking (e.g., with a pacifier); 
• Demand feedings; 
• Changes in position so that when the baby shakes, 
excoriation (irritation) of the skin does not occur; 
• Frequent skin care and diaper changes to prevent 
infection from excoriated skin; 
• Decreased stimuli in the hospital and/or home   
(e.g., a quiet, dimly lit room); 
• Appropriate dressing to avoid overheating;
• Gentle handling; and 
• Firm holding close to the body. 
Caring for an infant with NAS can be challenging for many 
parents. During the hospitalization of the infant, nursing staff 
should take the opportunity to teach parents the supportive 
measures listed above. Parents should also be advised of the 
persistent signs of abstinence that can last for as long as six 
months, which can include constant sucking and exaggerated 
rooting reflex, sweating, sensitivity to sounds, lessened 
responsiveness to visual stimulation, high-pitched crying, 
irregular sleep patterns and loose stools. These symptoms 
will generally not need any intervention with medications but 
supportive measures are essential (Weiner & Finnegan, 2010).
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To lessen the risks associated with their high-risk pregnancies, 
women who abuse drugs should be given access not only to 
specialized, comprehensive medical and obstetrical care but 
also to addiction counselling and psychosocial supports. U.S. 
Public Law 102-321, enacted in 1993, dictates that substance-
using pregnant women must have first priority for drug treatment 
and timely access to health care, and must be provided with 
appropriate child care and transportation assistance when 
receiving treatment (Finnegan & Kandall, 2005).
Drug abuse and dependence are complex conditions that present a number of substantial challenges for the healthcare system. Addiction can be likened to other chronic, relapsing diseases, with acute aggravations of varying severity followed 
by periods of dormancy. In some cases, only minimal treatment is required; in others, 
more intensive treatment is needed. 
For drug-dependent pregnant women and their unborn children, a treatment approach 
that combines comprehensive services, prenatal care and the stopping of illicit drug use 
is essential to avoiding negative outcomes. Fortunately, pregnant women, even those who 
are abusing drugs, generally want to do what’s best for their babies. This makes pregnancy 
a period of opportunity to initiate changes in the mother’s substance use patterns and 
steer her toward appropriate treatment services.
5.1.1 The evolution of the comprehensive 
services approach
U.S. Public Law 102-321 marked a significant change in 
attitudes toward women suffering from drug abuse and 
dependence. In his writings on the history of women and 
addiction, Kandall (2010) made a number of observations:
• The extent of female drug use has always been wider 
than acknowledged;
• Women were frequently inappropriately medicated 
or overmedicated by physicians and pharmacists, 
leading to substance abuse through self-medication;
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• Comprehensive, multidisciplinary treatment services for pregnant women who abuse drugs have 
demonstrated numerous positive outcomes for the mother and baby, including adequate prenatal 
care, improved maternal nutrition, reduced risk of premature birth, and decreased maternal and infant 
morbidity and mortality.
• A comprehensive treatment approach is one that combines a variety of services including medical and 
prenatal care, addiction counselling, psychosocial supports, child care services and transportation 
assistance.
• The stigma associated with drug abuse, particularly among pregnant women, presents a significant 
barrier to accessing treatment.
• Supervised medication-assisted treatment is an effective component of a comprehensive treatment 
plan for pregnant women who abuse drugs.  However, there is comparatively less research that has 
examined how a newborn is impacted by exposure to such treatment, which limits the ability to draw 
firm conclusions.
• Mothers undergoing medication-assisted treatment can breastfeed their babies except in certain 
circumstances when there is continued concomitant drug use or HIV positivity.
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5.1.2 A “one-stop” approach to drug 
treatment
Philadelphia’s Family Center, established in 1972 and still in 
operation today, has determined that the intertwining medical 
and psychosocial risk factors that typically characterize drug 
dependency during the perinatal period is best treated by a 
comprehensive, supportive and nonjudgmental approach. In 
particular, its approach encompasses the following:
• A wide range of treatment services (residential, 
outpatient, home-based, prison-based);
• Onsite methadone maintenance treatment and 
inpatient stabilization of opioid-addicted patients;
• Inpatient treatment of newborns exhibiting signs of 
withdrawal (through the Newborn Nursery Service at 
Thomas Jefferson University Hospital);
• Long-term residential drug treatment services   
(through My Sisters Place at Thomas Jefferson 
University Hospital);
• Family-based health care (obstetric, pediatric and 
general medical), which is made available to the baby, 
father, significant other, grandparents and whomever 
else the pregnant woman identifies as being important 
to her recovery;
• Multiple counselling and therapy modalities  
(individual, group and family);
• Counselling on sexual abuse and domestic violence;
• Services for children (day care, play therapy and 
parental training);
• Concrete services (transportation, housing and food);
• Educational training (job training and high school 
equivalency training);
• Advocacy services (legal, welfare and child 
protection); and 
• Aftercare. 
In addition, by providing all of these services from a single 
location, the Family Center Program makes it easier for pregnant 
women to access the multiple aspects of treatment, ultimately 
enhancing compliance with their treatment plans.
• Women are more vulnerable to social ostracism, 
vilification and prosecution because of their drug   
use; and
• Addicted women have typically been marginalized and 
politically ignored, resulting in them receiving little help 
for their substance abuse problems.
In the 1970s, the women’s rights movement created an 
atmosphere in which a more enlightened discussion of women 
and drugs could occur. This, in turn, enabled the development 
of a comprehensive model of care that could enable addicted 
women to receive medical, obstetric and psychosocial 
services under one roof (Finnegan et al., 1972). By 1975, the 
U.S. National Institute on Drug Abuse (NIDA) had launched 
innovative drug-treatment demonstration grants in six cities, all 
using pregnancy as the entry point. At the same time, programs 
such as the Family Center Program in Philadelphia, the Hutzel 
Hospital Program in Detroit and the Pregnant Addicts and 
Addicted Mothers Program in New York were pioneering efforts 
to provide pregnant and parenting women using substances 
with a network of comprehensive, inter-related services.
CREATING A NATIONAL PICTURE OF 
ADDICTIONS TREATMENT IN CANADA
Historically, there has not been a central place where 
Canadians could go for information about treatment services 
for substance use. As part of the National Treatment Strategy, 
an interactive map has been created to address this gap, 
providing information on:
• How treatment services for those suffering with 
substance abuse are organized;
• Provincial and territorial strategies for addressing 
substance use; and
• Treatment service summary data.
In addition, the National Treatment Indicators (NTI) project 
aims to provide a comprehensive picture of substance 
use treatment in Canada. The recently published National 
Treatment Indicators Report summarizes 2010–2011 
jurisdictional-level data on treatment services across the 
country.
Both the map and the NTI report are available at   
www.nts-snt.ca. 
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Figure 1. Family Center schema for the treatment of drug dependency in the perinatal period and aftercare
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dependence cannot be expected in such a short timeframe 
because treatment duration and intensity are both directly 
correlated to the recovery outcome. Women should therefore 
be engaged in treatment for an adequate period of time from 
pregnancy until the family is stable and safe. It is also important 
to reassess treatment needs periodically as multiple episodes 
of treatment might be necessary.
5.1.3 Outcomes of comprehensive services
Multiple studies have shown that comprehensive, 
multidisciplinary care for using drug pregnant women decreases 
illicit drug use, improves retention in treatment programs, 
increases the amount of prenatal care received, improves 
maternal nutrition, boosts maternal self-esteem, decreases 
maternal and infant morbidity and mortality, reduces the risk 
of premature birth, improves birth weights, creates home 
environments better suited for a newborn baby and enhances 
Comprehensive services like those offered by the Family Center 
Program require the collective effort of professionals from a 
multitude of disciplines, including physicians (e.g., addiction 
specialists, psychiatrists, obstetricians), pharmacists, nurses, 
social workers, psychologists, addiction counsellors and child 
development specialists. In addition, many of the activities 
designed to normalize the lives of the women enrolled in these 
kinds of programs are best accomplished in group settings 
that can address topics such as relapse prevention, life skills, 
problem solving, coping, parenting, child care and child 
development, women’s health, neonatal abstinence, and anger 
and stress issues (Finnegan et al., 1991).
Because enrolment in a comprehensive services program 
typically lasts only three to six months prior to delivery, the 
aim of such programs is to reduce illicit drug use and enable 
a more stable life situation. Complete recoveries from drug 
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history of alcohol or drug abuse. In a retrospective chart 
review of 121 women who received care at T-CUP 
from August 2000 to January 2006, Ordean (2011) 
found positive maternal and infant health outcomes 
when the women had received comprehensive care, 
with approximately 75% of newborns discharged to 
home in the care of their mothers.
The comprehensive services model is also used outside 
of North America. From their review of the management of 
drug misuse in pregnancy, Day and George (2005) from the 
University of Birmingham in the United Kingdom noted that a 
range of service models have been developed in response to 
specific local needs and positive results have been achieved. 
For example, they found evidence that residential treatment 
programs that include facilities to admit children with their 
parents have improved rates of retention in treatment and 
higher abstinence rates (Hughes et al., 1995). They also found 
that the more comprehensive a residential program, the better 
the outcomes (Stevens & Arbiter, 1995). However, significant 
improvement in the health of opioid-dependent pregnant 
women and their babies can occur if they are monitored as 
outpatients by specialist obstetric units with expertise in 
managing substance use (Dunlop et al., 2003). 
Day and George (2005) concluded that drug abuse is best 
managed through the development of a care plan that involves 
obstetric, neonatal and social services. They also noted that 
the predominantly negative attitudes toward pregnant women 
using substances must be taken into consideration, as these 
will have an impact on whether an individual seeks help and 
subsequently enters a treatment program.
In France, Brulet and colleagues (2007) evaluated the drug-
using behaviour and pregnancy outcomes of 114 opioid-
dependent women receiving multidisciplinary monitoring and 
psychosocial support at Montpellier University Hospital. Like 
the other studies mentioned above, their results also found 
that multidisciplinary prenatal care that included medical, social 
and psychological support decreased maternal and fetal risks 
during pregnancy.
mother-child attachment (Finnegan et al., 1991). In addition, 
substance abuse treatment programs integrated with prenatal 
care have proven to be effective in reducing maternal and fetal 
pregnancy complications and costs (Finnegan et al., 1972, 
1991; Armstrong et al., 2003).
Many programs have used treatment regimens similar to 
the one used by the Family Center Program over the years, 
with numerous studies finding that comprehensive services 
contribute to excellent outcomes for pregnant women and their 
babies. For example: 
• Reporting on the outcomes of women enrolled in 
New York Medical College’s Pregnant Addicts and 
Addicted Mothers Program, Green and colleagues 
(1979) found the number of prenatal visits correlated 
significantly with the newborn’s gestational age at 
birth. They concluded that better neonatal outcomes 
occurred when the mother joined a comprehensive 
services program early in pregnancy and attended 
relatively often. Similar findings were also reported by 
Suffet and Brotman (1984). After providing pregnant 
addicts and their infants with comprehensive medical, 
counselling and child development services, they 
found the most favourable outcomes were directly 
related to the amount and duration of prenatal care.
• In the 1990s, Johns Hopkins University in Baltimore, 
Maryland, assessed its comprehensive services for 
pregnant women using drugs attending the Center 
for Addiction and Pregnancy, which combines the 
disciplines of pediatrics, addictions, obstetrics and 
family planning. The university found that it was able 
to improve both maternal and neonatal outcomes, 
with infants showing developmental indices within the 
normal range. Treatment costs were also reduced 
as a result of the mother having fewer medical 
complications and decreased infant morbidity 
(Jansson et al., 1996).
• The Toronto Centre for Substance Use in Pregnancy 
(T-CUP) is a family medicine program that uses the 
“one-stop access” model to provide comprehensive 
services, including addiction counselling and pre- and 
postnatal medical care, to pregnant women with a 
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Pregnant women can also be at increased risk of attrition. Putting 
pregnant women on a waiting list, for example, results in the 
loss of a critical opportunity to provide treatment; in many cases, 
women are more likely to deliver their babies before being enrolled 
in the treatment program. The effect of wait times on substance 
abuse treatment completion in 10,661 pregnant women was 
studied in Baltimore, Maryland. Analyzing the women’s treatment 
admissions and discharges, the study found that shorter wait 
times are associated with increased treatment completion rates, 
especially in the ambulatory setting (Albrecht et al., 2011).
Stigma also presents a significant barrier to treatment. Women 
who feel guilt and shame about their substance use tend to have 
difficulty seeking and accessing the help they need. When they 
do reach out to healthcare professionals, women using drugs 
often encounter misinformation, denial, inaction and even punitive 
attitudes toward their substance use (Copeland, 1997; Grella, 
1997; Health Canada, 2001; Poole & Isaac, 2001; Cormier et 
al., 2004). 
In particular, Cormier and colleagues (2004) made a number of 
recommendations related to the treatment of women using drugs. 
One was to make treatment programming that addresses gender 
differences more easily accessible to women in Canada. Another 
concerned the blending of treatment for substance abuse, mental 
health and relationship violence, calling for linkages among these 
programs to be enhanced—or even integrated—to better address 
the interconnections among these health issues.
5.2 Prenatal care and the role of 
the obstetrician
Although they represent just one aspect of the comprehensive 
services model, obstetricians, gynaecologists and other 
healthcare providers (e.g., family physicians) have an important 
part to play in substance abuse treatment and intervention. 
They can influence the outcomes for pregnant women and their 
babies by providing appropriate information to encourage healthy 
behaviours, adhering to safe prescribing practices, and identifying 
and referring patients who are abusing drugs to addiction 
treatment professionals (American Congress of Obstetricians and 
Gynecologists [ACOG], 2006, 2011).
The role of the obstetrician is especially important given that 
substance-abusing women have considerable risk of maternal 
and fetal complications. Obstetricians should evaluate these 
5.1.4 Barriers to the delivery of 
comprehensive services
Although comprehensive service programs are becoming 
increasingly available, as of 2010 only 19 U.S. states had drug-
treatment programs for pregnant women and only nine gave 
priority access to pregnant women. In addition, many of these 
programs frequently do not provide child care, do not account 
for women’s family responsibilities or fail to provide affordable 
treatment (Guttmacher Institute, 2010). Under such restrictions, 
women who have not received treatment for drug dependence 
cannot be assumed to have rejected treatment (Flavin & 
Paltrow, 2010). Despite the many benefits associated with 
comprehensive services, it is evident that healthcare providers 
are still missing numerous opportunities to effectively intervene 
in the lives of pregnant women addicted to drugs. 
For example, Mann and colleagues (1992) found that while 
services to 4,539 newborns prenatally exposed to drugs were 
provided by the State of Florida in 1990, an estimated 5,911 did 
not receive services because of an overburdened healthcare 
system and a failure to identify women in need of treatment. 
That said, the number of substance-abusing women identified 
during pregnancy increased markedly from 1989 to 1990; as 
more pregnant women were given appropriate prenatal care 
and referred for drug abuse treatment, low birth weight in 
newborns prenatally exposed to drugs decreased from 55% in 
1989 to 26% in 1990.
Through personal interviews with 181 addicted women and 
a survey of 94 drug treatment programs in Washington, DC, 
Gershan (1995) examined the practices of prenatal care 
providers in detecting substance abuse among pregnant women 
and making referrals to treatment services. While a majority of the 
women (65%) had been asked about alcohol and drug use by 
physicians or nurses during their most recent pregnancies, 59% 
of those asked were not given any information about the effects 
of alcohol or drugs on pregnancy. More alarmingly, only 5% 
of those asked were referred to drug counsellors or treatment 
programs, even though 43% admitted to substance use and 
an additional 13% were using but did not admit it. Fortunately, 
with the increased availability of literature about drugs and 
pregnancy from government sources and advocacy groups, 
more healthcare professionals are now capable of providing 
information and making appropriate referrals.
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• Opioid-dependent women should be informed that 
newborns exposed to heroin, prescription opioids, 
methadone or buprenorphine during pregnancy are 
monitored closely for symptoms and signs of neonatal 
withdrawal. Hospitals providing obstetric care should 
develop a protocol for assessment and management 
of newborns exposed to opioids during pregnancy.
• Antenatal planning for intrapartum and postpartum 
pain medication can be offered for all women in 
consultation with appropriate healthcare providers.
• The risks and benefits of breastfeeding should be 
weighed on an individual basis because methadone 
maintenance therapy is not a contraindication to 
breastfeeding. 
5.2.1 Management of maternal nutrition
For many obstetricians, managing the nutritional intake of 
a substance-using pregnant woman can be particularly 
frustrating because it is often quite difficult to change a person’s 
established behaviours. Even so, nutritional counselling from 
trained dieticians, frequent weight checks and fetal surveillance 
for intrauterine growth restriction should be incorporated into 
routine obstetrical care for substance-abusing mothers (Keegan 
et al., 2010).
Nutritional counselling
Pregnant women abusing drugs should be counselled on 
the importance of a balanced diet and should be given 
recommendations for caloric intake and appropriate weight 
gain. Because dietary allowances of most vitamins and 
minerals increase during pregnancy, prenatal vitamins and iron 
supplements should be included in the daily diet. Iron deficiency 
anemia is a common problem in substance-abusing pregnant 
women; therefore, an additional 60–120 milligrams of iron is 
recommended. Vitamin C and folic acid are also important 
supplements for pregnant women, regardless of substance-
abusing status (Keegan et al., 2010).
Surveillance for intrauterine growth restriction and 
fetal weight
Alcohol and drug use are strongly associated with intrauterine 
growth restriction (ACOG, 2007). Because this is the case, 
surveillance for appropriate fetal growth and placental function 
is a critical component of care for pregnant women using drugs.
high-risk patients for poor maternal nutrition, intrauterine growth 
restriction, and poor placental perfusion and function. In the 
case of alcohol abuse, the possibility of fetal alcohol spectrum 
disorder accompanied by poor fetal growth and central nervous 
system abnormalities must be considered. Placental abruption 
and stillbirth are important additional considerations in the event 
of cocaine abuse (Keegan et al., 2010). 
As part of its goal to improve awareness of the issues related to 
substance use during pregnancy, the Society of Obstetricians 
and Gynaecologists of Canada has developed the following 
evidence-based recommendations for screening and managing 
problematic substance use during pregnancy and lactation 
(Wong et al., 2011):
• All pregnant women of childbearing age should 
be screened periodically for alcohol, tobacco and 
prescription and illicit drug use.
• When testing for substance use is clinically indicated, 
urine drug screening is the preferred method.
• Because policies and legal requirements with respect 
to drug testing of newborns can vary by jurisdiction, 
caregivers should be familiar with the regulations in 
their region.
• Healthcare providers should employ a flexible 
approach to the care of women who have substance 
use problems and should encourage the use of all 
available community resources. 
• Women should be counselled about the risks of 
periconception, antepartum and postpartum drug 
use.
• Smoking cessation counselling should be considered 
as a first-line intervention for pregnant smokers. 
Nicotine replacement therapy or pharmacotherapy 
can be considered if counselling is not successful.
• Methadone maintenance treatment should be the 
standard of care for opioid-dependent women during 
pregnancy. Other slow-release opioid preparations 
can be considered if methadone is not available.
• Opioid detoxification should be reserved for selected 
women because of the high risk of relapse to opioids.
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7 Fundal height is a measure of a pregnant woman’s belly to see if the gestational age is compatible with the uterus size. A baby growing inside the womb of a 
pregnant woman will have a fundal height that matches closely (if not exactly) with the amount of weeks the mother has been pregnant. For example, a woman who 
is 33 weeks pregnant should have a fundal height measurement of 32–34 centimetres.
Establishing effective lines of communication with pregnant 
women using substances can be difficult, especially when they 
present in the labour area with erratic, bizarre, angry or uncaring 
behaviour (Byrne & Lerner, 1992). One reason why pregnant 
women might present such behaviour is because they have 
taken drugs prior to arrival to the labour suite. Cocaine and 
heroin users will frequently obtain drugs when labour begins, 
fearing that pain medication will not be offered or be inadequate. 
In these instances, obstetricians can establish a trusting 
relationship by speaking in a calm voice, using appropriate 
physical contact and employing soft lighting, all of which can 
be beneficial while trying to gain control of a potentially chaotic 
situation (Byrne & Lerner, 1992).
When a substance-abusing woman presents in labour, selecting 
the correct anesthesia or analgesia is particularly important. 
Various studies have delineated dangerous combinations of 
drugs of abuse and certain medications generally used for 
alleviating pain or anesthesia (Kuczkowski, 2003, 2005; Ludlow 
et al., 2007). For example:
• Tobacco use affects the pulmonary system by 
increasing sputum and secretion production and by 
impairing gas exchange;
• Cigarette smoking can affect liver enzyme function 
and alter the metabolism of the induction agents used 
for general anesthesia; 
• Alcohol intoxication increases gastric acidity and 
diminishes the ability to protect the airway;
• The labouring patient with a history of opioid abuse 
can present with respiratory depression and arrest; 
• Cocaine-induced thrombocytopenia (a decrease 
in the blood platelets that assist in clotting) can 
present a contraindication to regional anesthesia and 
analgesia;
• Central nervous system effects commonly observed 
in amphetamine users, such as increased alertness 
and euphoria, can make placement of regional 
anesthesia difficult; 
• Patients presenting in labour with recent marijuana 
use often experience heart dysfunction and rapid 
heart rate;
Recommendations regarding surveillance for fetal growth 
and placental function generally involve regular uterine fundal 
height7 measurements and ultrasound evaluations, with 
particular attention paid to fetal head circumference and 
biparietal diameter (distance across the fetal head), abdominal 
circumference, amniotic fluid indices and Doppler velocimetry 
(measurement of the rate of blood flow through the umbilical 
artery). When intrauterine growth restriction is confirmed, the 
possibility of perinatal death or stillbirth becomes an important 
consideration. Although intrauterine growth restriction can 
almost never be reversed, careful surveillance is associated 
with a reduction in perinatal death (ACOG, 2007). 
Non-stress testing, contraction stress testing and the 
biophysical profile are three common tests used by obstetricians 
to assess fetal well-being. Ultrasound measurements of the 
biparietal diameter and fetal head circumference, abdominal 
circumference and femur length provide the most accurate 
estimated fetal weight. These measurements should be taken 
every two to four weeks if intrauterine growth restriction is 
suspected (Keegan et al., 2010). 
5.2.2 Delivery and labour
The timing of delivery can also be a challenge for obstetricians, 
who must carefully weigh the risk of prematurity versus the 
ongoing risk of intrauterine fetal death if poor fetal growth 
or placental insufficiency is suspected. Oligohydramnios or 
anhydramnios (a small amount or no amniotic fluid, respectively) 
as well as abnormalities in the uterine blood flow can all indicate 
the need for delivery. The complete absence of fetal growth 
observed in consecutive ultrasound evaluations two to four weeks 
apart can also provide a strong indication for the obstetrician to 
intervene with an early delivery (Keegan et al., 2010).
Management of the substance-using woman in labour can 
present additional challenges. Communication with the patient 
and management of anesthesia are of primary importance. 
Nurses, physicians and midwives must put the patient at 
ease and inform her of the potential for a variety of obstetric 
interventions, all of which will be done to maximize the likelihood 
of a positive outcome for her and her baby. 
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One form of contingency management is the token economy 
system, which has been shown to be successful with 
a diverse array of populations, including those suffering 
from addiction (Petry, 2001). Another is voucher-based 
contingency management, where patients earn vouchers 
(often exchangeable for prizes or program-specific privileges) 
contingent upon objectively verified abstinence or the 
achievement of specific behaviour-change goals (Petry et al., 
2007; Stitzer et al., 2007). In a series of controlled clinical trials, 
the voucher-based approach was shown to be the most reliable 
method for producing abstinence in cocaine users (Lussier et 
al., 2006; Prendergast et al., 2007). 
Contingency management has been effectively used to treat 
single-problem addictions as well as dual diagnoses (Drebing 
et al., 2007; Ghitza et al., 2008). Positive contingency rewards 
can also improve pregnancy outcomes; the 2010 Maternal 
Opioid Treatment: Human Experimental Research (MOTHER) 
Study found that escalating reinforcement procedures can 
help decrease drug abuse and increase outpatient attendance 
(Jones et al., 2010).
5.4 Medication-assisted 
treatment
Medication can become an essential part of an addict’s ongoing 
treatment plan, enabling opioid-addicted individuals to regain 
control over their lives.
Because drug use changes the way the brain works (i.e., by 
causing compulsive behaviour focused on drug seeking and 
use), medical treatment for substance abuse must address 
these neurological changes to be truly effective. Medications 
developed to treat opioid addiction, such as methadone and 
buprenorphine, work through the same receptors in the brain 
as the addictive drug but are less likely to produce the harmful 
behaviours that characterize addiction. These medications work 
by either activating opiate receptors8 in the brain but producing 
a diminished response, or by blocking these receptors and 
interfering with opioids’ rewarding effects (National Institute on 
Drug Abuse, 2012).
Although both methadone and buprenorphine effectively 
suppress opioid use, it is important to note that neither 
medication is a “cure” for opioid addiction.
• Marijuana can increase the sedative and hypnotic 
effects of anesthetic agents; and
• Heavy marijuana use can impair lung function.
With the potential complications expected when administering 
anesthesia to pregnant women using drugs in labour, regional 
anesthesia is usually the best choice. Regional anesthesia is 
considered safe for alcohol-abusing patients as long as they 
do not suffer from an underlying neuropathy or clotting disorder. 
It is also safe for opioid abusers, who can have diminished 
anesthetic requirements. (Conversely, chronic opioid abusers 
can actually have increased tolerance and therefore require 
higher doses than anticipated.) However, both regional and 
general anesthesia can be complicated in cocaine users. 
Propofol, a commonly used medication in the United States, 
has been shown to be effective for the induction of anesthesia 
in cocaine-abusing mothers (Ludlow et al., 2007). 
Unless there is a strong clinical indication to do so, pregnant 
women undergoing methadone maintenance therapy should 
not have their methadone withheld during labour because 
they will most likely experience withdrawal symptoms 
(Ludlow et al., 2007).
5.3 Contingency management
Stopping the use of illicit drugs is the best way to improve 
maternal and fetal health outcomes. Unfortunately, this is easier 
said than done. Individuals addicted to alcohol and other drugs 
often fail to stay off their drugs of choice because they will not 
go to or stay in treatment.
Contingency management is one approach that can be taken 
to improve patients’ motivation to remain in treatment. First used 
in the addiction field in the 1960s, contingency management is 
based on the idea that behaviour is more likely to continue if it 
is reinforced. By systematically rewarding desired behaviours 
and withholding reinforcement of undesired behaviours, 
contingency management is an effective strategy for reducing 
the use of alcohol and other drugs, improving attendance of 
treatment programs and reinforcing treatment goals such as 
complying with a medication regimen or obtaining employment 
(Miller, 1975; Higgins et al., 1993; Higgins & Petry, 1999).
8 Opiate receptors are proteins found in the spinal cord, brain and gastrointestinal tract. Opioids such as heroin, morphine and methadone bind to these receptors 
in the brain to reduce feelings of pain and cause feelings of euphoria.
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RAMONA
Ramona, 28, had been dating Carlos for just over 
a year. He treated her well and had lots of money. 
Having grown up poor, she thought he would be 
a good man to marry. But she was unaware that 
Carlos’ income came from dealing drugs. One 
night at a party, he cajoled her into snorting heroin. 
The only drug Ramona had tried in the past was 
marijuana. Although she didn’t like heroin at first, after 
several hits she found she enjoyed the high—and 
that it pleased Carlos. Her occasional use became 
increasingly frequent, until she was using heroin every 
day. Her life began to change. She found it hard to 
get up for work. Her parents noticed a shift in her 
personality and that she had gained a lot of weight. 
Carlos became abusive; Ramona became depressed. 
Then she discovered she was pregnant. Almost 
immediately, she sought to recover from her addiction 
because she was sick on a daily basis and about 
to lose her job. Fortunately, a friend referred her to 
a clinic that provided comprehensive services and 
methadone maintenance treatment for individuals 
dependent on heroin. After being evaluated for her 
addiction, psychiatric status and pregnancy, she 
was provided with high-risk obstetrical services, 
counselling and daily methadone. She could receive 
her methadone early in the morning and counselling 
after work twice weekly. She ended her relationship 
with Carlos, and is focusing on recovery and 
becoming a good parent. 
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Some of the side-effects of methadone maintenance therapy 
can include sweating, constipation, sexual difficulties, 
drowsiness and weight change (Centre for Addiction and 
Mental Health, 2008; Bonhomme et al., 2012). An increase 
in methadone dosage may cause drowsiness for up to three 
days, making driving and other activities that require alertness 
potentially more hazardous (New Brunswick Addiction Services, 
2005).
Regulation of methadone
In Canada, methadone is listed under Schedule I of Controlled 
Drugs and Substances Act. This means that, unless authorized, 
the possession, trafficking, importing and exporting of 
methadone are all illegal. To prescribe methadone for analgesia 
or for the treatment of opioid dependence, physicians must 
be exempted under Section 56 of the Act. The support of the 
physician’s licensing body is also normally required.
British Columbia, Saskatchewan, Ontario and Quebec have 
their own provincial guidelines that should be followed by 
practitioners prescribing methadone in those provinces. 
Health Canada has also produced guidelines for methadone 
maintenance treatment to be followed by all other provinces 
(Health Canada, 2002).
In the United States, the Controlled Substances Act classifies 
substances according to their currently accepted medical use 
as well as their relative abuse potential and likelihood of causing 
dependence. Drugs in Schedules II–V, including methadone 
and other opioids such as morphine and oxycodone (all of 
which are listed under Schedule II), have some accepted 
medical use and may therefore be prescribed, administered or 
dispensed for medical use. 
Methadone was approved by the U.S. Food and Drug 
Administration (FDA) in 1973 for medical use against heroin 
addiction and is currently the only opioid medication approved 
for medication-assisted treatment in pregnant women (CDC, 
2000). The FDA has also established five categories (A, B, C, 
D, X) to indicate the potential of a drug to cause birth defects 
if used during pregnancy. (It should be noted that risks from 
pharmaceutical agents or their metabolites in breast milk are 
not accounted for in these categories). Although approved 
by the FDA, methadone is listed as a Category C pregnancy 
5.4.1 Methadone 
A synthetic opioid, methadone is used medically as an 
analgesic for managing severe chronic pain and, more pertinent 
to this publication, as a maintenance medication in patients with 
opioid dependency. 
Methadone maintenance for opioid-dependent individuals 
began as a research project at the Rockefeller University in 
1964 in response to the burgeoning post-war heroin addiction 
epidemic (Joseph et al., 2000). Since then, it has been 
rigorously tested and safely used to treat opioid addiction for 
more than 40 years. 
Methadone works by blocking the craving for opioids (which 
is a major factor in relapse), suppressing the symptoms of 
opioid withdrawal for 24–36 hours and blocking the effects of 
administered heroin or other opioids (such as oxycodone). In 
addition, it does not cause intoxication or sedation, meaning 
it does not impair cognitive functions and has no adverse 
effects on mental capability or intelligence (Centers for Disease 
Control and Prevention [CDC], 2000). In a Cochrane review 
of 11 randomized clinical trials, methadone maintenance 
therapy appeared significantly more effective compared to non-
pharmacological approaches in retaining patients in treatment 
and in the suppression of heroin use (Mattick et al., 2009). 
Enrolment in methadone maintenance treatment also has the 
potential to reduce the transmission of infectious diseases 
associated with heroin injection, including hepatitis and human 
immunodeficiency virus (HIV; Joseph et al., 2000).
Because methadone offers similar effects to heroin and 
morphine but without the same intensity, properly dosed 
patients can reduce or cease their use of these illicit substances 
completely. Daily methadone doses of 80 milligrams or more 
have been shown to exert a definite blocking effect on heroin 
craving, with the exact dose depending on a variety of individual 
factors. Provided the dosage is appropriate for a given patient, 
he or she can be maintained for years on methadone. Given 
that methadone is a corrective rather than a curative treatment 
for heroin addiction, it should be prescribed for an indefinite 
period of time (Joseph et al., 2000).
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When coupled with comprehensive care, methadone 
maintenance for opioid-dependent pregnant women has been 
shown to reduce perinatal morbidity and mortality, largely due 
to reduced rates of low-weight births and improved treatment 
of maternal complications (Finnegan, 1991a; Jarvis & Schnoll, 
1994; Finnegan & Kandall, 2005). A systematic review of 
randomized controlled studies of methadone treatment 
during pregnancy also revealed an approximate threefold 
reduction in heroin use and a threefold increase in treatment 
retention relative to non-pharmacologic treatment (Rayburn & 
Bogenshutz, 2004). 
A recent Ontario study compared mortality rates of infants 
exposed to methadone to those of the general population 
using data from several provincial and national databases (Kelly 
et al., 2012). The authors concluded that children under the 
age of one year who were born to mothers on methadone 
maintenance therapy were not at increased risk for mortality.
Finally, mothers stabilized on methadone are more likely to 
retain custody because of the opportunities for child care, 
parenting education and life skills management offered at 
many methadone clinics that provide comprehensive services 
(CSAT, 2005).
Managing methadone dosage in pregnant women
Although the benefits are clear, methadone can be a potentially 
dangerous medication unless properly supervised. Therefore, 
it is highly controlled and pregnant women must make daily 
visits to an approved program to receive their medication 
dose, which will only suppress cravings for 24–36 hours. One 
of the most common side effects of methadone maintenance 
is neonatal abstinence syndrome (NAS) when the drug supply 
is interrupted at birth. (See Chapter 4 for a more in-depth 
discussion of NAS.) Fortunately, the risks to pregnant women 
and their unborn babies are few if the methadone dosage is 
properly managed. 
Studies on the pharmacology of methadone in pregnant women 
revealed that plasma methadone levels during pregnancy show 
marked intra-patient and inter-patient variability (Pond et al., 
1985). As pregnancy progresses, the same methadone dose 
produces lower blood methadone levels because of increased 
fluid volume, a larger tissue reservoir for methadone and altered 
opioid metabolism in both the placenta and the fetus. Because 
drug, which states that although animal studies have shown an 
adverse effect on the fetus and there have been no adequate 
and well-controlled studies in humans, the potential benefits 
may warrant its use despite the risk.
In addition, methadone maintenance is considered so vital 
for the health of opioid-addicted pregnant women that U.S. 
federal regulations require these women be given preference 
for admission to methadone maintenance treatment and 
that arrangements be made for proper medical care during 
pregnancy (Institute of Medicine, 1995). 
For a more detailed description of the various drug classifications 
and regulations used in the United States and Canada, please 
see the appendices.
Outcomes of methadone maintenance during 
pregnancy
Considered medically safe for pregnant women when used 
under proper supervision, methadone has long been the “gold 
standard” of treatment for opioid-dependent pregnant women 
(Dole & Nyswander, 1965; Joseph et al., 2000). 
Among heroin-abusing pregnant women, various studies 
(Mitchell, 1993; Institute of Medicine, 1995; Center for 
Substance Abuse Treatment [CSAT], 2005) have shown 
methadone maintenance to: 
• Reduce illegal drug use; 
• Improve maternal nutrition; 
• Increase the likelihood of prenatal care; 
• Permit a more stable intrauterine environment for 
the fetus, decreasing the chances of fetal oxygen 
deprivation; 
• Reduce the slowing of fetal growth and increase 
newborn birth weight; 
• Stabilize the mother’s daily routine, enhancing her 
ability to physically and psychologically prepare for 
birth; 
• Reduce obstetrical complications;
• Help remove the opioid-dependent woman from the 
drug-seeking environment and eliminate related illegal 
behaviours (such as prostitution); and
• Offer an opportunity for these women to restructure 
their lives toward the goal of continued stabilization 
after pregnancy.
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Challenges related to methadone maintenance in 
pregnant women
Although methadone maintenance is an effective treatment for 
opioid-dependent pregnant women, it does present a number 
of challenges to these women and their healthcare providers. 
Compared to men, women are more likely to have: 
• Total responsibility for child care; 
• Lower socioeconomic status; 
• Difficulty with transportation; 
• Greater barriers to treatment entry and retention; and 
• Different psychological, counselling and vocational 
training needs. 
Once the baby is born, the daily trips to the methadone clinic 
might become cumbersome or the mother might not feel well 
enough to make the effort to attend treatment to receive her 
methadone dose, which could lead her back to illicit drugs. A 
great deal of support is therefore necessary from her family as 
well as medical staff to keep her involved in her treatment.
In addition, if the baby remains in the hospital for treatment of 
NAS, it is very important for the mother to visit daily to develop an 
attachment to the infant. Again, support systems are essential.
Broader issues of treatment access and regulation are also of 
significant concern. For example, in 1998, the U.S. National 
Institutes of Health (NIH) issued a consensus statement on 
the treatment of opioid addiction, recommending methadone 
maintenance as the standard of care for pregnant women with 
opioid addictions (NIH, 1998). In particular, the NIH made the 
following recommendations:
• Methadone maintenance coupled with relevant social, 
medical and psychosocial services has the highest 
probability of being the most effective of all treatments 
for opioid addiction;
• Opioid-dependent persons under legal supervision 
(e.g., probation, parole, in prisons) should have 
access to methadone maintenance treatment;
women often experience symptoms of withdrawal during the 
later stages of pregnancy, dosage increases are required to 
maintain blood levels of methadone and avoid withdrawal 
symptoms (Whittmann, 1991). 
Physicians have historically taken a low-dose approach to 
methadone treatment, basing maternal dosage solely on the 
need to decrease the incidence and severity of NAS without 
consideration of the pregnant woman’s comfort. However, 
reduced methadone dosages may result in continued 
substance use with increased risks to both the pregnant 
woman and the fetus. Higher dosages for the pregnant woman 
(i.e., 50–150 milligrams per day), on the other hand, have been 
associated with increased weight gain, decreased illicit drug 
use, improved compliance with prenatal care and, in general, 
better neonatal outcomes (with the exception of the risk of NAS). 
Higher dosages early in pregnancy have also been associated 
with more normal fetal growth (Kandall et al., 1976).
Women receiving methadone prior to pregnancy will be initially 
maintained at their pre-pregnancy dosage. Pregnant women 
using heroin who are not yet on methadone when enrolling into 
treatment can be inducted onto methadone in an outpatient 
setting or, more preferably, admitted to hospital where they can 
be stabilized9 on the medication within 48–72 hours. During the 
hospitalization, the health status of the pregnant women can 
be evaluated and they can be provided with treatments for any 
medical complications that exist. Given the adverse effects of 
poly-substance use on both maternal and fetal health, prenatal 
patients also need to be monitored for their use of other licit or 
illicit substances while receiving methadone.
Although methadone therapy has been used consistently in 
pregnancy for more than four decades, no randomized trials 
comparing dosing regimens have been published on which 
to base specific therapeutic recommendations. As such, 
clinicians tend to use dosages that are individually determined 
and intended to keep both the woman and fetus subjectively 
and objectively comfortable and medically stable.
9 Stabilization of patients onto methadone is a method of increasing the dose upward from a base level so that withdrawal is prevented in both the pregnant mother 
and the unborn baby.
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not an appropriate or healthy choice. And while there are many 
hurdles still to overcome with regard to methadone regulations, 
policies and practical considerations—not to mention the existing 
stigma and prejudice toward pregnant women receiving this 
form of treatment—treatment professionals, research scientists 
and thousands of formerly addicted individuals will attest to the 
fact that methadone is a safe and effective treatment.
5.4.2 Buprenorphine
Methadone has been the standard of care for opioid-dependent 
pregnant women for several decades. However, if methadone 
is refused, cannot be tolerated or is unavailable, medication-
assisted treatment using buprenorphine—a semi-synthetic 
opioid agonist/antagonist—may be considered as long as 
informed consent is obtained and the physician clearly explains 
to the patient that there is limited clinical experience regarding 
the safety of its use during pregnancy when compared to 
methadone (CSAT, 2004).
Like methadone, buprenorphine treats opioid dependency 
by blocking the symptoms of withdrawal, and a number of 
studies in recent years have demonstrated its feasibility and 
effectiveness in the treatment of opioid-dependent patients. 
Through a review of the current evidence available on 
MEDLINE and the Cochrane Database of Systematic Reviews, 
Ducharme and colleagues (2012) from the McGill University 
Health Centre in Montreal found that buprenorphine has a long 
duration and less potential for abuse than methadone and for 
detoxification purposes is at least equivalent to methadone 
in terms of efficacy (Gowing et al., 2006). While they found 
that methadone has a slight advantage in terms of treatment 
retention, a stepped approach with initial use of buprenorphine 
followed by referral to methadone maintenance was also shown 
to be efficacious (Kakko et al., 2007). Citing the potential of 
buprenorphine to increase safety and treatment accessibility for 
opioid-dependent patients in Canada, Srivastava and Kahan 
(2006) from the Centre for Addiction and Mental Health (CAMH) 
suggested that buprenorphine might be a better initial choice 
for patients at greater risk of respiratory depression, such 
as the elderly or those taking benzodiazepines. However, in 
general, buprenorphine should be considered an alternative to 
methadone, not a replacement.
Side effects commonly seen with the use of buprenorphine 
include headaches, sweating, sleeping difficulties, nausea and 
• Political and medical leadership is needed to better 
educate the public and address the stigma and 
misunderstanding creating barriers to the expansion  
of methadone maintenance treatment;
• With better training of healthcare professionals and 
guidelines for accreditation, methadone could be 
prescribed and dispensed in a variety of medical 
settings, including physicians’ offices, primary care 
centres and pharmacies; and
• Funding of methadone maintenance must be 
increased, with coverage for treatment of opioid 
addiction included in both public and private insurance.
Although some of the NIH recommendations have been 
successfully implemented, federal agencies in the United 
States are still working to set others in place. To follow up on 
their implementation, the Legal Action Centre (2011) prepared a 
report for the American Association for the Treatment of Opioid 
Dependence examining the availability of medication-assisted 
treatment in the U.S. criminal justice system. Although an 
estimated 65% of individuals in American prisons or jails have 
a substance use disorder, with a substantial number of these 
individuals (many of them women in their childbearing years) 
addicted to opioids, this report revealed widespread denial of 
access to medication-assisted treatment. The report’s findings 
underline how access to treatment is not uniform across 
different sectors.
Some criminal justice agencies deny access to treatment 
according to a larger policy prohibiting the use of any prescribed 
controlled substance; however, such policies also are likely to 
violate the Americans with Disabilities Act or the Rehabilitation 
Act because of their disparate impact on opiate-addicted 
individuals in need of treatment. The failure to grant individuals 
who need treatment an exemption from such policies as a 
“reasonable accommodation” would also likely violate these 
anti-discrimination laws. And by forcing individuals receiving 
medication-assisted treatment to detoxify without appropriate 
medical supervision or delay provision of treatment, prisons 
and jails also risk violating the U.S. Constitution’s Fourteenth 
Amendment Due Process Clause (Legal Action Center, 2011).
It is clear that methadone maintenance is subject to a number 
of difficult ethical questions. For instance, some claim that 
substituting a highly addictive drug with a strong medication is 
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lower risk of causing physical and/or psychological dependence. 
Methadone, in comparison, is listed under Schedule II due to 
its higher potential for abuse. (For more information on these 
various drug classifications, please see the appendices.)
In 2000, the U.S. Drug Addiction Treatment Act expanded 
its clinical context of medication-assisted treatment to allow 
qualified physicians to dispense or prescribe approved 
Schedule III–V medications for the treatment of opioid addiction. 
Before this law came into effect, Schedule II treatments such 
as methadone could be dispensed only from a very limited 
number of addiction clinics. By making the less tightly controlled 
buprenorphine more readily available from the offices of specially 
trained physicians, patients now have greater access to the 
treatments they need. And as their therapy progresses, patients 
may even receive prescriptions for a take-home supply of the 
medication from their doctors. A database maintained by the 
Center for Substance Abuse Treatment (CSAT) helps patients 
locate qualified doctors across the United States (CSAT, 2004).
Under the Drug Addiction Treatment Act, the FDA originally 
approved two buprenorphine formulations for the treatment of 
opioid dependence:
• Buprenorphine hydrochloride (sold under the brand 
name Subutex®) was intended to be given during 
the first few days of treatment. Because of the 
possibility of diversion from its intended medical 
use, this product is no longer available except in                      
a generic form. 
• Buprenorphine hydrochloride plus naloxone 
hydrochloride (sold under the brand name 
Suboxone®) is currently prescribed for medication-
assisted treatment. This drug is supplied in tablets 
of 2 milligrams and 8 milligrams, both which must 
be placed under the tongue to dissolve. Naloxone, 
an opioid antagonist and FDA Category C drug, 
has been added to guard against intravenous 
abuse of buprenorphine. Because both mother and 
fetus will be dependent on the opioids used by the 
mother, administration of naloxone could precipitate 
withdrawal in both (CSAT, 2004).
Although the FDA has not yet approved the use of buprenorphine 
in pregnant women (as of this writing, the approval process 
mood swings. Like other opioids, it has also been associated 
with serious (and potentially lethal) breathing problems, 
especially when combined with alcohol or depressants. These 
effects usually peak in the beginning of treatment and may last 
a number of weeks (CSAT, 2004).
Regulation of buprenorphine in Canada
Buprenorphine has been available for the treatment of opioid 
dependence in Canada since October 2007. However, only 
buprenorphine combined with naloxone in a 4:1 ratio is available 
for maintenance treatment; the buprenorphine mono-product is 
currently not marketed in Canada and is only available through 
the Health Canada Special Access Program for specific 
clinical situations, such as during pregnancy. The approval of 
buprenorphine-naloxone by Health Canada provided Canadian 
physicians with a long-awaited new treatment option for 
opioid-addicted patients. (At that time, buprenorphine had 
been available in the United States since 2000.) Since then, 
physicians who have received specialized training are allowed 
to prescribe buprenorphine from their offices without having to 
obtain the Health Canada exemption necessary to prescribe 
methadone (Hariri, 2008).
Although a specific license is required to prescribe methadone 
in Canada, physicians who wish to prescribe buprenorphine-
naloxone must complete only a brief online training program. The 
continuing medical education (CME) course accredited by the 
College of Family Physicians of Canada is strongly recommended 
(Hariri, 2008). However, for physicians with less experience in 
treating opioid dependence, more exhaustive CME courses 
are also available (Ducharme et al., 2012). Clinical guidelines 
containing recommendations for the initiation, maintenance 
and discontinuation of buprenorphine treatment have also 
been prepared by organizations such as CAMH in Toronto 
(Handford, 2012) and the College of Physicians and Surgeons 
of Newfoundland and Labrador (2011). These guidelines 
will ultimately improve access to treatment and lead to safer 
prescribing and dispensing of buprenorphine across Canada.
Regulation of buprenorphine in the United States
Like methadone, buprenorphine has been classified as a 
Category C pregnancy drug by the FDA, meaning its potential 
benefits may outweigh the risk of birth defects. In addition, it is 
considered a Schedule III narcotic under the U.S. Controlled 
Substances Act, indicating moderate potential for abuse and a 
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JENNIFER 
Jennifer, 19, attends a prestigious university in Montreal. Her father 
owns a restaurant and her mother is a lawyer. Both hard workers, 
they’ve been largely absent during Jennifer’s teen years. To make 
up for it, they lavish her with money and gifts. For her last birthday 
she got a brand-new SUV. 
Jennifer was interested in boys from a young age. Now she 
spends a fair amount of time on social media sites chatting with 
guys she doesn’t know. Once she posted pictures of herself in her 
underwear, which led to an overwhelming number of inquiries and 
an invitation from one stranger to a party. She decided to go and 
ended up meeting other guys there with expensive cars and lots 
of cash. She really liked one of them: Tom. They started dating, 
and over time Tom convinced Jennifer he loved her and would 
take care of her. He asked her to move to New York with him. The 
idea was thrilling for Jennifer and, despite her parents’ objections, 
she decided to go. Once there, Tom forced Jennifer to take a job 
stripping. She wanted to go home, but he became abusive and 
controlling, threatening to harm her family and forbidding her to 
contact them.
By this point, Jennifer was smoking marijuana daily. Tom 
introduced her to cocaine as well. When Jennifer got pregnant, 
Tom became angry and severely assaulted her. She was taken 
to the city hospital, where she explained to a social worker how 
she had ended up in this situation. She was released into the 
custody of her parents, who had not heard from her in over a year. 
Although supportive of Jennifer, they are worried about the health 
of their grandchild.
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A comparative, multicentre clinical study of 158 high-dose 
buprenorphine patients and 101 methadone maintenance 
patients in France by Lejeune and colleagues (2006) found 
no major difference between the two drugs in terms of overall 
maternal or infant outcomes. The only differences found were:
• A higher rate of prematurity in the methadone group 
(possibly explained by confounding factors such as 
the use of tobacco or other drugs); and
• A mean age at onset of NAS of 81 hours for the 
methadone group and 66 hours for the buprenorphine 
group. 
They also observed that in utero exposure to buprenorphine 
resulted in NAS in more than 50% of exposed newborns. 
Overall, the onset and nature of buprenorphine-associated 
NAS were comparable but somewhat milder in intensity and 
shorter in duration than NAS associated with methadone 
(Lejeune et al., 2006). 
Studies have shown that abstinence symptoms following 
buprenorphine exposure last for approximately 15–21 days, 
typically appearing within 12–24 hours of birth and peaking at 
72–96 hours after birth. Concomitant nicotine exposure also 
appears to exacerbate the severity of buprenorphine-related 
NAS (Loustauneau et al., 2002).
5.4.3 Medication-assisted treatment and 
neonatal abstinence syndrome
Many of the available reports on the use of methadone and 
buprenorphine during pregnancy are limited in their significance 
because of confounding factors such as maternal use of 
alcohol and other drugs (the use of concomitant medication 
or abuse of other substances was rarely reported in detail), 
making it difficult to truly assess the impact of these medications 
(buprenorphine, in particular) on NAS frequency, intensity and 
duration. In addition, many reports were retrospective and had 
no appropriate control groups, or they examined treatment 
settings, dosages and exposure lengths too dissimilar to be 
accurately compared. Details were also lacking with regard 
to the treatment of NAS as well as the tools used to assess 
abstinence symptoms (Unger et al., 2010). More recent studies 
have therefore sought to clearly define the role of buprenorphine 
in comparison to methadone and to further delineate the effects 
of the two medications on exposed newborns, especially with 
regard to NAS. 
is still underway), women who are already on buprenorphine 
before becoming pregnant are allowed to continue treatment 
during pregnancy.
Although buprenorphine and buprenorphine-naloxone are 
less tightly controlled than methadone because of their lower 
potential for abuse and less dangerous consequences in 
overdose situations, the manufacturer of these drugs, in 
collaboration with the FDA and other agencies within the U.S. 
Department of Health and Human Services, has developed 
a comprehensive risk management program to deter abuse 
and diversion from their legitimate treatment use. This 
program involves educating physicians on the proper use of 
buprenorphine, the implementation of child-resistant packaging 
and close monitoring of drug distribution channels. Through its 
surveillance efforts, which include interviews with substance 
abusers and the monitoring of adverse event reports, the FDA 
is able to identify problems resulting from the availability of 
buprenorphine and, if necessary, take appropriate actions to 
protect public health (CSAT, 2004).
In addition, the provisions of the Drug Addiction Treatment Act 
include limits on the number of patients individual physicians 
are allowed to treat and special registration with the U.S. Drug 
Enforcement Administration for the use of buprenorphine, thus 
providing additional safeguards in the office-based treatment 
setting (CSAT, 2004).
Outcomes of buprenorphine maintenance during 
pregnancy
Buprenorphine has been used successfully in pregnant women 
for more than a decade, with numerous studies finding no 
adverse maternal effects and infants delivered both at term and 
with birth weights in the normal range. However, observations 
have varied concerning the frequency, intensity and duration of 
abstinence in newborns prenatally exposed to buprenorphine 
(Loustauneau et al., 2002).
International studies of more than 500 newborns exposed 
prenatally to buprenorphine found no increased risk of birth 
defects and reported low rates of premature birth (Fischer et 
al., 1998; Fischer, 2000; Johnson et al., 2001; Lejeune et al., 
2001; Lacroix et al., 2004). In addition, buprenorphine treatment 
during pregnancy does not appear to have any greater risks to 
the mother or the fetus than treatment with methadone (Jones 
et al., 2005; Fisher et al., 2006). 
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pregnant women were extensively evaluated throughout the 
study and their newborns underwent systematic assessment of 
NAS signs and symptoms using a modified Finnegan Neonatal 
Abstinence Score. 
MOTHER’s results showed that maternal outcomes in 
buprenorphine- and methadone-treated women did not 
differ significantly for any of the studied maternal outcomes, 
including weight gain, number of prenatal obstetrical visits, 
incidence of caesarean section, abnormal presentation, use of 
analgesia, positive drug screen for illicit opioids and medical 
complications at delivery. This suggests a similarity between 
the two medications with regard to their safety and efficacy in 
the treatment of opioid dependence in pregnant women (Jones 
et al., 2010).
The MOTHER Study also measured specific outcomes related 
to NAS. Again, the results showed no significant differences 
between buprenorphine and methadone with regard to the 
overall rate of NAS in which treatment was required, peak NAS 
score or the head circumference of the newborns. The study 
did find a reduction in the severity of NAS in buprenorphine-
exposed newborns based on decreases in the three inter-
related parameters: length of hospital stay, number of days 
required for treatment and the total amount of morphine needed 
to treat the NAS (Jones et al., 2010). 
There were also considerable differences in the outcomes 
recorded among the three major site groups (urban United 
States, rural United States and Vienna, Austria). Specifically, 
total morphine administered for NAS varied from less than five 
grams to 34 grams and the total days of morphine administration 
varied from less than five to nearly 18 (Baerwert et al., 2012). 
As a result, further evaluation is required to make appropriate 
judgments from these data.
It is also worth noting that there was a non-significant (but 
potentially clinically important) difference in the proportions of 
mothers discontinuing from the study, with buprenorphine-
exposed participants more likely than methadone-exposed 
participants to be dissatisfied with their medication (23% 
versus 2%, respectively). The study’s buprenorphine-induction 
protocol may have been one of the factors that contributed to 
the markedly different attrition rates.
In Sweden, Kakko and colleagues (2008) looked at the 
maternal buprenorphine and methadone dosages as well as 
the incidence, severity and duration of NAS in two consecutive 
case series of exposed newborns from 1982 to 2006. 
Measuring intrauterine growth, birth outcomes, malformations, 
neonatal adaptation, neonatal abstinence and infant mortality 
in 47 consecutive, prospectively followed buprenorphine-
exposed pregnancies and 35 consecutive, retrospectively 
analyzed methadone-exposed pregnancies, it was found that 
buprenorphine treatment results in better birth weight (primarily 
due to longer gestation) and reduced incidence of NAS requiring 
pharmacological treatment when compared to methadone. 
Specifically, NAS occurred in 40.4% of the buprenorphine-
exposed infants (with 14.9% requiring treatment) and 77.8% of 
those exposed to methadone (with 52.8% requiring treatment). 
And when buprenorphine treatment was started prior to 
pregnancy, NAS at any level was significantly less frequent than 
in women who initiated treatment after conception (26% versus 
60%, respectively).
In Finland, Kahila and colleagues (2007) studied 67 women 
maintained on buprenorphine where tapering doses or even 
total abstinence was encouraged. This treatment approach 
resulted in an NAS incidence of 76%, with 57% of the infants 
requiring treatment. (Two sudden infant deaths also occurred.) 
The low-maintenance dose of buprenorphine was also linked to 
lower treatment retention rates and higher rates of illicit drug use, 
both of which are associated with increased NAS incidence and 
severity. The results of this study strongly suggest that pregnant 
women should be treated with dosages appropriate to their 
addiction. Concerns about the impact of higher dosages on 
NAS do not seem to be warranted based on clinical research 
data (Cleary et al., 2010).
The MOTHER Study
Given the previous studies examining the differences between 
methadone and buprenorphine with regard to NAS, NIDA 
funded an international, multi-site randomized clinical trial to 
investigate the safety and efficacy of maternal and prenatal 
exposure to methadone and buprenorphine. The Maternal 
Opioid Treatment: Human Experimental Research (MOTHER) 
Study involved 131 opioid-dependent pregnant women (73 
on methadone and 58 on buprenorphine) who delivered their 
babies while retained in the study. Comprehensive care and 
contingency management was provided for all participants. The 
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opioids directly to buprenorphine in an outpatient setting in 
which there is no fetal monitoring or immediate obstetrical aid 
should maternal or fetal distress occur during induction onto 
buprenorphine, creating a situation in which the development of 
IAS was inevitable. As such, McCarthy recommends that “better 
methods of detecting intrauterine withdrawal, including animal 
models of buprenorphine induction, need to be developed 
as well as evaluations of amniotic fluid catecholamines and 
glucocorticoids in order to delineate a guaranteed safety to the 
fetus” (McCarthy, 2012). 
Despite these concerns, a considerable amount of useful 
information can still be derived from MOTHER’s results. For 
full remission of opioid addiction to be sustainable postpartum 
and across the patient’s lifespan, physicians cannot rely solely 
on medication. Instead, it is best to utilize a comprehensive 
treatment model that addresses the underlying multifaceted 
complexities within the pregnant woman’s life (Finnegan, 
1991b, 2010; Jones, Finnegan & Kaltenbach, 2012).
5.4.4 The need for a tailored treatment 
approach
Women who abuse drugs during pregnancy are not a 
homogeneous group. They enrol in treatment programs at 
varying times in pregnancy, use a wide range of drugs (some 
of which are more dangerous to the developing fetus than 
others) and have been abusing drugs for differing lengths of 
time. They also enrol in treatment with various amounts of 
trauma, mental illness and social problems. Determining the 
most appropriate medication for opioid-dependent pregnant 
women must therefore be made on a patient-by-patient basis, 
taking into consideration each woman’s history of opioid abuse 
and dependence, medical circumstances, and previous and 
current treatment experiences and preferences. 
A specific treatment plan should be developed that meets 
the individual needs of each woman, taking into account the 
risk-benefit ratio of the medication and involving priority order 
initiation so the issues most dangerous to both the mother 
and the fetus can be dealt with first. Although these treatment 
plans can be long and complex, with the dedication of the 
professional staff and the cooperation of the pregnant women, 
recovery is achievable.
Questions and concerns about the MOTHER Study
Although the MOTHER Study has made an important 
contribution to the literature on opioid addiction during 
pregnancy, several questions remain about its clinical value 
and that of similar research studies. For example, to eliminate 
confounding in the results, MOTHER used stringent criteria 
for the inclusion of participants and excluded women using 
benzodiazepines and alcohol, both of which are quite prevalent 
in clinical populations of women using drugs. This prompted 
criticism from Newman and Gevertz (2011), who said the 
study lacked relevance to clinical decision making because its 
subjects were highly selected and atypical of real-world addiction 
medicine practice. They also claimed the protocol used in the 
study would be difficult to replicate in actual clinical practice 
and likely be unacceptable to the majority of patients. Additional 
concern was expressed over the need for the mothers to stay 
in hospital for stabilization onto the study medications and the 
need for the newborns to stay in hospital for observation for 10 
days after birth even in the absence of NAS. 
The degree of superiority of buprenorphine was also 
considered limited due to the fact that the three measures that 
decreased with buprenorphine exposure can all be influenced 
by non-pharmacological means. Newman and Gevertz (2011) 
concluded that more research is needed to guide clinicians 
in providing evidence-based care for opioid-dependent 
pregnant women.
In response to the concerns raised by Newman and Gevertz, 
Jones and colleagues (2012) wrote an editorial clarifying that 
because the MOTHER study was designed as an efficacy 
trial rather than an effectiveness trial, many of the limitations 
mentioned were not appropriate.
Among clinical service providers, another area of concern about 
the MOTHER Study was the safety of the fetus. McCarthy 
(2012) hypothesizes that intrauterine abstinence syndrome 
(IAS) can occur when pregnant women are inducted onto 
buprenorphine or when methadone tapering occurs, creating 
an adverse environment for the developing fetal brain that can 
result in long-term health effects. McCarthy claims MOTHER 
provided no protocol establishing the safety of going from illicit 
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approach for the treatment of opioid-addicted pregnant women, 
research has consistently illustrated its limitations—most 
notably, high rates of patient attrition and relapse with the risk 
of infections, illicit drug use and criminality (Luty et al., 2003).
Medically supervised withdrawal from opioids is generally not 
recommended for pregnant women except in extraordinary 
circumstances, particularly because it is physically and 
emotionally stressful at a time when their energy needs to be 
conserved for pregnancy, recovery and care for the newborn 
child (Finnegan, 1991a; McCarthy, 2012). Adverse maternal 
and infant outcomes, including decreased gestational age and 
increased incidence of low birth weight, have been associated 
with medical withdrawal during pregnancy. Intrauterine fetal 
demise has also been documented, even when medical 
withdrawal is conducted under the most optimal conditions. 
Relapse is also prevalent following medical withdrawal, with 
women returning to illicit drug use at an incidence of 41–96 % 
(Jones et al., 2008). 
The decision to attempt medically supervised withdrawal must 
therefore be made between the obstetrician, the pregnant 
woman and her counsellor. According to CSAT, if the decision 
is made to attempt a medical withdrawal regimen, it could 
be most safely accomplished during the second trimester 
(Mitchell, 1993). Although no controlled trials have been 
conducted to verify the proposed regimen, CSAT has advised 
that opioid withdrawal could be achieved through stabilization 
with methadone followed by a very gradual reduction of the 
methadone dosage. Fetal movement should be monitored 
twice daily and obstetrical stress tests should be performed at 
least twice weekly. Medically supervised withdrawal should be 
discontinued and no further decrease in methadone dosage 
should be ordered if the regimen causes fetal distress or 
threatens to cause preterm labour.
5.4.5 Breastfeeding while undergoing 
medication-assisted treatment
Health Canada, the American Academy of Pediatrics, the 
World Health Organization and many other major health 
authorities all agree that breast milk is the most complete form 
of nutrition for infants, with its mix of vitamins, protein and fat 
providing numerous benefits for health, growth, immunity 
and development.
Whether treated with buprenorphine or methadone, women 
should be encouraged to remain on their current medication 
when they become pregnant and not switch to the other. If 
stabilized on methadone, a pregnant woman should continue 
on methadone unless there is an appropriate clinical reason for 
change. Women who become pregnant on buprenorphine and 
are well stabilized should not be changed over to methadone 
under any circumstances. Transitioning from either medication to 
the other when stabilized can create the chance for withdrawal 
in both the women and the fetus with the potential to relapse to 
illicit opioid drugs (Jones, Finnegan & Kaltenbach, 2012).
However, because buprenorphine is not currently marketed 
in Canada and the safety of using naloxone during pregnancy 
has yet to be determined, the clinical practice guidelines for 
the use of buprenorphine-naloxone developed by the CAMH 
recommend that pregnant women receiving that formulation be 
switched to buprenorphine monotherapy (Handford, 2012).
Regardless of the medication taken, the dosage should be 
re-assessed periodically during pregnancy for adjustments, 
especially in the third trimester, to maintain medication plasma 
levels and thereby reduce (or eliminate) other drug use and 
maintain abstinence (Pond et al., 1985).
While randomized clinical trials, prospective and retrospective 
data have shown NAS to be less severe in infants exposed 
to buprenorphine compared to methadone, it should be 
remembered that NAS is an easily identifiable and treatable 
condition. NAS should therefore comprise only one aspect of the 
complete risk-to-benefit ratio that patients and physicians must 
consider when making medication decisions during pregnancy 
(Jones et al., 2010; Jones, Finnegan & Kaltenbach, 2012). 
Medically supervised withdrawal
Although maintenance is the preferred treatment for pregnant 
women, some highly motivated women (or those facing 
logistical or geographic barriers preventing them from accessing 
medication-assisted treatment) may opt instead for medically 
supervised withdrawal (also known as detoxification) during 
pregnancy. In some cases, these women may have been 
stable on methadone and requested medical withdrawal before 
delivery; others may have simply refused to be maintained on 
methadone at all and want to be drug-free before delivery. 
Yet while medically supervised withdrawal remains a popular 
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reports were published, most clinicians still felt comfortable 
recommending breastfeeding to methadone-treated mothers 
who expressed an interest in doing so, provided they were 
HIV negative, compliant with a treatment plan and did not 
use other licit or illicit drugs (American Academy of Family 
Physicians, 1996).
Buprenorphine is also detected in lactating women, passing 
into the breast milk at a plasma-to-milk ratio of approximately 
1.0. Absorption of buprenorphine from breast milk is much less 
than other opioids; because buprenorphine is not absorbed 
well by mouth, infants are exposed to only 10–20% of the 
total buprenorphine available in the breast milk (Johnson et al., 
2001, 2003; Lejeune et al., 2001; Loustauneau et al., 2002). 
Studies have shown minimal effects on NAS in breastfed 
infants exposed to buprenorphine, most likely because of the 
drug’s low oral bioavailability (Auriacombe & Loustauneau, 
2001). The literature includes reports on approximately 40–50 
women who were maintained on buprenorphine and who 
breastfed after delivery (Lejeune et al., 2001; Loustauneau et 
al., 2002; Johnson et al., 2003). These reports indicate that 
the buprenorphine present in breast milk does not appear 
to suppress NAS because it is not pharmacologically active 
in low doses. Additionally, NAS has not been observed after 
the cessation of breastfeeding by women maintained on 
buprenorphine (Loustauneau et al., 2002). 
Recommendations and guidelines
Although the packaging on buprenorphine formulas Subutex®10 
and Suboxone® advise mothers treated with these medications 
not to breastfeed, CSAT states that any effects of these 
medications on the breastfed infant would be minimal and that 
breastfeeding is therefore not contraindicated. However, given 
the limited literature in this area, physicians are advised to use 
their professional judgment in their recommendations.
This statement was echoed by the American Congress of 
Obstetricians and Gynecologists, which said that although 
minimal levels of methadone and buprenorphine are found 
in breast milk regardless of the maternal dose, breastfeeding 
should be encouraged in patients who are not HIV positive, do 
not use additional drugs and have no other contraindications 
(ACOG, 2012).
In its report entitled Breastfeeding and Maternal and Infant 
Health Outcomes in Developed Countries, the U.S. Department 
of Health and Human Services summarized the results of a 
meta-analysis of the existing literature concerning breastfeeding 
and various infant and maternal outcomes. It found that babies 
that are breastfed typically have lower incidences, reduced risk 
and/or decreased severity of acute otitis media (middle ear 
infections), atopic dermatitis (a type of eczema), gastrointestinal 
infections, lower respiratory tract diseases, asthma, diabetes, 
childhood leukemia and sudden infant death syndrome 
(Ip et al., 2007).
The mother also benefits greatly from breastfeeding. The 
incidence of certain cancers (most notably, breast, uterine, 
endometrial and ovarian) is reduced in women who breastfeed. 
The physical closeness associated with breastfeeding is also 
essential to the mother’s emotional health, helping to reduce 
feelings of anxiety and promoting a stronger maternal-infant 
attachment (Ip et al., 2007). The swaddling associated with 
breastfeeding may also help reduce NAS symptoms while 
contributing to greater bonding between mother and infant 
(ACOG, 2012).
Given the many positive outcomes associated with 
breastfeeding, for opioid-dependent women undergoing 
medication-assisted treatment, the decision to breastfeed 
their newborns is an extremely important one to make. But 
can the mother who is receiving treatment with methadone or 
buprenorphine safely breastfeed her baby?
Methadone and buprenorphine levels in breast milk
Methadone is detected in breast milk at very low levels. Studies 
have found the ratio of breast milk to maternal blood plasma 
concentrations to range from 0.05 to 1.2. Maternal doses of 
25–180 milligrams of methadone produce very small quantities 
of the medication in the breast milk, providing approximately 
0.05 milligrams per day of methadone to the baby (Wojnar-
Horton et al., 1997; McCarthy & Posey, 2000).
In recent reports, breastfeeding has been shown to diminish the 
duration of methadone-associated NAS symptoms (Abdel-Latif 
et al., 2006; Jansson et al., 2008) not only due to the limited 
oral bioavailability of methadone but also through enhanced 
mother-child bonding (Lim et al., 2009). Yet even before these 
10 This formulation is not currently marketed in Canada.
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The Vermont Buprenorphine Practice Guidelines from 
the Vermont College of Medicine provide more specific 
recommendations. If breastfeeding is declined by the mother, 
she should be placed on buprenorphine-naloxone immediately 
after delivery or continue methadone. If breastfeeding is 
accepted, the obstetrician should consult with the mother’s 
pediatric provider to confirm they are aware of her medication-
assisted treatment. If the newborn is not receiving methadone 
or morphine for NAS treatment, the mother can be placed on 
buprenorphine-naloxone. However, if the newborn is being 
treated with methadone or morphine for NAS, buprenorphine 
should be continued until the newborn is off medication or 
weaned from breast milk.
The clinical practice guidelines for the use of buprenorphine-
naloxone developed by CAMH acknowledge that buprenorphine 
has been measured in maternal breast milk and suggest that 
breastfeeding can be considered only after weighing the risks 
and benefits of buprenorphine exposure (Handford, 2012).
Based on these recommendations, infants of mothers who 
are undergoing medication-assisted treatment should be 
able to benefit from the many advantages of breast milk, just 
like any other child. Moreover, the psychological benefits of 
breastfeeding are extremely important, especially in cases 
where opioid dependence complicates the pregnancy.
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1
Early     
Childhood 
Outcomes
The long-term development of children born to drug-dependent women is a significant concern, not only for the mothers of these children but also for the medical professionals involved in their care.
Substantial evidence has shown that the outcomes of early childhood development echo 
throughout an individual’s entire life, meaning prenatal exposure to drugs can have long-
lasting negative effects. For example, studies on the impact of prenatal stress suggest many 
of the biological factors acting on the fetus are associated not only with the development 
of cardiovascular and metabolic disorders during adulthood but also with a number of 
psychological abnormalities and behavioural disorders (Lester & Padbury, 2009).
6
Such findings have led to the development of theories such as 
the “fetal origins of adult disease,” which postulates that a variety 
of common factors influence both intrauterine growth and adult 
physiological systems (Barker, 1992, 2002; Welberg & Seckl, 
2001). The various environmental factors active during prenatal 
life serve to “program” an infant’s developing systems. Prenatal 
exposure to drugs and alcohol is likely one of the many factors 
that can alter the typical “set points” for physiologic, metabolic 
and behavioural outcomes (Lester & Padbury, 2009). 
As the outcomes of infants born to alcohol-abusing women 
were reviewed in Chapter 4, this section focuses primarily on 
how maternal opioid and cocaine use affects child development. 
For more information on the early childhood outcomes of infants 
prenatally exposed to cannabis, please refer to the review 
conducted by Porath-Waller (2009) on behalf of the Canadian 
Centre on Substance Abuse.
6.1 Challenges in assessing child 
development outcomes
Maternal drug use has long been associated with numerous 
long-term adverse effects on children exposed in utero. However, 
evaluating the direct impact of such drug use on childhood 
development can be challenging for a variety of reasons. 
First, a number of studies (Kandall, 2010; National Institute on 
Drug Abuse [NIDA], 2011) have shown that early childhood 
development is dependent on a wide range of concomitant 
individual, family and environmental factors beyond prenatal 
drug use, including:
• Poverty and other socioeconomic disadvantages; 
• The amount of prenatal and medical care received by 
the mother;
• Whether the pregnancy was wanted or unwanted; 
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At a Glance
• There are challenges associated with evaluating the direct effects of prenatal drug exposure 
on childhood development as it is influenced by a wide range of individual, familial and 
environmental factors.
• Although there are mixed reports as to whether prenatal exposure to cocaine is significantly 
associated with deficits in cognitive and motor development, such exposure has been shown 
to increase the risk of delays in language development.
• Supervised methadone maintenance treatment during pregnancy does not appear to 
negatively affect the development and cognitive functioning of children evaluated up to 4.5 
years of age.
• Research on the effects of maternal opioid use during pregnancy on the postnatal growth 
and development of the child are limited and subject to various methodological limitations. 
There are reports suggesting that prenatal exposure to opioids increases the risk of 
neurodevelopmental impairment, however this finding is complicated by issues of poverty and 
the environment in which the child lives.
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are actually the result of poor maternal nutrition, stress, infection 
and poor prenatal care, all of which are common co-morbid 
factors in women using drugs (Thadani et al., 2004). 
6.1.1 Myths and misconceptions
Because of the challenges mentioned above, studies examining 
the links between maternal drug use and early childhood 
development can have considerable limitations. Furthermore, 
published studies might report “facts” that have not necessarily 
been proven by sound research. All of this has contributed to 
a multitude of misconceptions on the development of children 
exposed prenatally to drugs (Evan B. Donaldson Adoption 
Institute, 1997). For example: 
• “Every child who is exposed to drugs and alcohol will 
have problems later in life.” Studies have shown that 
not all infants are negatively affected by prenatal drug 
exposure and that a variety of factors contribute to 
children’s outcomes (Zuckerman, 1994).
• “Children exposed prenatally to cocaine are 
severely and permanently brain damaged.” While 
neurobehavioural abnormalities have been reported 
in newborns exposed to cocaine, other studies have 
not reported such outcomes. Moreover, the problems 
observed do not equate with severe or permanent 
brain damage. In one study, no developmental 
differences were found in cocaine-exposed children 
compared to non-exposed children at both two and 
three years of age (Zuckerman, 1994).
• “Children with FAS or FAE will not be able to succeed 
in school.” A diagnosis of FAS or FAE does not 
necessarily mean that a person will be unable to 
graduate from high school or attend post-secondary 
education (Kleinfeld, 1993).
• “A positive environment can do little to promote the 
development of exposed children.” Research has 
shown that negative outcomes in drug-exposed 
children can actually be ameliorated by supportive 
home environments and quality parenting (NIDA, 
2011). In a study of the developmental outcomes of 
children born to heroin-dependent mothers, Ornoy 
and colleagues (1996) found that any developmental 
delays were likely owing to severe environmental 
deprivation in the home and the fact that one or 
both parents were dependent on drugs, rather than 
prenatal drug exposure.
• The nutritional intake of the child; 
• Medical illness and other inherent biological risk 
factors;
• The presence of sexually transmitted diseases;
• Pollution levels; 
• Violent crime;
• Schooling and education; 
• The amount of family and community support 
received; and 
• The level of neglect and physical abuse experienced 
by the child. 
Chronic maternal stress may also influence childhood 
development and is related to low birth weight and preterm 
birth with hypothesized pathways via neuroendocrine, immune 
and vascular mechanisms that may influence both the timing of 
delivery and utero-placental transfer of nutrients.
Second, even when looking at the issue of maternal 
substance use, there are a number of variables that make it 
difficult to come to definitive conclusions (Bada et al., 2002; 
Kandall, 2010). These include: 
• Changes in maternal drug use patterns over time; 
• Concomitant drug use (both licit and illicit), which can 
potentially confound a study’s data; 
• Judgmental questioning of the women studied, which 
may obscure actual drug use;
• “Objective documentation” not uniformly used to 
measure exposure;
• The ability of the physical and social environment to 
alter the effect of illicit drugs or treatment medications; 
• Maternal drug dosages not being defined in many 
studies; 
• Terms such as “drug exposed” and “drug affected” 
not being properly defined;
• Unequal examination of biological effects versus 
environmental effects; and 
• The inability to maintain a cohort of children, meaning 
many studies include only a small number of subjects.
Because of the potential for all these factors to play a role in 
childhood development, a 2003 U.S. National Institute on Drug 
Abuse conference on placental biology and fetal development 
concluded that it is extremely difficult to determine if the 
detrimental effects seen in children exposed to drugs in utero 
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11 Infants born prematurely were tested when they reached the specific ages of the study periods by adjusting their ages. For example, for the one-month 
examination, a 38-week-old infant was tested at six weeks of age after birth.
Lifestyles Study went on for many years, using a battery of 
developmental tests at various ages throughout infancy and 
childhood in a large cohort of children (Messinger et al., 2004). 
Specifically, it looked at childhood development across three 
domains:
• Child: Physiology, attention, temperament, social 
interaction, attachment, cognition, language, motor 
development;
• Maternal: Psychological distress, depression, self-
esteem, attachment, parenting stress, IQ, drug history 
and use; and 
• Context: Social class, neighbourhood, social 
support, home environment, social services, violence, 
acculturation. 
At the ages of one, two and three years, 1,227 children from 
the longitudinal cohort were studied, 655 of whom were not 
exposed to cocaine or opioids in utero. Outcomes were 
measured using the Bayley Scales of Infant Development 
(BSID). While cocaine-exposed infants scored lower on the 
BSID Mental Developmental Index (MDI) (compared to those 
not exposed to cocaine) and opioid-exposed infants scored 
lower on the BSID Psychomotor Developmental Index (PDI) 
(compared to infants not exposed to opioids), these deficits 
were not notable when researchers controlled for birth weight 
and various environmental factors (Messinger et al., 2004).
6.2 The Maternal Lifestyles Study
Given the common misconceptions regarding the development 
of children exposed to drugs in utero, it is critical that any research 
looking into this issue is appropriately designed and expertly 
conducted. One example of such research is the Maternal 
Lifestyles Study. Initiated in the early 1990s, this longitudinal 
study of cocaine and opioid exposure on neurodevelopmental 
outcomes used a large matched comparison cohort at four 
diverse sites: Brown University, the University of Miami, the 
University of Tennessee and Wayne State University. Its 
participants were mostly African-Americans receiving public 
assistance (Lester et al., 2002; Bada et al., 2005). 
6.2.1 Developmental outcomes of infants
A total of 658 drug-exposed and 730 comparison infants 
were matched according to race, gender and gestational 
age. Exposure to drugs was determined by meconium assay 
and self-report. At one month corrected age,11 infants were 
tested using the Neonatal Intensive Care Unit (NICU) Network 
Neurobehavioral Scale (NNNS) and an acoustical cry analysis. 
Both the exposed and non-exposed groups were compared, 
adjusting for the following covariates: alcohol, marijuana, 
tobacco, birth weight, social class and study site. Separate 
analyses were also conducted for levels of cocaine exposure. 
On the NNNS, cocaine exposure was related to lower arousal, 
poorer quality of movement and self-regulation, non-optimal 
reflexes and higher rates of hypertonia (increased muscle tone), 
with most effects maintained after adjustment for covariates. 
Some effects were also found for opioids, alcohol, marijuana 
and birth weight (Lester et al., 2002).
With regard to acoustic cry characteristics, this study found that 
cocaine-exposed babies had a louder, higher-pitched cry with 
less resonance in the upper vocal tract. There was also more 
turbulence in the cries of heavily exposed infants. However, few 
cry effects remained after adjustment for covariates, suggesting 
they are not the result of cocaine use alone but most likely 
because of poly-drug use (Lester et al., 2002).
6.2.2 Developmental outcomes of toddlers
In addition to studying the growth and behavioural parameters of 
infants born to cocaine- and opioid-using mothers, the Maternal 
WHAT IS THE NNNS?
Developed for the U.S. National Institutes of Health as 
part of the Maternal Lifestyles Study, the NNNS assesses 
both neurological integrity and behavioural function. It 
also documents the range of withdrawal and stress signs 
likely to be observed during the examination of drug-
exposed infants. (Traditionally, scales that measure neonatal 
abstinence are treated separately from neurological and 
behavioural evaluations.) 
Through this comprehensive approach, the NNNS allows 
for the creation of symptom-oriented intervention plans for 
drug-exposed infants. In addition, repeated observations 
can inform clinical practice while accommodating the 
dynamic nature of the developing child.
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of the children involved with the Maternal Lifestyles Study to 
determine whether the differences noted develop into clinically 
significant deficits.
6.3 Effects of cocaine exposure on 
child development
In addition to the Maternal Lifestyles Study, several other studies 
on the effects of prenatal cocaine exposure on cognitive, motor 
and language development have been published; however, 
they vary with regard to their methodological rigour. 
6.3.1 Cognitive development
Frank and colleagues (2001) reviewed nine peer-reviewed 
studies published between 1992 and 2000, with five of the 
nine reporting no cocaine-related effects on mental or physical 
development. In the remaining studies, only subtle cocaine-
related effects remained (none of which maintained their 
significance when controlled for multiple covariates), causing 
the reviewers to conclude the effects of cocaine exposure on 
child development were not discernible from the effects resulting 
from other contextual factors such as prematurity, assessment 
age and other prenatal drug exposures (Frank et al., 2001). 
Larger prospective cohort studies, however, have suggested a 
more complex picture. For example, a pair of studies examining 
the effects of in utero cocaine exposure on the BSID MDI found 
lower overall scores as well as dose-dependent effects on infant 
development (Singer et al., 2001b; Lewis et al., 2004). Among 
cocaine-exposed preterm infants with very low birth weights, 
one study found a 10-point difference in mean MDI scores at 
three years of age (Singer et al., 2001b). Other longitudinal 
studies have shown more subtle effects of cocaine exposure 
on MDI scores (Behnke et al., 2002; Mayes et al., 2003). 
With an almost equal number of prospective studies reporting 
no cocaine-related effects on cognitive development after 
adjusting for covariates, it has been suggested that prenatal 
exposure to cocaine is simply a marker for subtle declines in 
MDI performance that might become less distinct with control 
for other variables such as low birth weight, exposure to human 
immunodeficiency virus (HIV), disruptions in maternal care, 
lower socioeconomic status and maternal vocabulary scores 
(Frank et al., 2001; Messinger et al., 2004).
6.2.3 Conclusions from the Maternal 
Lifestyles Study
Although the Maternal Lifestyles Study showed that significant 
mental, motor and behavioural deficits are not associated 
with cocaine and opioid exposure, it did conclude that the 
caregiving environment has a considerable impact on childhood 
development. Non-optimal environments can exacerbate 
neurobehavioural vulnerabilities, potentially turning the small 
differences in functioning caused by drug exposure into much 
larger deficits (Lester et al., 2002). The researchers also 
proposed that certain neurobehavioural characteristics could 
provide markers for later deficits, such as poor self-regulation in 
cocaine-exposed infants and the high-pitched, hyperphonated 
cries (cries with a qualitative break in the cry sound to a very 
high basic pitch) in cocaine, opioid or alcohol-exposed infants. 
Environmental risk may also interact with neurobehavioural risk; 
for example, lethargic infants might be more at risk of neglect 
and excitable infants might be more at risk of abuse.
Because cocaine can have latent effects that cannot be 
observed during infancy, it may be that cocaine affects areas 
of the brain that do not manifest until children are older. (Among 
adult cocaine users, the most common cognitive deficits are 
problems with executive function such as decision making, 
judgment and planning. The site of action for cocaine in the brain 
involves several areas thought to be instrumental in promoting 
these executive functions [Bolla et al., 1998; Breitner & Rosen, 
1999].) Because cocaine’s effects are so subtle among infants, 
especially when studied in the context of poly-drug use, Lester 
and colleagues (2002) recommended long-term follow-up 
WHAT IS THE BSID?
Through a series of developmental play tasks, the BSID 
assesses the motor, language and cognitive development 
of infants and toddlers from one to 42 months of age. Raw 
scores are converted into two standardized scores: the MDI 
and PDI. These are used to determine the child’s performance 
compared to typically developing children of the same age.
BSID scores can also be used to identify children who are 
developmentally delayed and chart a child’s progress after 
the initiation of an intervention program. While, the BSID has 
poor predictive value and does not measure future ability, it is 
considered a good screening device for identifying children in 
need of early intervention.
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GERALD
Gerald was born to Genevieve, who had been dependent on heroin 
and prescription opioids during her pregnancy. As soon as she realized 
she was pregnant, Genevieve enrolled in a comprehensive drug 
treatment program in Vancouver. The clinic was very user-friendly, with 
specific treatment plans dedicated to assuring healthy pregnancies 
and outcomes. She was prescribed methadone along with addiction 
counselling. She also attended numerous classes on mothering, child 
development and family management. The pregnancy went smoothly 
and Genevieve delivered a healthy baby boy. 
Genevieve was told that 60 to 80% of babies exposed to methadone 
experience abstinence in the neonatal period, affecting their central 
nervous, gastrointestinal, respiratory and autonomic nervous systems. 
Gerald was at risk for this condition. On the second day of life, he 
began to demonstrate symptoms that required treatment. Although 
his withdrawal was fairly severe and prolonged, doctors were able to 
control the symptoms and eventually wean him off morphine, which 
had been used to relieve the symptoms resulting from his in utero 
exposure to methadone. Genevieve was very attentive to the baby 
while he was in the hospital and visited as often as she could. Gerald 
came home when he was four weeks old, still with some mild irritability 
but that resolved quickly.
Because Genevieve had received training in how to support him 
through his symptoms, Gerald did well. He met his developmental 
milestones at ages one, two and three. The parenting sessions 
Genevieve participated in during her treatment helped her parent her 
son and his three year-old sister successfully. She read to them daily 
and took them to children’s events in the community. When Gerald 
reached the fourth grade, he was at the top of his class academically 
and had an outgoing personality. Genevieve was assured Gerald was 
headed for success in his future life.
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on the fetus’ monoaminergic neurotransmitter systems and by 
impairing the parent-to-child interactions critical to language 
development (Malakoff et al., 1999).
Because language development during early childhood is 
determined by many interacting genetic and environmental 
influences, from the clinicians’ perspective, viewing prenatal 
cocaine exposure within the lens of cumulative risk may help 
to identify affected children in need of remediation. And moving 
forward, studying language development in cocaine-exposed 
children as they grow into adolescence will help shed light 
on the pathways linking language functioning to other social, 
academic and behavioural childhood outcomes (Bandstra 
et al., 2003). 
6.3.4 Effects on older children
Although the evaluation of infants with prenatal drug exposure 
is essential to determining if early intervention is necessary, 
the follow-up of these children into adolescence is equally 
important. While longitudinal studies that evaluate children 
well into their teenage years are costly and difficult to conduct, 
several have been successfully accomplished. 
The most prominent study of this kind was conducted by Lester 
and LaGasse (2010), who reviewed 42 studies conducted 
between 1996 and 2008. Their results suggest that prenatal 
cocaine exposure has a number of unique effects on children 
up to 13 years of age, including a variety of problems related 
to behaviour, attention, language and cognition. In addition, a 
dose-response relationship was associated with the resulting 
behavioural problems, indicating that heavier exposure to 
cocaine produces more substantial effects. They also found 
weaker evidence of adverse effects from prenatal cocaine 
exposure on IQ and overall academic achievement. 
Some of the more specific findings reported by Lester and 
LaGasse (2010) include:
• Girls exposed prenatally to cocaine but not alcohol 
are more aggressive;
• Boys exposed prenatally to both cocaine and alcohol 
are more delinquent;
• Cocaine exposure is associated with both attention 
deficit hyperactivity disorder (ADHD) and oppositional 
defiance disorder; and
6.3.2 Motor development
In general, prenatal cocaine exposure has not been shown 
to affect typical motor development as assessed by the BSID 
PDI. In the review conducted by Frank and colleagues (2001) 
cited earlier, only two of the studies showed significant cocaine-
related effects on PDI scores. In the more recent review by 
Bandstra and colleagues (2010), only one study (Lewis et al., 
2004) showed a direct cocaine-related effect on PDI scores 
among infants one to three years of age. 
That said, several studies have found PDI scores to be affected 
by the timing and severity of the infant’s cocaine exposure. For 
example, Richardson and colleagues (2008) found lower scores 
were predicted by maternal cocaine use during the second 
trimester, while Frank and colleagues (2002) demonstrated a 
significant relationship between low birth weight and lower PDI 
scores in the infants of mothers who reported heavy cocaine 
use. In a longitudinal analysis of global motor development 
from 1–18 months conducted by Miller-Loncar and colleagues 
(2005), it was shown that motor skills for cocaine-exposed 
infants were, on average, lower than the norm, with deficits most 
evident between the ages of one and four months. However, 
the infants studied recovered to normal motor function by 
approximately 18 months of age.
6.3.3 Language development
Prenatal cocaine exposure also presents a risk for language 
delays in early childhood. A longitudinal study of children 
through three years of age by Morrow and colleagues (2004) 
found that infants exposed to cocaine in utero had lower total 
language scores than their non-exposed counterparts. These 
results were partially mediated through fetal growth (Morrow 
et al., 2003). They also observed that increased levels of 
prenatal cocaine exposure were associated with increased 
deficits in expressive language functioning. Similarly, two 
studies conducted by Singer and colleagues (2001a, 2001b) 
showed that expressive language skills were more adversely 
affected in cocaine-exposed infants who had very low birth 
weights and that heavily exposed infants showed lower auditory 
comprehension and poorer overall language skills than those 
with lighter or no cocaine exposure. 
It is thought that the mechanisms underlying this effect include 
disruptions in attentional processing through a direct impact 
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Although some differences between these two groups were 
observed among preschool children, in general, methadone-
exposed infants functioned within the normal range of 
development up to two years of age. For example, Lifschitz 
and colleagues (1985) used a multifactorial analysis and found 
that, when sociodemographic, biological and health factors are 
taken into consideration, the outcomes of methadone-exposed 
children do not differ from those of other high-risk infants 
(based on variables identified as being predictive for cognitive 
performance, such as the amount of prenatal care, prenatal risk 
and conditions in the home).
During this period, few studies involved children older than two 
years of age. In Philadelphia, Kaltenbach and Finnegan (1989) 
evaluated methadone-exposed children at the ages of 3½ and 
4½ years using the McCarthy Scales of Children’s Abilities 
(MSCA) and a neurological examination. Their results compared 
favourably with a study done in Detroit (Strauss, 1979) that 
examined methadone-exposed children at five years of age. 
Both studies found no differences between the exposed and 
non-exposed comparison groups on the MSCA General 
Cognitive Index or any of the MSCA subscales, although the 
scores in Detroit were overall much lower than those reported 
in Philadelphia. This variation might reflect the large number 
of confounding variables present within opioid-dependent 
women, who frequently use other drugs, including alcohol and 
benzodiazepines, in addition to methadone. 
• Cocaine-exposed children were more likely to have 
smoked cigarettes by the age of 10½ years.
Because the studies reviewed had reasonably large samples 
and were adjusted for a variety of confounding variables, Lester 
and LaGasse (2010) suggest the effects noted are indeed “true” 
cocaine effects. Of the 42 studies reviewed, 20 were based on 
samples of more than 300 children, with all studies combined 
representing 14 different cohorts totalling 4,419 children. With 
such a large population, statistical control for many prenatal and 
postnatal confounding variables can occur.
It should be noted that not all of the studies reviewed evaluated 
the same areas. However, with the evaluations currently 
available, it is clear that children exposed to cocaine in utero 
should be assessed on a regular basis so that appropriate 
interventions can be provided, if necessary.
6.4 Effects of opioid exposure on 
child development
Few long-term studies of children exposed prenatally to opioids 
have been conducted, with the majority focusing on maternal 
methadone and heroin use (Hans, 1996). While there is great 
interest in studying the effects of buprenorphine or prescription 
opioids such as hydrocodone and oxycodone on early 
childhood development, no studies have yet been published 
on the effects of these drugs on the child after the neonatal 
period (Lester & LaGasse, 2010).
6.4.1 Methadone
Numerous short- and long-term research studies on the 
neurobehavioural and developmental outcomes of methadone-
exposed children in the United States were published in the 
late 1970s and 1980s, including studies of cohorts of children 
from Chicago (Hans, 1989), Philadelphia (Kaltenbach, Graziani, 
& Finnegan, 1979; Kaltenbach & Finnegan, 1984, 1987, 1988, 
1989), New York (Johnson, Diano, & Rosen, 1984; Rosen & 
Johnson, 1982), Detroit (Strauss, Lessen-Firestone, Chavez, & 
Stryker, 1979; Strauss & Reynolds, 1983) and Houston (Wilson 
1989; Wilson, Desmond, & Wait, 1981; Wilson, McCreary, 
Kean, & Baxter, 1979; Lifschitz, Wilson, Smith, & Desmond, 
1985). These studies evaluated children born to mothers 
undergoing methadone treatment for opioid dependency and 
compared their scores on the BSID to children born to women 
who were not drug dependent but were from comparable 
socioeconomic and racial backgrounds. 
WHAT IS THE MSCA?
The MSCA assesses the cognitive development and motor 
skills of children 2½ to 8½ years of age. A wide range of 
puzzles, toys and game-like activities is used to evaluate each 
child on five different scales: 
• Verbal (comprehension and use of language);
• Quantitative (mathematical ability);
• Perceptual Performance (ability to conceptualize and 
reason without words);
• Memory (short-term recall of words, numbers, 
pictures and tonal sequences); and 
• Motor (fine and gross motor coordination). 
In addition to individual scores for each scale, the Verbal, 
Quantitative and Perceptual Performance scales are 
combined to yield the General Cognitive Index, an index of 
overall intellectual functioning expressed as a mental age 
equivalent between 1½ and 12½ years of age.
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The results reported by Kaltenbach and Finnegan (1989) 
in Philadelphia differed from those reported by Wilson and 
colleagues (1979, 1981, 1989) in Houston, who noted 
differences between heroin-exposed children and those in 
three different comparison groups, including a drug environment 
group, a high-risk group and a socioeconomic group.
Maternal medical and obstetrical complications can also 
influence the child’s outcome. However, the data reported by 
Kaltenbach and Finnegan (1989) suggest that methadone 
treatment during pregnancy, in the context of comprehensive 
services, does not impair the development and general 
cognitive functioning of children evaluated up to age 4½ years.
6.4.2 Heroin
In the review conducted by Lester and LaGasse (2010), some 
of the more notable studies on the effects of heroin on child 
development included:
• Sowder (1980): In an evaluation of 126 children 
ranging in age from eight to 17 who were born to 
heroin addicts, this study found that school absence, 
academic failure and behavioural problems were 
more common in heroin-exposed children than in a 
comparison group of non-exposed children from the 
same neighbourhoods. 
• de Cubas and Field (1993): In a study of 20 children 
aged six to 13 with prenatal exposure to methadone 
and a control group of non-exposed children, the 
researchers found no significant differences on 
cognitive tests (although methadone exposure was 
associated with lower IQ). The methadone-exposed 
children also tended to exhibit greater anxiety, 
aggression and rejection than those in the control 
group, and more behaviour problems were reported 
by the mothers of these children.
• Hans (1996): In a 10-year follow-up on 36 
methadone-exposed children, this study found drug-
exposed children made more errors on attentional 
(i.e., continuous performance) tasks and were 
somewhat more likely to receive ADHD and disruptive 
behaviour diagnoses when compared to a similar 
group of comparison children. 
In addition to these findings, some studies have suggested 
that the chaotic lifestyle inherent with heroin use has as much 
of an effect on child development as in utero exposure to the 
drug itself. In such high-risk home environments, similar learning 
and behavioural problems have been reported in school-age 
children whether they were exposed to drugs in utero (Olofsson 
et al., 1983) or just living with drug-dependent parents without 
prenatal exposure (Nichtern, 1973; Hejanic, Barredo, Hejanic, 
& Tomelleri, 1979). 
Conversely, in comparing the neurological and behavioural 
functioning of opioid-exposed children aged six to 15 to non-
exposed children living with parents or caregivers who use 
opioids, Davis and Templer (1988) found the opioid-exposed 
children had perceptual, motor and attentional functioning 
impairments not seen in the non-exposed children. Similar 
results were found by Moe (2002), who evaluated 64 heroin-
exposed children with minimal postnatal social risk and 52 
comparison children using the MCSA at 4½ years of age. In 
this study, social risk was controlled by studying the children 
born to drug-using parents who were then placed in foster or 
adoptive care designed specifically for at-risk infants. Lower 
scores were found in the heroin-exposed children despite the 
minimal social risk. 
Finally, a series of studies on the development of children aged 
five to 12 (Ornoy et al., 2001; Gogtay et al., 2004) found those 
born to and raised by their heroin-dependent parents had 
impaired verbal, performance, reading and mathematical skills. 
In comparison, children who were born to heroin-dependent 
mothers but adopted at a young age had normal intellectual 
and learning abilities with only some reduced function on 
performance IQ. A high rate of ADHD was reported in all children 
born to parents with heroin dependency, including those who 
were adopted; however, the highest rate was found among 
children who were raised at home by their heroin-dependent 
mothers.
Reports on the long-term effects of prenatal opioid exposure 
on postnatal growth and development are limited. As evident 
from these varying and conflicting findings, data can be difficult 
to interpret for a number of methodological reasons, including 
small sample sizes, poorly defined comparison groups and 
difficulty controlling for environmental variables (Bandstra et al., 
2010). To further complicate the scarcity of literature, difficulties 
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CAROLE
Carole is a 29-year-old lawyer in Toronto who grew up in an affluent 
family with two parents who were both physicians. Medicine didn’t 
appeal to Carole: she was drawn to the field of law. She ended up 
in a criminal practice, which was very high-pressured—both the 
work and the competition to become a partner. 
Carole felt she had no time to enjoy life. But when her friends 
insisted she celebrate her birthday with them, she decided she 
could justify a night out. They went to a dance club. The more she 
drank, the more relaxed she became. Toward the end of the night, 
a friend of a friend introduced her to heroin: it made her feel relaxed 
and euphoric.
Given the pressures of her everyday life, Carole found herself 
craving the relief and release that she’d experienced with heroin. 
She tried it a few more times when she had the chance and 
eventually found herself seeking opportunities to party after hours. 
The heroin use spilled over into her daily work. When she was tense 
or anticipating a court appearance, a hit or two of heroin eased the 
pressure. Carole hid her habit from her husband.
Eventually, she realized she was addicted to the drug. She went 
to her physician, who referred her to a psychiatrist who treated 
heroin-addicted individuals with a newly available medication 
called buprenorphine-naloxone. Because she was very motivated, 
Carole stabilized rapidly. Two months later she discovered she was 
pregnant: while she’d been using heroin she had not been regular 
about taking her birth control pills. Her obstetrician said she could 
be switched to buprenorphine during pregnancy through a special 
Health Canada program and, although her baby might go through 
withdrawal, it would probably be mild and short-lived. Carole was 
determined to stay healthy and to recover from her addiction with 
the help of her physician and the medication.
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associated with the studied population—in particular, high 
attrition rates and the lifestyle variability that characterizes the 
drug abuse culture—are prevalent (Hunt et al., 2008). 
However, the studies available suggest that infants exposed 
to opioids in utero are at increased risk of neurodevelopmental 
impairment (Ornoy et al., 2001; Hunt et al., 2008). While the home 
environment clearly plays a significant role in the development of 
opioid-exposed children, the magnitude of its effect is still unclear 
(Ornoy et al., 1996, 2001; Hunt et al., 2008).
6.5 Prenatal drug exposure 
leading to addiction later in life
A common question about children exposed prenatally to 
drugs is whether they will be at greater risk for drug abuse and 
addiction when they grow older. Like the other developmental 
outcomes discussed in this chapter, the answer is not readily 
available. While prenatal drug exposure might lead to future 
drug problems, it is most likely that multiple factors influence or 
contribute to future drug use or addiction. 
For example, in a systematic review of articles on the association 
between childhood sexual abuse and the development of 
substance-related disorders in adolescence or adulthood, 
Maniglio (2011) showed that while sexual abuse is definitely 
a risk factor for such disorders, it is not the only risk factor. 
Although this study had limitations, it is consistent with the fact 
that the majority of women who present to treatment centres 
have a history of sexual abuse. Maniglio’s study therefore 
points out the importance of identifying childhood sexual abuse 
and providing appropriate interventions to help prevent future 
substance abuse.
6.6 Implications
When interpreting the effects of prenatal drug exposure 
on early childhood development, Bandstra and colleagues 
(2010) remarked that unlike traditional models of behavioural 
teratology (the study of congenital abnormalities), which are 
typically based on animal research with optimized control of the 
postnatal environment, real-world infants develop within very 
complex social and environmental conditions, all of which can 
influence functional and behavioural capacities. As such, it can 
be extremely difficult to determine the specific effects of drugs 
on the developmental process. Moreover, the environment can 
have a direct impact on the expression or magnitude of the 
effect of prenatal drug exposure.
Researchers agree that prenatal exposure to drugs is just one 
of the many factors than can influence a child’s development. 
Many believe that the postnatal environment likely has a greater 
impact than prenatal drug exposure in determining a child’s 
developmental outcomes, with the importance of responsive 
parenting well established (Bandstra et al., 2010). Multiple 
factors can moderate or mediate the effects of prenatal drug 
exposure on the caregiving attachment relationship and, 
ultimately, infant development. For example, cocaine-abusing 
mothers often use other substances and typically reside in 
high-risk environments characterized by poverty, poor nutrition, 
ongoing substance use and family instability. These factors, 
combined with prenatal drug exposure, can increase maternal 
stress and compromise the quality of the parenting—which, 
in turn, can have an adverse impact on infant development 
(Freier, 1994; Espinosa et al., 2001; Johnson, 2001; Eiden 
et al., 2006).
In addition to the teratogenic effects of drugs on development, 
it has been suggested that non-teratogenic effects might also 
exist. Lester and Padbury (2009) have presented a model in 
which drugs act as an intrauterine stressor that disrupts the 
neuroendocrine environment and genetic programming of fetal-
placental development.
Based on these findings, existing intervention strategies 
developed for other at-risk children can offer guidelines for 
working with drug-exposed children and their families, potentially 
preventing or alleviating future developmental problems. In 
addition, specialized treatment programs supported by parent 
education services can help ameliorate the adverse effects of 
in utero drug exposure (Kronstadt, 1991; Twomey et al., 2010).
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JACQUELINE
Jacqueline was born in London, Ontario. Her mother, Joanne, had taken 
a number of drugs during her pregnancy including heroin, cocaine and 
benzodiazepines. She had also smoked tobacco and marijuana cigarettes. 
Joanne did not receive prenatal care or any addiction treatment until a 
few weeks before delivery, at which point she was placed on methadone. 
Jacqueline was born preterm and experienced a prolonged withdrawal, 
requiring hospital care for many weeks. Joanne visited regularly, carefully 
holding and feeding her, and was adamant about taking her baby home. 
She vowed to stay off street drugs, remain in treatment and provide a  
good home. 
After Jacqueline’s discharge, a social worker planned a series of follow-
up visits. Joanne became quite anxious about these visits, worried 
Jacqueline might be taken away from her. She and her boyfriend, who 
was not Jacqueline’s father, decided to move to Winnipeg. This disruption, 
combined with the poor conditions in which they lived after the move, 
brought considerable stress to their lives. Soon Joanne was using drugs 
again. She fed and bathed Jacqueline, but didn’t stimulate or play with her. 
They never read books to her, the TV was on constantly and she had very 
few toys.
At four years of age, Jacqueline was taken to the doctor for a severe 
respiratory infection. The doctor observed her mother was depressed and 
discovered, in conversation, that she was consuming mood-altering drugs. 
On follow-up, when Jacqueline was physically better, the doctor noted the 
child was behind in her developmental milestones. She was referred to a 
clinic for evaluation and possible treatment. The cause of her slow progress 
could not be determined: it might have been because of her in utero drug 
exposure (which was complicated by withdrawal and overdose, leading to 
hypoxia), the environmental deprivation, or both. Jacqueline was referred to 
a guidance clinic to receive interventions for her developmental delay, while 
Joanne was referred to a drug rehabilitation clinic for her addiction.
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A Call   
to Action
7
Despite this need, the history of addictions research is one in 
which women (and particularly pregnant women) have largely 
been kept in the shadows. Most of the research that has been 
done has largely been androcentric in focus and, in many 
cases, has even been stigmatizing and accusatory toward 
women who use drugs. The recommendations presented 
here are aimed at bringing pregnant women affected by drugs, 
alcohol and tobacco out of the shadows and to situate their 
stories within the complex communities in which they live.
In particular, the present Call to Action identifies a pressing 
need for:
• A wider distribution and understanding of the latest 
biomedical research among treatment providers and 
their clients; 
• A multidisciplinary approach to treatment, health 
promotion and prevention;
Because pregnancy is arguably one of the most developmentally complex periods for a mother and her child, the use of licit and illicit drugs, alcohol and tobacco during this time presents a number of unique health and social challenges. Fortunately, 
pregnancy can also offer a window of opportunity during which a woman’s motivation 
for behaviour change—including her substance use patterns—may be heightened. To 
this end, it is vitally important that the professionals who provide health care to pregnant 
women are well informed of the latest clinical evidence and research.
• A framing of the latest biomedical research in the 
Canadian context; 
• More available therapies and a better understanding 
of their effects on the fetus;
• Increased efforts to reduce the stigma and 
discrimination faced by women who are pregnant and 
using substances; and
• A consideration of the evidence in this report within 
the context of specific populations.
7.1 Improving treatment provider 
and client education
Written with the treatment provider in mind, the aim of this 
report is to share the latest information on the medical and 
biological consequences of substance use during pregnancy. 
It should be seen as part of the educational and motivational 
toolkit that treatment providers can use to connect with women 
during their pregnancy, a period when they are most likely 
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At a Glance
• Healthcare providers require accurate information regarding the risks of substance use during pregnancy and 
concrete approaches for reducing the harms associated with this behaviour.
• Healthcare and substance use treatment providers should share information regarding the effects of substance 
use with women of a childbearing age to increase their awareness of the risks of such behaviour during 
pregnancy.
• Treatment interventions should be multifaceted and integrate biomedical and psychosocial approaches to 
care for and support pregnant women who use substances. Collaborations between professionals, family and 
community supports are integral to addressing the complexities of substance use.
• Clinicians and researchers should continue to investigate the effects of medication-assisted treatment for opioid 
dependence on pregnant women and infants. 
• The stigma associated with substance use in general—specifically substance use during pregnancy and while 
parenting—must be addressed by all members of society. Framing addiction in the neurological context could 
help to reduce the media’s propensity to sensationalize the plight of infants born with substance exposure and, 
in turn, improve awareness and understanding among the general public. 
• Factors related to substance use during pregnancy such as ethnicity, income and geography should be 
explored by researchers to enhance the development of effective, tailored services for women and their children. 
• The unique experiences of youth should be acknowledged, especially as drug use can affect the neurological 
pathways responsible for judgment and decision making, which are malleable until the mid-20s. 
• Substance use can profoundly affect the earliest stages of human development and have adverse outcomes 
that carry into early childhood and beyond. Healthcare providers need to explore these issues more fully 
with their patients and provide unbiased, compassionate information to women of childbearing age and their 
partners.
108 Canadian Centre on Substance Abuse
SUBSTANCE ABUSE IN CANADA - Licit and Illicit Drug Use during Pregnancy
services, our goal should be to approach pre- and postnatal 
support for women in a coordinated and integrated manner, 
regardless of the setting. In addition to the system-based 
benefits of such collaboration and integration, the learning of 
integrated knowledge in a consistent and supportive manner for 
women during pregnancy may represent a motivating influence 
on their personal health care. 
There are several existing resources that can be adopted or 
tailored for those working with pregnant women, including 
the Competencies for Canada’s Substance Abuse Workforce 
(www.ccsa.ca/Eng/Priorities/Workforce/Competencies) 
and the Trauma-informed Care Toolkit (www.cnsaap.ca/Eng/
ProfessionalToolkits/Treatment_Issues/TraumainformedCare).
At the same time, it is important to recognize that community 
and clinical programs need to be scientifically supported and 
rooted in strong, research-based evidence, and this should be 
a key goal for all treatment, prevention and health promotion 
programming. We know from the literature that some of the 
most well-evaluated programs in Canada that address high-risk 
drug-involved women and their families do so through a one-
stop, supportive and comprehensive service delivery model. 
In the future, it will be important to establish evaluative norms 
that would enable programs to be objectively evaluated against 
internationally accepted standards relating to the clinical, 
community and treatment literature. 
7.3 Applying the evidence to the 
Canadian context
This report provides a comprehensive, global understanding of 
the key biomedical issues pertaining to the effects of substance 
use during pregnancy. It is not meant to focus on any one 
specific country. While it does highlight some Canadian data, it 
is not a report on the state of affairs in Canada per se. Moving 
forward, it will be important to identify gaps in the existing 
Canadian literature—as well as opportunities where we can 
draw greater understanding from the literature—to help provide 
further Canadian-specific context to some of the important 
themes outlined in this report. 
It is worth noting that Canada has a National Treatment Strategy 
aimed at strengthening the services and supports available to 
those with substance use problems. A variety of national and 
regional organizations have also demonstrated leadership in 
to access healthcare supports and may be more inclined to 
address the potential harms associated with their substance 
use. In this context, it is important to underline the educational 
value of informing treatment providers about what is happening 
biologically to the fetus and to provide them with information 
about harm-reduction measures that can be taken by a 
pregnant woman and her community. 
As has been demonstrated in the field of mental health, a 
non-judgmental treatment provider who can effectively relay 
information on the biological context of substance use during 
pregnancy can help prevent any sense of blame and therefore 
inaction on the part of the substance-using woman.
7.2 Adopting a multidisciplinary 
approach to treatment, health 
promotion and prevention
Data collected over the past several decades have consistently 
identified a high prevalence of psychosocial issues among 
women who abuse substances. Concurrent disorders and the 
issue of trauma can render women’s care extremely complex at 
times, requiring a multifactorial response. A better understanding 
of these issues, which frequently are antecedents to substance 
use, is essential if treatment, prevention and health promotion 
efforts are to make a positive difference in the lives of women 
who use alcohol, drugs or tobacco during pregnancy. 
While the biomedical focus of the report did not permit an 
in-depth analysis of the many complex psychosocial factors 
associated with substance use during pregnancy, the report 
does include an important chapter on psychosocial issues 
(Chapter 3), as well as an emphasis on the importance of a 
comprehensive care setting (Chapter 5). It is important to 
underscore the psychosocial themes such as those related 
to victimization that are included in this report and it is worth 
stressing the centrality of the family and community in any 
treatment response or health promotion and prevention effort. 
To this end, this Call to Action encourages ongoing efforts to 
integrate biomedical and psychosocial approaches to care 
for and support pregnant women who use substances. While 
discipline- and profession-specific training is necessary, there 
is a serious need for a collaborative approach to training and 
professional development that integrates areas of expertise. 
Whether in hospitals, correctional facilities or community health 
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based framework for making decisions about the treatment 
choices available to pregnant women, so as to avoid obstetrical 
complications and help ensure the well-being of newborns. 
7.5 Reducing the stigmatization  
of women who use substances 
during pregnancy
Most substance-using pregnant women face difficult social 
realities—challenges that can be worsened as they encounter 
stigma and discrimination within the healthcare system. These 
realities are depicted in the brief vignettes found in each chapter 
of this report, which present fictionalized accounts of what is 
happening in the field as experienced by both frontline healthcare 
workers and the women they care for. While recognizing that 
these vignettes represent only a snapshot of the full spectrum of 
clinical case contexts, they do capture some of the challenges 
experienced by community and healthcare workers in some 
settings. The information contained in this report provides 
a context for understanding the vignettes and illustrates why 
supporting pregnant women is the best available option. 
It is important to point out that the media play a significant 
role in shaping society’s perceptions of women who use 
substances during pregnancy and the resulting stigmatization 
of these women and their children. Specifically, the media have 
frequently used pejorative labels such as “addicted babies,” 
“the littlest addicts,” “crack babies,” “meth babies” and “babies 
battling addiction” to describe infants exposed to drugs in utero. 
While attempts have been made to discourage the use of such 
terms by treatment providers and researchers alike, many are 
still picked up and reinforced by the general public. 
Moving forward, efforts to explain the basis of addiction in brain-
related terms might be helpful in addressing the use of such 
labels. The latest research suggests that addictions primarily 
reflect pathological disturbances to brain systems associated 
with reward and motivational processes; that is, severe 
alterations within systems that regulate our ability to identify 
which things to obtain and which to avoid. Viewing addictions 
and related harmful behaviours in this way frames them in health 
terms that are not dissimilar from other health issues. 
By forcing an understanding of addiction that is grounded in 
basic health-related principles, such framing can provide an 
educational perspective that can help to overcome stigma. 
For example, by highlighting the neurobiological basis of 
this area, including the Public Health Agency of Canada, the 
Canada Northwest FASD Research Network and the British 
Columbia Centre of Excellence for Women’s Health.
7.4 Gaining a better understanding 
of pharmacotherapies
We must continue to learn more about how the fetus responds 
to substance-related pharmacotherapies such as methadone 
and buprenorphine. There is therefore a strong need for 
clinicians to develop safe protocols to protect pregnant women 
and the fetus during treatment for opioid dependence. For 
clinicians, the best-known practice at this time is to assure a 
woman’s comfort to prevent any cause for hypoxia (oxygen 
deprivation) in the fetus, such as when immediate abstinence 
occurs. (Maternal abstinence can cause fetal abstinence, 
which can cause hypoxia that contributes to intrauterine growth 
restriction.) In their efforts to do the very best for the pregnant 
woman, the fetus and the newborn, clinicians must use the 
best available medical, clinical and scientific knowledge. 
In addition to clinical considerations, it is important to stress 
the need for more research in the pharmacotherapy field. While 
there are considerable data on the effects of opiate exposure 
in adults, including literature on methadone and buprenorphine 
use in pregnant women, more remains to be learned about the 
effects of exposure to opiate-based medications on the fetus 
and, in particular, the extended properties of these medications. 
In this regard, more research is encouraged on the similarities 
and differences in the effects of methadone, buprenorphine 
and buprenorphine-naloxone formulations on the developing 
fetus. Such research would create a greater understanding 
about the efficacy and safety of opiate-related treatments on 
the developing fetus, thereby strengthening the evidence-
NATIONAL TREATMENT STRATEGY
Canada’s National Treatment Strategy is aimed at providing 
direction and recommendations to strengthen the services 
and supports available to Canadians with substance 
use problems. Implementation is currently underway for 
recommendations made in four key areas: 
• Leadership; 
• Knowledge exchange;
• Promoting a tiered model of services and supports; 
and 
• System monitoring.
Source: National Treatment Strategy Working Group, 2008.
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addiction, it becomes clear that babies cannot be “addicted”; 
instead, the passive transfer of drugs from mother to fetus 
creates in the newborn a physiologic dependence on the drugs 
used by the mother. This understanding illustrates not only the 
moral and ethical problems of pejorative labels, but also the 
inaccuracy of such labels given what we now know about the 
biological basis of addiction.
7.6 Meeting the needs of specific 
populations
Given the biomedical focus of this report, attention to specific 
populations, while noted, was not emphasized. However, 
because specific populations can present unique challenges as 
well as unique opportunities for support and treatment, diversity 
across social conditions and inequities such as income, race, 
geographic location, sexuality, disability, language, heritage and 
culture must be acknowledged. 
Youth represent one such population. We need to better connect 
with the unique circumstances of youth, accounting for the full 
biopsychosocial continuum of specific youth populations. For 
example, at the social end of the continuum, young women 
may use substances to control their weight or body image. 
Recognizing this, it is worth thinking about what we can learn 
from the tobacco and alcohol industries with regard to the 
successful prevention and health promotion efforts that have 
been undertaken for a variety of age groups. At the biological 
end of the continuum, it is important to underline new knowledge 
derived from neuroscience indicating that the human brain is 
not yet fully developed during adolescence and the neural basis 
of executive function, which can affect judgment and choice, 
continues to develop through a person’s mid-20s. We must 
also recognize that these life stages are not necessarily uniform 
from one young person to another. Both of these examples 
underline the importance of generating knowledge specific to 
the unique circumstances of distinct populations of youth. 
In addition, the unique circumstances and backgrounds of 
women who use drugs, alcohol or tobacco during pregnancy 
need to be accounted for in any response. These circumstances 
include, for example, the historical impacts of colonization on 
the lives of First Nations, Inuit and Métis women in Canada. 
Aboriginal women experience some of the highest rates of 
poverty and interpersonal violence in Canada. For their healing, 
linkages with traditional culture and identity provide key support.
7.7 Conclusion
As a society, we need to continue to learn more about substance 
use, abuse and addiction generally, as is evident in the evolving 
definition of addiction presented in the most recent version 
of the Diagnostic and Statistical Manual of Mental Disorders. 
It follows that healthcare professionals must continually 
update their content-specific knowledge so they can best 
assist women experiencing substance-use challenges while 
pregnant and better understand the nature of substance use 
disorders and their related harms. In the context of this report, 
it is of particular interest to highlight the field of epigenetics, an 
emerging field that is helping to explain the interactions between 
nature and nurture. By providing a platform for understanding 
how environment and experience can modulate the expression 
of genetic and biology processes (e.g., explaining differences 
between identical twins despite their identical genetic make-
up), the knowledge derived from epigenetics can help connect 
psychosocial and biomedical perspectives.
To meet the needs of women who use and become addicted 
to drugs, we need to continue our efforts to understand the 
multifactorial aspects of addiction and the effects of in utero 
exposure on offspring. Gaining this understanding will take 
many more dedicated researchers and clinicians, supportive 
infrastructures and a strong policy focus that recognizes the 
multidimensional nature of these challenges. Yet as we propose 
to find “solutions” to treatment and prevention, we must keep 
in mind that we also need to focus on what is actually working 
today. As new knowledge emerges in the field, we have the 
tendency to sometimes look at it as a “magic bullet” without 
keeping at the centre of our vision what is already known 
to be working. For example, because we already know that 
empowering women to make their own choices and “meeting 
them where they are at” is effective, this consideration should 
be at the forefront of any new knowledge as it is uncovered.
The most recent epidemiological data in Canada indicates 
a decline in substance use in both males and females. We 
also know that binge drinking has increased among college-
aged women—and that the alcohol industry is increasingly 
marketing to this group and other women. And we also know 
that advances in the neurosciences are happening at lightning 
speed. Once again, it is important to know from all perspectives 
what is being uncovered to help contextualize what we are 
learning together in the research lab, the clinic, the classroom 
and the living room. 
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Appendix A: U.S. Food and Drug 
Administration Pregnancy 
Categories
In 1979, the U.S. Food and Drug Administration (FDA) 
established five categories (A, B, C, D, X) to indicate the potential 
of a drug to cause birth defects if used during pregnancy. The 
placement of a drug into one of these categories is determined 
by the reliability of the drug’s documentation as well as its risk-
to-benefit ratio. It should be noted that these categories do not 
account for risks conferred by pharmaceutical agents or their 
metabolites in breast milk. 
The FDA uses the following definitions for its pregnancy 
categories:
Category A: Adequate and well-controlled studies 
have failed to demonstrate a risk to the fetus in the first 
trimester of pregnancy (and there is no evidence of risk 
in later trimesters).
Category B: Animal reproduction studies have failed 
to demonstrate a risk to the fetus and there are no 
adequate and well-controlled studies in pregnant 
women.
Category C: Animal reproduction studies have 
shown an adverse effect on the fetus and there are 
no adequate and well-controlled studies in humans, 
but potential benefits may warrant use of the drug in 
pregnant women despite potential risks.
Category D: There is positive evidence of human fetal 
risk based on adverse reaction data from investigational 
or marketing experience or studies in humans, but 
potential benefits may warrant use of the drug in 
pregnant women despite potential risks.
Category X: Studies in animals or humans have 
demonstrated fetal abnormalities and/or there is positive 
evidence of human fetal risk based on adverse reaction 
data from investigational or marketing experience, and 
the risks involved in use of the drug in pregnant women 
clearly outweigh potential benefits. 
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Appendix B: Controlled 
Substances Act (United States)
Signed into law in 1970, the U.S. Controlled Substances Act 
is divided into five schedules, with all pharmaceutical agents 
regulated under federal law classified according to their 
currently accepted medical use as well as their relative abuse 
potential and likelihood of causing dependence. Drugs listed in 
Schedule I have no currently accepted medical use and may 
not be prescribed, administered or dispensed for that purpose. 
Drugs in Schedules II–V, however, have some accepted use 
in treatment and may therefore be prescribed, administered or 
dispensed for medical use. 
Some examples of the controlled substances in each schedule 
are as follows:
Schedule I: These substances have a high potential 
for abuse and no currently accepted medical treatment 
use. In addition, there is a lack of accepted safety for 
the use of these substances under medical supervision. 
Substances listed in Schedule I include heroin, 
lysergic acid diethylamide (“LSD”), cannabis, peyote, 
3,4-methylenedioxymethamphetamine (“ecstasy”) and 
methaqualone (Quaaludes®).
Schedule II: These substances have a high potential 
for abuse, potentially leading to severe psychological or 
physical dependence. While they do have a currently 
accepted medical treatment use, there may be severe 
restrictions on such use. Substances listed in Schedule 
II include morphine, methadone, hydromorphone, 
oxycodone (OxyContin®), cocaine, phencyclidine 
(“PCP”), amphetamine (Adderall®), methamphetamine, 
methylphenidate (Ritalin®) and barbiturates such as 
amobarbital and pentobarbital. 
Schedule III: These substances have a lesser 
potential for abuse than those listed in Schedules I and 
II. Their abuse may lead to moderate or low physical 
dependence and/or high psychological dependence. 
Substances listed in Schedule III include buprenorphine, 
benzphetamine, ketamine, anabolic steroids such 
as oxandrolone, products containing less than 15 
milligrams of hydrocodone per dosage unit (Vicodin®) 
and products containing not more than 90 milligrams of 
codeine per dosage unit (Tylenol® with codeine).
Schedule IV: These substances have a low potential 
for abuse relative to those listed in Schedule III. However, 
there is still the potential for physical or psychological 
dependence. Substances listed in Schedule IV include 
propoxyphene (Darvon®) as well as benzodiazepines 
such as alprazolam (Xanax®), diazepam (Valium®), 
clonazepam, clorazepate, lorazepam, midazolam, 
temazepam and triazolam.
Schedule V: These substances have a low potential for 
abuse relative to those listed in Schedule IV and consist 
primarily of preparations containing limited quantities 
of certain narcotics. Generally used for antitussive, 
antidiarrheal and analgesic purposes, substances listed 
in Schedule V include cough medicines containing not 
more than 200 milligrams of codeine per 100 milliliters 
or per 100 grams (Robitussin AC®, Phenergan® with 
codeine).
For a complete list of all of the substances included in each 
schedule of the Controlled Substance Act, please refer 
to the U.S. Food and Drug Administration’s website at: 
http://www.fda.gov/regulatoryinformat ion/legislat ion/
ucm148726.htm.
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Schedule III








• Some barbiturates, including pentobarbital and 
amobarbital
• Medications combining hydrocodone and 
acetaminophen (Vicodin®) 
Schedule IV
• Anabolic steroids such as oxandrolone
• Benzodiazepines such as alprazolam (Xanax®), 
diazepam (Valium®) and triazolam
• Most other barbiturates, including those used 
as general anesthetics or considered to be mild 






• Synthetic and natural forms of precursors such 
as acetic anhydride, lysergic acid, norephedrine, 
piperidine, potassium permanganate, acetone, 
hydrochloric acid, sulphuric acid and toluene
For a complete list of all of the substances included in each 
schedule of the Controlled Drugs and Substances Act, 
please refer to the Government of Canada’s website at 
http://laws-lois.justice.gc.ca/eng/acts/C-38.8.
Appendix C: Controlled Drugs and 
Substances Act (Canada)
Passed in 1996, the Controlled Drugs and Substances Act is 
Canada’s federal drug control statute. Repealing the previous 
Narcotic Control Act as well as parts of the Food and Drug Act, 
it establishes a series of schedules pertaining to the control 
of certain drugs, their precursors and other substances. The 
schedules outlined by the Controlled Drugs and Substances 
Act can be amended the Governor in Council as deemed 
necessary in the public interest.
Except as authorized under the regulations, no person shall:
• Possess a substance listed under Schedules I–III;
• Traffic in a substance listed under Schedules I–IV;
• Import or export a substance listed under Schedules 
I–VI; or
• Produce a substance listed under Schedules I–IV.

















• 4-hydroxybutanoic acid (“GHB”)
• Flunitrazepam (Rohypnol®) 
Schedule II
• Cannabis and its preparations, derivatives and similar 
synthetic preparations (but not including non-viable 
cannabis seed or mature cannabis stalks without 
leaves, flowers, seeds or branches)
